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Jill Kimberly Badin 
 
CORONARY SMOOTH MUSCLE CELL CYTODIFFERENTIATION AND 
INTRACELLULAR Ca2+ HANDLING IN CORONARY ARTERY DISEASE 
 
Metabolic syndrome (MetS) affects 1/3 of all Americans and is the clustering of 
three or more of the following cardiometabolic risk factors: obesity, hypertension, 
dyslipidemia, glucose intolerance, and insulin resistance. MetS drastically increases the 
incidence of coronary artery disease (CAD), which is the leading cause of mortality 
globally. A cornerstone of CAD is arterial remodeling associated with coronary smooth 
muscle (CSM) cytodifferentiation from a contractile phenotype to proliferative and 
osteogenic phenotypes. This cytodifferentiation is tightly coupled to changes in 
intracellular Ca2+ handling that regulate several key cellular functions, including 
contraction, transcription, proliferation, and migration. Our group has recently elucidated 
the time course of Ca2+ dysregulation during MetS-induced CAD development. Ca2+ 
transport mechanisms, including voltage-gated calcium channels, sarcoplasmic reticulum 
(SR) Ca2+ store, and sarco-endoplasmic reticulum Ca2+ ATPase (SERCA), are enhanced 
in early, mild disease and diminished in late, severe disease in the Ossabaw miniature 
swine. Using this well-characterized large animal model, I tested the hypothesis that this 
Ca2+ dysregulation pattern occurs in multiple etiologies of CAD, including diabetes and 
aging. The fluorescent intracellular Ca2+ ([Ca2+]i) indicator fura-2 was utilized to measure 
[Ca2+]i handling in CSM from lean and diseased swine. I found that [Ca2+]i handling is 
enhanced in mild disease with minimal CSM phenotypic switching and diminished in 
severe disease with greater phenotypic switching, regardless of CAD etiology. We are 
confident of the translatability of this research, as the Ca2+ influx, SR Ca2+ store, and 
SERCA functional changes in CSM of humans with CAD are similar to those found in 
 vii   
Ossabaw swine with MetS. Single-cell RNA sequencing revealed that CSM cells from an 
organ culture model of CAD exhibited many different phenotypes, indicating that 
phenotypic modulation is not a discreet event, but a continuum. Transcriptomic analysis 
revealed differential expression of many genes that are involved in the osteogenic 
signaling pathway and in cellular inflammatory responses across phenotypes. These 
genes may be another regulatory mechanism common to the different CAD etiologies. 
This study is the first to show that CSM Ca2+ dysregulation is common among different 
CAD etiologies in a clinically relevant animal model.  
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CHAPTER 1: INTRODUCTION 
Obesity 
 Obesity, as defined by a BMI greater than or equal to 30.0, is a growing epidemic 
in the United States (Fig. 1.1). Currently, 39.8% of adults and 18.5% of children are obese 
in the US [1]. This is clearly a growing public health crisis that negatively affects health, 
quality of life, and national healthcare budgets. In the United States alone, healthcare 
costs of obesity and obesity-related health conditions are $275 billion/year, which is more 
than 20% of total healthcare spending [2]. 
 While obesity was once considered an issue exclusively for developed nations, the 
presence of obesity had doubled worldwide from 1980 to 2008, and currently over 600 
million people are classified as obese [3]. In children, the global obesity rate has increased 
from 8% in 1980 to 13% in 2013 [3]. The obesity rate in children is a growing concern, as 
juvenile obesity is associated with both adipocyte hyperplasia and hypertrophy [4]. 
Juvenile adipocyte hyperplasia increases the risk for obesity in adulthood, indicating that 
the obesity epidemic will only become exponentially worse in the future.  
 Human evolution has helped fuel the obesity epidemic. In the hunter-gatherer 
stage of human evolution, there were times of feast and famine that occurred cyclically 
with the seasons. Individuals who were better able to store calories in the form of adipose 
tissue were favored in times of food shortage [5]. While this “thrifty genotype” was useful 
tens of thousands of years ago, the current constant abundance of affordable, calorie-rich 
food coupled with a sedentary lifestyle, humorously referred to as our “obesogenic 
environment,” has only exacerbated the obesity epidemic [5-7]. 
Metabolic Syndrome 
 Obesity is one of the main risk factors associated with metabolic syndrome (MetS), 
which is defined by the American Heart Association (AHA) as the clustering of three or 
more of the following five cardiometabolic risk factors: central obesity, insulin resistance, 
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glucose intolerance, hypertension, and dyslipidemia [8]. More specifically, MetS is 
clinically defined by a blood pressure >130/85 mmHg, a fasting blood glucose >100 mg/dL, 
an HDL-C level <40 mg/dL for men or <50 mg/dL for women, a triglyceride level >150 
mg/dL, and a BMI ≥30.0 kg/m2 [8]. MetS affects 1 in 3 Americans and greatly increases 
the risk of developing comorbidities such as type 2 diabetes, non-alcoholic fatty liver 
disease (NAFLD), and coronary artery disease (CAD) [8]. MetS and its comorbidities 
significantly raise health care costs and are a burden on national economies [9]. 
 While each individual component of MetS increases the risk for cardiovascular 
events, a positive MetS diagnosis triples the risk for adverse cardiovascular outcomes [10] 
(Fig. 1.2, adapted from [10]). Several studies have determined that patient MetS score is 
associated with increased Gensini score, a measurement of CAD severity [11-14]. It is 
readily apparent that when these metabolic abnormalities are clustered together there is 
a greatly enhanced risk of cardiovascular events, indicating that MetS is greater than the 
sum of its parts.   
Coronary Artery Disease 
 CAD is responsible for 1 in 7 deaths in the United States and is the leading cause 
of mortality globally [8]. The cost of CAD in the United States was estimated at $108.9 
billion and was the second most expensive hospital discharge diagnosis in 2011 [8, 15]. 
The incidence of CAD is expected to rise 40.6% with a doubling in the resulting medical 
costs by the year 2030 [8, 15].  
Healthy coronary arteries have three distinct layers. The adventitia is composed 
mainly of connective tissue, the tunica media is the largest layer and is composed mainly 
of contractile coronary smooth muscle (CSM) cells, and the tunica intima is a one-cell-
thick layer of endothelial cells that are in constant contact with the lumen (Fig. 1.3A-E, 
adapted from [16]). However, CAD is accompanied by the pathophysiological remodeling 
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of the coronary arteries that restricts blood flow to the myocardium, resulting in myocardial 
infarction and other adverse cardiovascular events.  
CAD is initiated by endothelial damage or dysfunction leading to the upregulated 
expression of adhesion molecules that bind to circulating macrophages. Chemoattractant 
cytokines regulate the transmigration of these macrophages into the arterial wall, where 
they engulf lipid depositions including oxidized low-density lipoproteins (ox-LDL) and 
progress into foam cells. Contractile CSM cells that populate the media layer 
dedifferentiate into proliferative, synthetic cells and are recruited into the developing lesion 
where they secrete extracellular matrix (ECM) proteins, including collagen, which 
contributes to plaque stabilization and outward remodeling. As the lesion continues to 
form, debris from apoptotic CSM and other cells as well as lipid droplets accumulate to 
form a necrotic core. Further CSM dedifferentiation into an osteogenic phenotype 
contributes to the deposition of hydroxyapatite crystals in the ECM, resulting in vascular 
calcification (Fig. 1.4, adapted from [17, 18]). Detailed mechanisms of CSM phenotypic 
switching and vascular calcification are described later in this work. Later stages of CAD 
are associated with increased cardiac mortality, risk of plaque rupture, and clinical 
narrowing of the lumen. Although the heart has a low coronary flow reserve, a blockage 
of about 75-80% of the lumen is required to have any detrimental effects on myocardial 
health, so CAD may remain clinically silent for decades [19].  
Type 2 Diabetes 
Diabetes mellitus (DM) is composed of heterogeneous metabolic diseases that 
result in hyperglycemia due to pancreatic beta cell failure, insulin resistance in peripheral 
tissues, or both [20]. There are two main classifications of DM: type 1 diabetes (T1D) and 
type 2 diabetes (T2D). T1D is the autoimmune destruction of pancreatic beta cells, leading 
to a complete dependence on exogenous insulin. The onset of T1D usually occurs before 
age 40, with the average age of diagnosis around 14 years [21]. T2D is the progressive 
 4 
loss of pancreatic beta cell function and is responsible for 90-95% of DM cases in North 
America [8]. T2D is a complex condition resulting from long-term glucose intolerance and 
insulin resistance. As such, it is a common comorbidity with MetS and is a major risk factor 
for cardiovascular diseases including CAD. It has been well-documented that humans with 
DM and MetS develop greater CAD severity and have a higher incidence of cardiovascular 
events than individuals with MetS alone [14, 22-26]. Like obesity, T2D is a growing 
epidemic. In 2014, an estimated 31 million adults in the United States have T2D, ¼ of 
those cases undiagnosed, costing the US $245 billion a year in medical expenses [8, 27].  
T2D has a complex and dynamic etiology, as it is a progressive disease that 
manifests clinically as chronic hyperglycemia over the course of decades and is usually 
coupled with other cardiometabolic conditions. The pathophysiology of T2D follows a 
pathway eventually leading to beta cell failure [27]. The first stage of T2D is beta cell 
compensation. Peripheral insulin resistance necessitates an increase in glucose-
stimulated insulin secretion (GSIS) of pancreatic beta cells, which is done both by 
increases in overall beta cell mass and in beta cell hypertrophy [28]. As such, this stage 
is accompanied by hyperinsulinemia. T2D progresses when beta cells can no longer 
compensate for the peripheral insulin resistance and glucose intolerance, resulting in a 
state of hypoinsulinemia [29]. This impaired GSIS could be due to glucotoxicity, where 
chronic hyperglycemia causes a depletion of insulin secretory granules from beta cells, 
and/or lipotoxicity, where increased fatty acid levels lead to infiltration of pancreatic islets 
and beta cell dysfunction [28, 29]. 
Studying the interplay between T2D and obesity is of utmost importance, as 
individuals with T2D are being diagnosed earlier and living longer, leading to an increased 
risk of developing cardiovascular complications [29]. 
The positive energy balance of obesity leads many cellular processes to become 
imbalanced. An excess of nutrients stimulates adipose tissue to release tumor necrosis 
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factor alpha (TNFα) and IL-6, leading to a pro-inflammatory state that is a common factor 
in obesity, MetS, and T2D [30-32]. An increased serum level of these inflammatory 
mediators have been found to reduce the synthesis and secretion of adiponectin, an 
adipocyte that normally functions as an insulin sensitizer and anti-atherosclerotic agent 
[33, 34]. Indeed, patients with T2D have a lower level of circulating adiponectin than their 
normoglycemic counterparts [35]. Adiponectin has been found to reduce NADPH oxidase 
activity, so a lower level of adiponectin is correlated to increased ROS generation [35, 36]. 
The resulting increase in ROS contributes to reduced insulin secretion in beta cells, insulin 
resistance in skeletal muscle and adipocytes, and endothelial dysfunction, all mechanisms 
of T2D and atherogenesis [37]. Finding the common disease mechanisms of these 
comorbidities is important, as it could lead to pharmacotherapies that can treat multiple 
different linked conditions.  
Aging as a Risk Factor for Cardiovascular Disease 
 William Osler, a prolific physiologist and one of the founders of Johns Hopkins 
University, once said, “A man is as old as his arteries” [38]. Indeed, aging is a major 
unmodifiable risk factor for CAD. An advanced age is associated with increased risk of 
developing several cardiometabolic abnormalities, with 54.9% of the population aged 60 
and over having MetS [39]. In 2010, adults 65 years and older had a T2D rate of 26.9%, 
well above the rate of 9.4% for the general population [8]. The incidence of CAD increases 
progressively with age, with more than 50% of CAD-related deaths occurring in those aged 
75 and older [40, 41]. In fact, is it hypothesized by some that the rise of T2D is mainly due 
to the aging population, as the incidence of MetS has remained relatively constant for the 
past decade [42]. 
 Even physiologically healthy aging is associated with several cardiometabolic 
changes that are independently associated with MetS and CAD, such as increases in 
plasma low density lipoprotein cholesterol (LDL) and triglyceride levels, making the aged 
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vasculature more susceptible to disease [43].  Age-associated increases in NADPH 
oxidase activity increase cellular concentrations of reactive oxygen species (ROS), which 
contributes to the activation of NF-κB leading to an increased inflammatory state [44-47]. 
This inflammatory state is associated with the upregulation of many inflammatory 
cytokines, chemokines, and adhesion molecules that promote atherosclerosis [44, 48-53]. 
High concentrations of ROS are also known to inactivate NO, which, along with the age-
related decline in eNOS activity, causes impairments in vasodilation [47]. Several 
structural differences in aged vessels, such as increased collagen content, decreased 
elastin content, and changes in Ca2+ homeostasis, contribute to arterial stiffening and 
subsequent age-related hypertension [47, 54]. Elderly patients exhibit more extensive 
vascular calcification associated with lipid oxidation and inflammation [55, 56]. Detailed 
mechanisms of vascular calcification are described later in this work.  
 Aging is associated with cellular senescence, which is accompanied by growth 
arrest, DNA damage, telomere shortening, and reduced proliferation [54]. The 
senescence-associated secretory phenotype contributes to age-related diseases by 
secreting effectors such as IL-6, IL-8, and MCP-1 that alter the ECM and impair the 
functioning of surrounding cells [47, 57]. Atherosclerotic plaques even in young subjects 
showed signs of cellular senescence, indicating that atherosclerosis may be classified as 
premature vascular aging [54]. Indeed, arterial intima/media thickening is a process 
associated with aging independent from atherosclerosis [58]. Overall, the aging cellular 
milieu contributes substantially to the pathophysiology of coronary atherosclerosis.  
Coronary Circulation 
 All the risk factors described so far in this work increase the risk of developing 
cardiovascular diseases, including CAD. As such, physiological knowledge of the coronary 
circulation is of utmost importance.  
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The heart is the only organ in the body that supplies blood to itself. The left and 
right main coronary arteries branch from the left and right ostium in the proximal aorta 
directly above the aortic semilunar valve. Unlike every other organ, blood flows into the 
coronary arteries mainly during diastole when the myocardium is relaxed and there is 
some level of retrograde flow in the proximal aorta [19]. The left main coronary artery 
(LCA) branches into the left anterior descending (LAD) artery, which lies in the anterior 
interventricular groove, and the circumflex (CFX) artery, which lies in the left 
atrioventricular groove. The right coronary artery (RCA) lies in the right atrioventricular 
groove. These large conduit arteries wrap around the heart, eventually narrowing and 
branching into first, second, and third order resistance arterioles. These resistance 
arterioles extensively branch into microvessels and infiltrate the myocardium transmurally 
to deliver oxygen to the myocardium (Fig. 1.5, adapted from [19]).  
As the heart has a very high oxygen demand, if coronary blood flow is perturbed 
or reduced even to a small degree it will have negative effects on the myocardium and 
result in adverse health consequences.  
Coronary Smooth Muscle  
 CSM cells reside in the media layer of coronary arteries and are responsible for 
relaxation and contraction that regulates coronary blood flow. CSM are spindle-shaped 
cells ranging from 5-10 μm in diameter and 50-600 μm in length [59]. CSM are associated 
with sustained, tonic contractions while smooth muscle from veins and nonvascular 
tissues are associated with rapid, phasic contraction [16, 60]. Unlike striated muscle, CSM 
lacks an organized subcellular contractile filament structure [16, 60]. Instead, CSM 
contains thin filaments composed of actin, tropomyosin, and binding proteins such as 
myosin light chain kinase (MLCK), caldesmon, and calponin, and thick filaments 
composed mainly of myosin [16, 61]. The thin filaments are anchored into membrane 
plaques at the polar ends of the cell membrane and dense bodies in the cytoplasm [16]. 
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These structures are similar to the Z-lines in striated muscle. The intracellular filament 
lattice structure is highly plastic, allowing the CSM to rapidly adapt and provide contractile 
forces over a wide length range [62].  
CSM cell contraction can be accomplished through mechanical stimuli, chemical 
stimuli, and electrical stimuli [16]. For this work, I will focus on the latter, also termed 
“excitation-contraction coupling.” Depolarization of the plasma membrane leads to the 
influx of extracellular Ca2+ via voltage-gated calcium channels (VGCC) where it binds to 
calmodulin, activating MLCK which phosphorylates myosin light chain (MLC) [16, 60, 63]. 
MLC phosphorylation in the presence of ATP causes the formation of cross-bridges 
between myosin heads and actin filaments, resulting in contraction [16, 60]. CSM 
relaxation can be accomplished by the decrease of intracellular Ca2+ either through efflux 
mechanisms or by sequestration into the sarcoplasmic reticulum (SR) [60, 61]. Since 
intracellular Ca2+ concentration is largely responsible for CSM contraction, tight Ca2+ 
regulation is vital for CSM function and is reviewed in detail in the following section of this 
work.  
Cell-cell communication between CSM cells is accomplished by gap junctions, 
which form a functional syncytium that enables the free flow of small molecules and ions 
[61]. Therefore, depolarization and repolarization can spread freely from one cell to 
another, resulting in a concerted action of contraction and relaxation [16, 61]. 
Simultaneous, controlled contraction and relaxation is vital for arterial function and 
regulation of blood flow.   
Coronary Smooth Muscle Intracellular Ca2+ Regulation 
Extracellular Ca2+ can enter the cell through VGCC after membrane depolarization 
or through transient receptor potential (TRP) channels, which are activated by ligands 
such as G proteins, phosphoinositides, and diacylglycerol and do not require membrane 
depolarization [16, 64]. Intracellular Ca2+ ([Ca2+]i) can exit the cell via plasma membrane 
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Ca2+ ATPases (PMCA) or sodium-calcium exchangers (NCX). [Ca2+]i can also be buffered 
by the SR via the sarco-endoplasmic reticulum Ca2+-ATPase (SERCA), where 
sequestered Ca2+ can be released by inositol trisphosphate receptors (IP3R) and 
ryanodine receptors (RyR) to rapidly increase the concentration of [Ca2+]i (Fig. 1.6).  
As [Ca2+]i must be tightly controlled, how these Ca2+ transporters interact with the 
changing concentrations of Ca2+ in the cellular environment is immensely important. 
Phospholamban (PLN) inhibits SERCA activity when cytosolic concentrations of Ca2+ are 
low, but high [Ca2+]i activates Ca2+/calmodulin kinase (CaMKII), which phosphorylates 
PLN leading to the disinhibition of SERCA [65]. In this way, [Ca2+]i homeostasis can be 
maintained. However, when the SR Ca2+ store is depleted, a Ca2+ sensing protein located 
in the SR membrane called STIM1 activates Orai1 and TRPC channels on the plasma 
membrane, which cause an efflux of Ca2+ that can be re-sequestered into the SR by 
SERCA [63, 66, 67]. This process is referred to as store-operated Ca2+ entry (SOCE). 
Ca2+ can also be released from the SR via RyR when there is a rise in [Ca2+]i, a process 
called Ca2+-induced Ca2+-release (CICR) [16]. These localized increases in [Ca2+]i can 
activate Ca2+-dependent K+ channels, leading to repolarization and closure of VGCC [16]. 
All these mechanisms work in harmony to contribute to the function and Ca2+ homeostasis 
of CSM. 
Smooth Muscle Phenotypic Modulation and [Ca2+]i Handling Alterations 
  Differentiated, contractile CSM have a low proliferation rate and are largely 
stationary [68]. However, CSM can dedifferentiate into a proliferative, migratory phenotype 
that secretes ECM proteins as a wound-healing response in times of stress [68]. As CAD 
is associated with a constant low level of inflammation and cellular stress, CSM continually 
dedifferentiate into other phenotypes, contributing to disease pathology. These 
dedifferentiated CSM cells can migrate to the growing plaque, secrete ECM proteins, and 
rapidly proliferate, contributing to disease pathology [68, 69].  
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Phenotypic modulation is closely coupled to changes in [Ca2+]i handling, as [Ca2+]i 
controls many cellular functions such as migration, proliferation, and transcription (Fig. 
1.6). This is accomplished by Ca2+-dependent transcription factors such as serum 
response factor (SRF), cAMP response element binding (CREB), and nuclear factor of 
activated T-cells (NFAT) [69]. Ca2+ signaling in contractile CSM depends on local [Ca2+]i 
signaling in the form of Ca2+ sparks and waves on a background of low global [Ca2+]i. The 
low [Ca2+]i that facilitates this kind of [Ca2+]i handling is mostly attributable to the SERCA 
pump, which has been shown to sequester more than 70% of [Ca2+]i [70, 71]. Local 
dramatic increases in [Ca2+]i activates SRF, which binds to the serum response element 
in the promoter region of target genes, many of which are involved in contraction and 
contractile phenotypic maintenance [68, 69]. SERCA dysfunction results in an inability to 
sequester Ca2+, leading to greater store-operated Ca2+ entry via transient receptor 
potentiation (TRP) channels, STIM-1, and Orai1 and a dramatic, sustained increase in 
[Ca2+]i [70, 72, 73]. High global [Ca2+]i activates Ca2+/calmodulin-dependent protein kinase 
II, which phosphorylates CREB allowing for its translocation to the nucleus where it serves 
as a transcription factor for genes involved in survival and proliferation [73]. Similarly, high 
global [Ca2+]i increases the activation of calcineurin, which dephosphorylates and thus 
activates NFAT, where it promotes transcription of genes involved in the immune response 
[72]. In this way, [Ca2+]i handling patterns regulate gene expression and ultimately 
phenotype. This is referred to as excitation-transcription coupling.  
Previously, my group has described paradoxical trends in CSM [Ca2+]i handling 
alterations in swine models of MetS-induced CAD. Ca2+ influx after membrane 
depolarization and SERCA function have been found to both increase [74-76] ([77, 78] 
and decrease [79, 80] in disease. However, these studies used different breeds of swine 
that were fed an atherogenic diet for varying lengths of time with different comorbidities. 
My lab has recently resolved this discrepancy, elucidating the time-course of changes in 
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[Ca2+]i handling during the progression of MetS-induced CAD. [Ca2+]i handling alterations 
occur in a biphasic manner, with enhanced Ca2+ influx, SR Ca2+ store, and SERCA 
function occurring in early, mild disease that was diminished in late, severe disease [81]. 
While this CSM [Ca2+]i handling alteration pattern has been established in MetS-induced 
CAD, the [Ca2+]i handling alteration patterns of other etiologies of CAD have yet to be 
determined.  
Coronary Artery Calcification 
Coronary artery calcification (CAC) is the accumulation of hydroxyapatite crystals 
in the ECM, a process resembling endochondral bone formation [82, 83]. There are two 
main types of CAC: intimal calcification and medial calcification, also known as 
Monckeberg’s sclerosis. Intimal calcification is associated with CAD and spotty 
calcification (microcalcification) increases plaque instability and rupture [84], while 
Monckeberg’s sclerosis is associated with diabetes and chronic kidney disease and 
decreases vascular compliance [85]. These pathologies follow different mechanisms, so 
for this project I will focus on intimal calcification.  
 CAC is one of the most reliable predictors of future cardiovascular events, even in 
asymptomatic individuals [86, 87]. Individuals with CAC had a 4-10 times greater risk for 
a cardiac event [88]. The extent of CAC is usually correlated to the progression of CAD 
[84, 89]. In a seminal 1994 study by Fleckenstein-Grün and colleagues, it was found that 
vascular calcification increases in an exponential fashion throughout the progressive 
stages of atherosclerosis [90]. This relationship could be due to the close association of 
CAC with inflammation [82, 85, 86, 91-93], apoptosis [85, 86, 89, 93], oxidative stress [85, 
86, 89], endoplasmic reticulum stress [89], hyperglycemia [84, 86, 94], and dyslipidemia 
[85, 89, 93], which are all also mechanistically linked with CAD progression. Indeed, the 
extent of CAC increases with the number of MetS risk factors, similar to CAD severity [10, 
14, 95]. 
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 CSM cytodifferentiation is necessary for the initiation and progression of CAC [91, 
96, 97]. When CSM dedifferentiate into a proliferative phenotype, the cells synthesize and 
secrete ECM proteins that serve as the nidus for vascular calcification [91, 96]. As stated 
previously, this proliferative phenotype is associated with increased basal cytosolic Ca2+ 
levels, VGCC activity, SR Ca2+ store, and SERCA function [75, 76, 81]. Continued stress 
signals such as cytokines and ROS in the cellular milieu contribute to further CSM 
dedifferentiation into an osteogenic phenotype [91, 93]. In this phenotype, certain 
osteogenic transcription factors like runt-related transcription factor 2 (Runx2), Sox9, and 
osterix promote the transcription of several genes that are normally expressed in bone, 
such as alkaline phosphatase (ALP), receptor activator of nuclear factor kappa-Β ligand 
(RANKL), and osteocalcin [91, 98].  
 Osteogenic CSM contribute to CAC by the increased release of exosomes that 
contain calcifying cargo (Fig. 1.7) [82, 92]. Under physiological conditions, exosomes 
traffic cargo that includes minerals, lipids, proteins, calcification inhibitors, and miRNA 
between cells [99, 100]. This represents another avenue of cell-cell communication. 
However, in osteogenic CSM, exosome secretion is enhanced and its contents change to 
contribute to the vascular calcification process. Calcification inhibitors such as matrix Gla 
protein (MGP) and fetuin-A are downregulated, while calcification promotors such as 
annexins A2, A5, and A6, phosphatidylserine (PS), matrix metalloproteinase-2 (MMP-2), 
and hydroxyapatite crystals themselves ae upregulated [82, 92, 97, 99]. Furthermore, the 
miRNA content is modified to include more miRNA transcripts that promote continued 
expression of the osteogenic phenotype, contributing to prolonged CAC progression [100]. 
When exosomes from calcifying vascular smooth muscle cells from rats with chronic 
kidney disease were co-cultured with vascular smooth muscle cells from healthy 
littermates, the recipient cells experienced phenotypic switching to an osteogenic 
phenotype and increased calcification [96]. 
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Enhanced exosome shuttling and pro-calcifying cargo are, at least in part, a result 
of altered [Ca2+]i homeostasis. Calcifying exosomes have been identified in proliferative 
CSM, which exhibit higher basal [Ca2+]i levels that may result from increased Ca2+ influx 
via VGCC, increased release from intracellular Ca2+ stores, or decreased Ca2+ efflux that 
is characteristic of this phenotype [75, 76, 96, 101]. A higher basal [Ca2+]i level has been 
connected to the exosomal downregulation of calcification inhibitors and the enrichment 
of calcification promoters [97, 101]. This Ca2+ overload, especially upon switching to an 
osteogenic phenotype where Ca2+ handling alterations favor decreased Ca2+ buffering, 
leads to the increased release of calcifying exosomes. Chelation of intracellular Ca2+ and 
certain Ca2+ channel blockers such as verapamil and diltiazem have been found to block 
exosome shuttling and vascular calcification [90, 97]. Therefore, I can conclude that CSM 
phenotypic switching from a contractile phenotype to a proliferative and osteogenic 
phenotype and subsequent changes in [Ca2+]i handling serve as the driver for vascular 
calcification via exosomes.   
Ossabaw Miniature Swine 
Ossabaw miniature swine were first introduced to a small island off the coast of 
Georgia in the 1500s by Spanish explorers [102]. Due to ecological barriers, the Ossabaw 
swine have been confined to the island where they have thrived for hundreds of years. A 
recent eradication effort has focused on this invasive species, but not before a 
subpopulation was transferred to a breeding colony at Indiana University to be used for 
biomedical research purposes [102].  
Ossabaw swine exhibit a “thrifty genotype,” similar to humans, and thus have a 
propensity to develop all the risk factors associated with MetS when kept in captivity with 
a constant food supply, more so than any other swine model (Fig. 1.8, adapted from [103]; 
Table 1.1, adapted from [102]). Their size and cardiovascular anatomy and physiology are 
incredibly similar to humans, and Ossabaw have been found to develop diffuse, human-
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like coronary plaques [80]. Ossabaw swine have been used as an animal model to 
successfully recapitulate MetS [103, 104], CAD [80, 81], CAC [105, 106], NAFLD [107-
109], and other human cardiometabolic diseases [110-112].  
Summary 
The prevalence, severity, and cost of obesity, MetS, and CAD have plagued the 
United States and the world at large. Understanding how CSM [Ca2+]i handling and 
homeostasis are altered in disease states is of utmost importance, as this divalent cation 
plays a role in a great number of cellular functions. This thesis work seeks to elucidate 
whether some major etiologies of CAD, including MetS, diabetes and aging, work through 
similar cellular mechanisms of [Ca2+]i handling disruption to contribute to the common 
pathophysiology of CAD. I am particularly interested in SR Ca2+ store capacity, as SR Ca2+ 
store capacity and release are essential in Ca2+ signaling and homeostasis.  
Major Hypotheses 
1. SR Ca2+ store capacity is correlated with coronary smooth muscle cytodifferentiation 
and subsequent arterial remodeling in Ossabaw miniature swine models of different CAD 
etiologies. 
2. Proliferative and osteogenic coronary smooth muscle cells will exhibit altered 
transcriptomic profiles and SR Ca2+ store capacity depending on disease progression.  
3. CSM SR Ca2+ store capacity changes in humans with coronary artery disease (CAD) 










Figure 1.1: Obesity trends among U.S. adults. Over the past 25 years every state has 
seen a marked increase in the prevalence of obesity in the adult population. Figure 
adapted from [113]. 
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Figure 1.2: Presence of MetS increases a patient’s risk of coronary heart disease 
mortality. A positive diagnosis of MetS has been shown to increase patient mortality due 
to cardiovascular events, even when adjusting for conventional cardiometabolic risk 





Figure 1.3: Histology of the vascular wall elucidates its structure. (A) Schematic 
representation shows that both conduit arteries (left) and resistance arterioles (right) have 
similar structure. The intima is shown as a single-cell layer of endothelial cells, the media 
contains smooth muscle cells, and the thickness of this layer is dependent on the size and 
function of the artery. The adventitia, composed of collagen and other extracellular matrix 
proteins, surrounds the artery. The arterial layers are separated by layers rich in elastin 
that give the arterial wall plasticity. The internal elastic lamina (IEL) separates the intimal 
and media layers, while the external elastic lamina (EEL) separates the media layer and 
the adventitia. (B) Verhoeff van Gieson’s histological stain of a large conduit coronary 
artery shows the neointima (NEO), media layer (M), EEL, and IEL. A branch site (BR) can 
also be seen. (C) Masson’s trichrome histological stain of a large conduit coronary artery 
shows smooth muscle (red) in the media (M, yellow double-headed arrow) and collagen 
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(c, blue) in the adventitia. There is also some positive collagen staining between smooth 
muscle cells in the media. (D) Arterial tree shows a large conduit artery branching into 
resistance arterioles, which then branch into microvessels. White arrows indicate sites of 
atheroma development, as visualized by the white “cotton ball-like” structures at the 
branch points. (E) Masson’s trichrome histological stain of a venule highlights the collagen 
(c, blue) in the adventitia and smooth muscle (red) in the media (M). Note the difference 
in media thickness and smooth muscle cell content between the arteries and this venule. 


















Figure 1.4: Progression of CAD. A healthy artery will have an intimal layer that is 
comprised of a single layer of endothelial cells. Initial endothelial dysfunction causes the 
overexpression of adhesion molecules that attract circulating macrophages which turn into 
foam cells when they engulf ox-LDL particles. This causes a fatty streak that can advance 
to a preatheroma, characterized by expansive smooth muscle cell proliferation and 
migration into a growing neointima layer along with foam cell accumulation. Atheromas 
accumulate cholesterol crystals and begin to occlude the artery. Smooth muscle synthesis 
and secretion of extracellular matrix proteins like collagen can form a fibrous cap, leading 
to a biomechanical stabilization of the plaque. Complicated lesions can contain a necrotic 
lipid core, thinning of the fibrous cap, and clinical occlusion. Vascular calcification in the 
form of hydroxyapatite deposition is usually readily apparent in complicated lesions, but 
recent evidence suggests this calcification process occurs in much earlier stages of plaque 





Figure 1.5: Anatomy of the coronary circulation. LA = Left atrium; CFX = Circumflex 
artery; LAD = Left anterior descending artery; LV = Left ventricle; IVV = Interventricular 
vein; RV = Right ventricle; RCA = Right coronary artery; RA = Right atrium; PV = Posterior 










Figure 1.6: Calcium transporters in CSM. Ca2+ influx is accomplished with voltage-gated 
Ca2+ channels (VGCC) and transient receptor potential (TRP) channels. Intracellular Ca2+ 
can be sequestered into the sarcoplasmic reticulum (SR) via the sarco-endoplasmic 
reticulum Ca2+ ATPases (SERCA). Ca2+ release from the SR is accomplished through 
ryanodine receptors (RyR) and inositol 1,4,5-trisphosphate receptors (IP3R). Ca2+ efflux is 
achieved through plasma membrane Ca2+ ATPases (PMCA) and sodium-calcium 
exchangers (NCX). Sustained [Ca2+]i elevation can change gene expression through 
excitation-transcription coupling. For example, elevated [Ca2+]i leads to increased 
Ca2+/calmodulin binding, which activates Ca2+/calmodulin-dependent protein kinase II 
(CaMK). CaMK phosphorylates the cAMP response element-binding protein (CREB), 
enabling its translocation to the nucleus where it serves as a transcription factor for genes 
involved in survival and proliferation. 
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Figure 1.7: Vascular calcification requires CSM phenotypic switching. Synthetic 
CSM (sCSM) is associated with a decrease in contractile markers such as smooth muscle 
myosin heavy chain (SM-MHC), an increase in SERCA activity and SR storage capacity 
[81], and increased vesicle transport. sCSM also synthesize and secrete extracellular 
matrix proteins such as collagen and elastin that form the nidus for calcification. 
Osteogenic CSM (oCSM) is associated with an increased expression of 
osteo/chondrogenic genes such as Runx2, decreased SERCA activity and SR storage 
capacity [81], and an increase in calcifying exosome secretion. These calcifying exosomes 
deposit their cargo, which includes hydroxyapatite crystals and pro-calcifying proteins, on 




Figure 1.8: Their “thrifty genotype” predisposes Ossabaw miniature swine to 
obesity. When given an atherogenic diet, Ossabaw swine reliably develop obesity and 
other risk factors for MetS, making these swine excellent models to study MetS-induced 


















Table 1.1: Comparison of MetS risk factors in Yucatan and Ossabaw swine† 
Characteristic Yucatan Ossabaw Reference 
Obesity No Oss>Yuc 
[74, 80, 103, 104, 107, 108, 
110, 115-148] 
Insulin resistance No Yes 
[80, 103, 107, 110, 112, 116, 
123-127, 130, 132, 133, 135, 




[74, 76, 80, 103, 104, 107, 110, 
112, 116, 117, 120, 121, 123-
125, 127, 130, 132, 133, 135, 




[74, 76, 80, 103, 107, 112, 115, 
116, 118, 121, 122, 124, 125, 
132, 134-137, 145, 146, 148, 




[77, 103, 107, 110, 112, 115, 
116, 121-125, 130, 132, 135, 
138, 146-148, 152, 153, 155, 
157, 159, 161] 
Hypertension No Yes 
[74, 103, 104, 107, 115, 118, 
121, 123-125, 127, 132, 135, 
138, 146, 148, 151] 











CHAPTER 2: ALLOXAN-INDUCED DIABETES EXACERBATES CORONARY 
ATHEROSCLEROSIS AND CALCIFICATION IN OSSABAW MINIATURE SWINE WITH 
METABOLIC SYNDROME 
Background 
 Metabolic syndrome (MetS) affects more than one-third of all adults in the United 
States and is defined by the American Heart Association as the presence of three or more 
of the following conditions: central obesity, impaired glucose tolerance, hyperinsulinemia, 
dyslipidemia in the form of either elevated triglycerides or decreased HDL cholesterol, and 
hypertension [162]. MetS has been shown to be associated with increased risk of 
developing type 2 diabetes, which is rapidly increasing in incidence in the United States. 
Both type 2 diabetes and MetS are independently associated with increased risk of 
developing coronary heart disease, which continues to be the leading cause of death in 
the United States [162, 163].  
Although studies on human subjects have consistently shown that diabetes 
exacerbates MetS-induced coronary artery disease (CAD) [14, 23, 25, 26, 164], studies in 
swine models have failed to reach a consensus regarding the effects of concurrent 
diabetes and MetS on CAD severity [157, 158, 165-168].  
  In this study, I further investigated the effects of diabetes in augmenting CAD in 
the Ossabaw miniature swine. The Ossabaw swine has been characterized as a clinically 
relevant animal model with the natural propensity to develop MetS, contributing to CAD 
without genetic manipulation due to their “thrifty genotype” that allows for excess fat 
storage [81, 102, 106-108, 114, 124, 169]. As these swine with diet-induced MetS develop 
diffuse, human-like plaques [80], I tested the hypothesis that CAD will be more severe in 
pigs with the comorbidity of diabetes as opposed to MetS alone. I also determined whether 
the pattern of impaired [Ca2+]i handling in mild through advanced CAD/CAC is noted in 
MetS swine with diabetes. This will further strengthen the role of Ossabaw swine as a 
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clinically relevant animal model for investigating human CAD and studying the complex 
interplay between MetS and diabetes.  
Methods 
Animals and Induction of Diabetes 
All experimental procedures involving animals were approved by the Institutional 
Animal Care and Use Committee at Indiana University School of Medicine with the 
recommendations outlined by the National Research Council and the American Veterinary 
Medical Association Panel on Euthanasia [170, 171]. Alloxan, a pancreatic beta cell toxin, 
was administered intravenously to Ossabaw miniature swine of mixed gender aged 4-7 
months to induce diabetes. Briefly, alloxan (100-175 mg/kg; Sigma Chemical Co., St. 
Louis, MO) was dissolved in 14 mL of 1M NaOH and 20 mL of 0.9% NaCl, for a final 
volume of 34 mL and a pH of 7.4. The alloxan solution was delivered through a 0.20-μm 
sterile filter into the jugular vein via a central venous line. To protect against possible renal 
toxicity, animals were given 250 mL of 0.9% NaCl through intravenous drip prior to and 
after alloxan delivery (for full protocol, see Appendix A). The pigs were fed ad libitum and 
received 24 hours of critical care following induction of diabetes to monitor for 
hypoglycemic shock. Ossabaw swine responded heterogeneously to alloxan; therefore, 
pigs that did not incur sufficient beta cell damage with the first alloxan dose, as indicated 
by normoglycemia (fasting bG < 100 mg/dL), were administered a repeat dose (75-150 
mg/kg) 48 hours after the initial dose. Swine were placed into two groups: non-responders 
that were normoglycemic (Metabolic Syndrome-Alloxan; MetS-A) and responders that 
were hyperglycemic, with a fasting blood glucose greater than 100 mg/dL (Metabolic 
Syndrome/Diabetic-Alloxan; MetS/D-A). All swine (n = 8 in each group) were fed a 
hypercaloric atherogenic diet for 6 months (1000-1350 g/day) consisting of 43% of total 
caloric intake from fat, 16% from protein, and 41% from carbohydrates. Swine in the 
MetS/D-A group received insulin glargine according to an algorithm previously published 
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in my lab [120] to maintain glycemic control below 300 mg/dL, a clinically relevant 
hyperglycemic level [172]. Full insulin therapy is outlined in Table 2.1. Food adjustment 
was included to prevent wasting syndrome, a common condition seen in diabetic animals 
[120, 173]. For healthy control, an additional subset of Ossabaw swine (Lean; n = 9) were 
fed a standard chow diet (1000 g/day) yielding 11% of the total caloric intake from fat, 18% 
from protein, and 71% from carbohydrates (5L80; Purina Test Diet, Richmond, IN). A 
fourth group of Ossabaw swine with diet-induced MetS, without alloxan exposure, was 
included for metabolic comparisons (MetS; n = 10). Body weight in all groups was 
monitored weekly. 
Metabolic Phenotyping 
Blood was collected pre-alloxan, post-alloxan, 3 months post-diet induction, and 
at time of sacrifice (6 months post-diet induction) for analysis (ANTECH Diagnostics, 
Fishers, IN). 
Intravenous Glucose Tolerance Test 
To assess pancreatic beta cell response to glucose, a 50% glucose solution (0.5 
g/kg) was injected intravenously via the central venous line. To obtain fasting glucose 
concentration, blood samples (3 mL) were taken at –10, –5, and 0 min before glucose 
injection, then at 5, 10, 20, 30, 40, 50, and 60 min after glucose injection. Blood glucose 
values were monitored by use of an Accu-Chek Advantage glucose meter, and plasma 
insulin values were obtained by insulin assays done at the Indiana University School of 
Medicine Diabetes Research Core. A tail cuff was used to measure peripheral blood 
pressure throughout the procedure. MetS/D-A swine did not receive their daily insulin 
glargine injection on the day of testing.  
Meal Tolerance Test 
Pigs were given a standard meal (1000-1350 g chow) and allowed 45 minutes to 
eat the entire meal. Blood (3 mL) was sampled before administration of the meal (fasting) 
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and again at 1, 2, 5, 7, and 24 hours post-feeding. Blood glucose values were monitored 
by use of an Accu-Chek Advantage glucose meter. Eight lean swine and three swine in 
each the MetS, MetS-A, and MetS/D-A groups were used as a sampling group of the 
overall postprandial glucose clearance trend. MetS/D-A swine did not receive their daily 
insulin glargine injection on the day of testing.  
Intravascular Ultrasound 
After an overnight fast, swine were anesthetized via intramuscular injection of 2.2 
mg/kg xylazine and 5.5 mg/kg Telazol (Fort Dodge Animal Health, Fort Dodge, IA). Swine 
were intubated and anesthesia was maintained with 2-4% isoflurane in 100% O2. The 
isoflurane level was adjusted to maintain anesthesia with stable hemodynamics. Heart 
rate, aortic blood pressure, respiratory rate, and electrocardiographic data were 
continuously monitored throughout the procedure. Following a right femoral artery cut-
down, a 7 F introducer sheath was inserted for access and heparin was administered (200 
U/kg). Next, a 7 F guiding catheter (Amplatz L, Cordis, Bridgewater, NJ) was advanced to 
the left main coronary ostium. A 3.2 F, 45 MHz intravascular ultrasound (IVUS) catheter 
(Revolution, Volcano, Corp., Rancho Cordova, CA) was advanced over a percutaneous 
transluminal coronary angioplasty guide wire and positioned in the left anterior descending 
(LAD) artery. Automated IVUS pullback was performed and recorded at 0.5 mm/sec and 
30 frames/second. Pigs were euthanized after the IVUS procedure via cardiectomy and 
coronary arteries were removed for further analysis. Still frame IVUS pullback images 
were obtained and analyzed offline at 1 mm intervals. Percent plaque burden and calcium 
index measures were obtained using ImageJ software (1.48v, National Institutes of Health, 
USA). 
Immunohistochemistry 
Sections from the tail of the pancreas were placed in 10% phosphate-buffered 
formalin for 24-48 hours then embedded in paraffin. Tissue sections were stained with 
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guinea pig anti-insulin ready-to-use polyclonal antibody (Agilent, Santa Clara, CA) as a 
marker for beta cells by the Department of Pathology at Indiana University School of 
Medicine (Indianapolis, IN). Images were captured using a Leica DM 3000 
photomicroscope and analyzed with ImageJ software. Relative beta-cell mass was 
quantified by calculating the percentage of 3, 3' diaminobenzidine (DAB)-stained nuclear 
area to the total nuclear area using the ImmunoRatio ImageJ plugin. 
Histology 
Coronary artery segments from the proximal LAD (2-4 mm in length) were placed 
in 10% phosphate-buffered formalin for 24-48 hours, then transferred to 70% ethanol. 
Histology was performed in the Department of Anatomy and Cell Biology at Indiana 
University School of Medicine (Indianapolis, IN). All images were captured with a Leica 
DM3000 microscope connected to Leica Application Suites V4.1 software (Leica 
Microsystems GmbH, Wetzlar, Germany) and analyzed using (Adobe Photoshop® CS6) 
(for full protocols, see Appendices B, C, and D).  
Intracellular Free Calcium Imaging 
Whole-cell intracellular free Ca2+ levels were measured at room temperature (22 
to 25 °C) by using the fluorescent Ca2+ indicator fura-2 AM (InCa++ Ca2+ Imaging System, 
Intracellular Imaging, Cincinnati, OH) as previously described [76, 80, 125, 174]. Briefly, 
freshly dispersed smooth muscle cells from the LAD were incubated with 3.0 μM fura-2 
AM (Molecular Probes, Eugene, OR) in a shaking water bath at 37 °C for 45 min before 
being washed in a solution containing low Ca2+ concentration (for full protocol, see 
Appendix E). An aliquot of cells loaded with fura-2 AM was placed on a coverslip contained 
within a constant-flow superfusion chamber that was mounted on an inverted 
epifluorescent microscope (model TMS-F, Nikon, Melville, NY). Cells were superfused 
with various solutions at a constant rate of 1-2 mL/min, including solutions that contain 80 
mM K+ to induce Ca2+ influx, 5 mM caffeine to induce sarcoplasmic reticulum store release, 
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and 2 mM barium to measure voltage-gated calcium channel activity (for solution recipes, 
see Appendix F). Fura-2 was excited by light from a 300 W xenon arc lamp that was 
passed through a computer-controlled filter changer containing 340 nm and 380 nm 
bandpass filters. The fluorescence emission at 510 nm was collected by using a 
monochrome charge-coupled device camera (COHU, San Diego, CA). Whole-cell fura-2 
fluorescence was expressed as the 340 nm/380 nm ratio of fura-2 emission. 
IVUS Analysis 
The proximal 45 mm of the LAD was used for all IVUS analysis. All analysis was 
conducted by two blinded operators. To analyze for wall coverage, the circumference of 
the vessel cross-section was divided into 16 equal segments. Percent wall coverage was 
then calculated as: (total # of segments containing a thickened intimal layer ÷ 16) X 100. 
Wall coverage was quantified for the proximal 45 mm of the artery, in 1 mm intervals. To 
analyze for plaque burden, the external elastic lamina (EEL) area and lumen area were 
measured using ImageJ. Percent plaque burden was then calculated as: (EEL area - 
lumen area)/EEL area X 100. Plaque burden was quantified for the proximal 45 mm of the 
artery, in 1 mm intervals. To analyze for calcification, the entire IVUS pullback for the 
proximal 45 mm was viewed a minimum of two times. Calcification was defined as any 
strongly echogenic signal with acoustic shadowing. When identified, the frame numbers 
in which the deposit appeared and disappeared were noted to calculate the length. A 
representative frame of each deposit was used to calculate the arc angle using ImageJ, 
with each ray following the acoustic shadowing and the vertex at the center of the vessel 
lumen. If multiple deposits were identified per cross-section, the angles were added 
together. Calcium index for each artery was calculated as: (total length of calcification/ 45 





Statistical analysis was performed using GraphPad Prism 5.0 (San Diego, CA). 
Student’s t-test, one-way analysis of variance (ANOVA) with Newman-Keuls post-hoc 
analysis, or two-way ANOVA with Bonferroni post-hoc analysis was performed. Data are 
represented as mean ± SEM. p < 0.05 was considered statistically significant. 
Results 
Ossabaw swine cardiometabolic characteristics 
The swine in the MetS, MetS-A, and MetS/D-A groups were obese and had higher 
levels of total cholesterol compared to swine in the lean group (Table 2.2). The MetS/D-A 
group had greater total cholesterol and serum triglycerides than all other groups. The 
AST/ALT ratio was also increased in the MetS/D-A group as compared to the lean control, 
indicating possible liver dysfunction. However, there was no significant difference in 
creatinine and blood urea nitrogen (BUN) levels between the MetS/D-A and the lean 
groups, indicating normal kidney function (Table 2.2). Taken together, these metabolic 
data show that the MetS/D-A swine had more severe MetS than the other groups, despite 
being fed identical atherogenic diets.  
Assessment of glucose clearance from a meal tolerance test 
Blood glucose was monitored 7 hours after administration of a meal and revealed 
that blood glucose measurements were significantly higher in the MetS-A and MetS/D-A 
swine when compared to lean swine (Fig. 2.1A). This is further supported by area under 
the curve analysis, which shows that MetS-A swine exhibit postprandial hyperglycemia as 
compared to the MetS and lean group, and this hyperglycemia is exacerbated in the 
MetS/D-A swine (Fig. 2.1B).  
Assessment of glucose clearance from an intravenous glucose tolerance test 
Blood glucose was monitored 60 minutes after intravenous administration of a 
bolus of glucose and revealed that blood glucose measurements were significantly higher 
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in the MetS, MetS-A, and MetS/D-A groups when compared to the lean group (Fig. 2.2A). 
However, while area under the curve analysis revealed that the MetS, MetS-A, and 
MetS/D-A groups had impaired glucose clearance when compared to the lean control 
group (Fig. 2.2B), only the MetS/D-A swine exhibited a higher fasting blood glucose over 
lean (Fig. 2.2C).  
Assessment of serum insulin levels during the intravenous glucose tolerance test  
Serum levels of insulin were measured during IVGTT (Fig. 2.3A). All swine groups 
except MetS/D-A showed a robust insulin peak at 20 minutes after the glucose bolus (Fig. 
2.3A). Area under the curve analysis revealed that MetS/D-A swine exhibit 
hypoinsulinemia compared to the lean, MetS, and MetS-A groups (Fig. 2.3B).   
Assessment of pancreatic beta cell mass 
Although the MetS-A swine did not exhibit postprandial or fasting hyperglycemia 
(Figs. 2.1B and 2.2C) or significant hypoinsulinemia (Fig. 2.3B), they show a decrease in 
pancreatic beta cell area compared to lean, non-alloxanized swine (Fig. 2.4). MetS/D-A 
swine show an even greater decrease in beta cell mass (Fig. 2.4), which is reflected in 
their postprandial and fasting hyperglycemia and their hypoinsulinemia (Figs. 2.1B, 2.2B-
C, and 2.3B).  
IVUS assessment of coronary artery disease severity 
After angiography was employed to locate the LAD and circumflex (CFX) coronary 
arteries for catheter placement (Fig. 2.5A), cross-sectional images of the arteries were 
collected by automated IVUS pullback (representative IVUS still frames in Fig. 2.5B-C). 
MetS-A swine exhibited greater percent wall coverage compared to lean swine, while 
MetS/D-A swine exhibited greater percent wall coverage compared to both lean and MetS-
A swine (Fig. 2.5D). Additionally, MetS/D-A swine exhibited greater percent plaque burden 
compared to lean and MetS-A swine (Fig. 2.5E). These data suggest that MetS/D-A swine 
have greater CAD severity than the lean and MetS-A groups. 
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IVUS assessment of coronary artery calcification (CAC) 
CAC was measured both by calculating the calcium index from IVUS images (Fig. 
2.6A) and from Von Kossa histological staining (Fig. 2.6B). Most calcified lesions were 
determined to be spotty calcification. MetS/D-A swine had a significantly greater IVUS-
derived calcium index than lean and MetS-A swine (Fig. 2.6C). The IVUS-derived 
measures show strong positive correlation to the percent calcification values calculated 
from histological analysis (Fig. 2.6D). These data are strong evidence that MetS/D-A 
swine have more severe CAC compared to the lean and MetS-A groups. 
Assessment of effects of diabetes on CSM [Ca2+]i regulation  
Figure 2.7A-B shows representative [Ca2+]i responses from a CSM cell isolated 
from a lean swine. I assessed the caffeine-sensitive SR store release in the absence of 
extracellular Ca2+ to measure the sarcoplasmic reticulum (SR) storage capacity. The 
MetS-A swine had an elevated SR store that was diminished to control levels in the 
MetS/D-A swine (Fig. 2.7C). The time to half recovery to baseline was higher in the 
MetS/D-A swine, indicating impaired plasmalemmal [Ca2+]i extrusion mechanisms (Fig. 
2.7D). When voltage-gated calcium channel (VGCC) activity was assessed using a Ba2+ 
challenge, CSM cells from MetS-A swine exhibited an increased Ba2+ influx rate and net 
accumulation of Ba2+, but this decreased to lean control levels in the MetS/D-A swine (Fig. 
2.7E). These data suggest that CSM [Ca2+]i is different in animals with the comorbidities 
of  MetS and diabetes compared to animals with only MetS.   
Discussion 
There is a pressing need to establish an animal model for the common 
comorbidities of MetS and diabetes. This study shows for the first time that Ossabaw 
swine, which are a clinically relevant animal model already utilized for the study of MetS 
[103, 104], CAD [80, 81], CAC [106, 114], non-alcoholic steatohepatitis [107-109], and 
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other diseases [110, 112], can be used to study MetS/diabetes and the complications and 
mechanisms associated with those comorbidities.  
Using metabolic analyses such as IVGTTs, MTTs, and insulin assays, as well as 
immunohistochemistry to determine pancreatic beta cell damage, I show that alloxan 
treatment induced a diabetic state, as defined as fasting hyperglycemia and 
hypoinsulinemia. Furthermore, using in vivo intravascular ultrasound imaging I show that 
MetS swine with alloxan-induced diabetes had increased circumferential wall coverage, 
plaque burden, and calcium index compared to swine with MetS alone.  
While this study determined that diabetes exacerbates MetS-induced CAD in a 
clinically relevant porcine model, it does not delve into the mechanisms that drive this 
accelerated atherosclerosis. It has been reported that hyperglycemia can contribute to a 
dyslipidemic state by producing circulating advanced glycation end-products (AGEs) that 
bind lipoproteins and delay their clearance [177], generate intracellular ROS [178], and 
increase expression of adhesion molecules [178, 179]. Chronic high levels of glucose can 
also lead to mitochondrial dysfunction, resulting in increased superoxide production which, 
in turn, increases inflammation and ox-LDL levels [179, 180]. All these metabolic and 
transcriptional changes lead to the acceleration of the atherosclerotic process. Diabetes 
and dyslipidemia are often comorbidities due at least in part to this mechanism, and 
diabetic patients are at a much greater risk for developing cardiovascular diseases [179, 
181]. 
Recently, much attention has been given to the diseased vessel’s paracrine effects 
on surrounding tissues. For example, inflammation in the vasculature results in smaller, 
de-differentiated adipocytes around the plaque area [35]. In fact, the cross-talk between 
perivascular adipose tissue (PVAT) and the diseased vasculature is a growing field that 
has generated great interest [182]. My group has showed that PVAT potentiates leptin-
induced endothelial dysfunction and increases vasomotor tone in coronary arteries of 
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Ossabaw swine [136, 138]. Ossabaw swine can be used as a clinically relevant animal 
model for future studies delving into the mechanisms responsible for this bidirectional 
communication. 
While IVUS is a robust method for determining plaque morphology in vivo, it cannot 
determine plaque composition. Future studies should investigate whether plaque 
morphology changes in the presence of diabetes. This is of particular interest, as diabetes 
is associated with plaques that are more vulnerable to rupture [183]. Intravascular 
photoacoustic ultrasound includes morphological imaging and has chemical specificity to 
determine lipid content inside atherosclerotic plaque [70, 184-186]. This advancement will 
enable longitudinal characterization of plaque composition in vivo during progression of 
coronary atherosclerosis and calcification [70]. 
Ca2+ is an important second messenger that plays a vital role in contraction [68, 
187], proliferation [68, 70], migration [184, 185], and transcription [186, 188]. Recently, my 
lab has clarified that CSM [Ca2+]i handling dysfunction occurs in a biphasic manner during 
CAD progression, with SR Ca2+ store capacity and sarco-endoplasmic reticulum Ca2+ 
ATPase (SERCA) function being upregulated in early, mild CAD and downregulated in 
late, more severe CAD [81]. Additionally, it has previously been shown that plasmalemmal 
Ca2+ extrusion mechanism function, as measured by the time to half recovery, is 
decreased in advanced disease [76]. These Ca2+ handling alterations can be seen in CSM 
from MetS-A swine, which exhibited changes associated with mild CAD, and in CSM from 
MetS/D-A swine, which exhibited changes associated with more severe CAD.  
Increased VGCC and SERCA function are associated with greater CSM 
proliferation [81]. While the MetS-A swine had increased VGCC and SERCA function, they 
only exhibited greater percent wall coverage compared to lean swine. MetS/D-A swine 
exhibited both greater percent wall coverage and percent plaque burden, even though 
their VGCC and SERCA activity was comparable to lean swine. This could be due to the 
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severity of the metabolic conditions, which is proportional to the duration of MetS. The 
MetS/D-A swine could have exhibited a longer period of CSM proliferation before VGCC 
and SERCA activity decreased back down to baseline, while the MetS-A swine were still 
undergoing proliferation at the time of euthanasia. Future studies should investigate the 
effect of the diabetic state on CSM proliferation.  
High serum Ca2+ and phosphorous may contribute to the increased CAC seen in 
the MetS/D-A swine [101]. However, serum Ca2+ is not significantly elevated when 
compared to the lean swine and, while serum phosphorous is elevated in the MetS/D-A 
swine, it is still comparable to the MetS-A group. Therefore, the greater CAC seen in the 
MetS/D-A group cannot be contributed to the uremic milieu alone. It is hypothesized in 
several papers that impairments in [Ca2+]i buffering can lead to Ca2+ overload and 
subsequent vascular calcification [101, 189]. The changes in SERCA and VGCC function 
and the dysfunction seen in the calcium extrusion mechanisms, which include the sodium-
calcium exchanger and the plasma membrane calcium ATPase, could lead to the 
increased calcification seen in histology and IVUS analysis. However, even though 
MetS/D-A swine have impaired Ca2+ extrusion mechanisms, they only exhibit spotty 
calcification. Calcification is “spotty” if the arc of calcium is less than 90 degrees [176]. 
Spotty calcification has been reported to destabilize atherosclerotic plaques and increase 
the incidence of acute myocardial ischemia [190, 191]. Therefore, although spotty 
calcification is a precursor to macrocalcification, it has serious clinical implications [192]. 
Future studies should focus on [Ca2+]i dysregulation and vascular calcification in diabetic 
swine fed an atherogenic diet for a longer period of time.  
Overall, I found that MetS swine with alloxan-induced diabetes had greater CAD 
severity and calcium handling that was indicative of severe CAD while normoglycemic 
MetS swine showed less severe CAD and calcium handling that was indicative of mild 
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CAD. This mirrors the patterns seen in human studies [14, 23, 25, 26, 164] and establishes 
Ossabaw swine as a relevant animal model for MetS/diabetes.  
There is no shortage of literature investigating the role of diabetes in exacerbating 
CAD in the context of MetS in swine models. However, there have been conflicting results 
in these studies. Gerrity et al. showed that diabetic/hyperlipidemic Yorkshire pigs 
developed more stenotic and advanced atherosclerotic lesions, compared to the 
nondiabetic/hyperlipidemic control group [165]. Additionally, my group has shown that the 
induction of diabetes in Sinclair and Yucatan miniature pigs with hyperlipidemia leads to 
increased CAD development [167]. In contrast, a recent study by Al-Mashhadi et al. 
showed that Yucatan minipigs with a PCSK9 gain-of-function mutation developed severe 
hyperlipidemia, but no augmentation of CAD with the induction of diabetes by 
streptozotocin (STZ) [166]. However, because of the dramatic effect increase in LDL 
cholesterol levels and subsequent CAD development in this transgenic model, it is unclear 
if a contribution of hyperglycemia to atherogenesis was present, but masked by the 
severity of disease. Ludvigsen et al. showed that diet-induced atherosclerosis in Gottingen 
minipigs was not augmented by STZ-induced diabetes, but the sample size in this study 
(n = 6) was not large enough to be conclusive [168]. Interestingly, another study from my 
group found that in Yucatan swine diabetes without dyslipidemia was not enough to 
increase early atheroma [157]. This study also showed that hyperlipidemic diabetic swine 
did not exhibit greater CAD severity than swine with hyperlipidemia alone [157]. This may 
have been because of the large effect of plasma lipids that nullified the synergistic effects 
of diabetes. 
None of the previously mentioned studies used Ossabaw miniature swine, for 
which there is remarkably similarity to human MetS and CAD [80]. Ossabaw swine 
develop more severe CAD with diabetes on a MetS background, which is similar to results 
seen in human patients. Thus, this study provides support for Ossabaw swine as an 
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excellent model for translation to human clinical medicine. Taken together, the data in this 
study provide evidence supporting the use of Ossabaw swine in future studies that 
investigate mechanisms or outcomes of diabetes superimposed on a MetS background. 
By having a reliable, clinically relevant animal model that recapitulates human disease 
researchers can be far more certain of the translatability of their research.  
Conclusion 
In conclusion, swine exhibiting both MetS and alloxan-induced diabetes have more 
severe CAD and coronary artery calcification when compared to swine with only MetS as 
measured by IVUS. Additionally, coronary smooth muscle from swine with MetS alone 
show similar calcium handling alterations as mild CAD, and swine with both MetS and 
diabetes show similar calcium handling alterations as more severe CAD. Ossabaw swine, 
similar to humans, reliably develop more severe CAD with the comorbidities of diabetes 
and MetS, which supports their use as a clinically relevant animal model for future studies 





Figure 2.1: Impaired glucose clearance after a meal tolerance test in MetS/D-A 
swine. (A) Plasma glucose was monitored for 7 h after a meal, which revealed the lean 
and MetS group had comparable glucose clearance and the MetS/D-A group had impaired 
glucose clearance. p values are compared to lean group. (B) Area under the curve 
analysis shows postprandial hyperglycemia in the MetS/D-A swine as compared to all 
other groups. *p < 0.05 compared with lean swine; †p < 0.05 compared with MetS swine; 










Figure 2.2: IVGTT supports the conclusion that MetS/D-A swine exhibit impaired 
glucose clearance. (A) Blood glucose levels were tested for 60 min after a bolus of 
glucose (0.5 mg/kg body weight). p values are compared to lean group. (B) Area under 
the curve analysis shows impaired glucose clearance in the MetS-A and MetS/D-A groups. 
(C) MetS/D-A swine exhibited a fourfold higher fasting blood glucose before the bolus of 
glucose was administered. *p < 0.05 compared with lean swine; †p < 0.05 compared with 
MetS swine; ‡p < 0.05 compared with MetS-A swine. (Lean = 10; MetS = 5; MetS-A = 8; 








Figure 2.3: Serum insulin levels were lower in the MetS/D-A group than in the MetS-
A group. (A) Insulin levels were measured at minutes 0, 10, 20, 40, and 60 during the 
IVGTT protocol. (B) Area under the curve analysis revealed that MetS/D-A swine exhibited 
hypoinsulinemia as compared to the swine in the lean and MetS groups. *p < 0.05 
compared with lean swine; †p < 0.05 compared with MetS swine. (Lean = 10; MetS = 5; 




Figure 2.4: IHC shows diminished pancreatic beta cell mass in MetS-A and MetS/D-
A swine. Immunohistochemical analysis using antibodies against insulin revealed that 
beta cell mass was decreased in MetS-A swine as compared to lean swine, and even less 
in MetS/D-A swine. Taken together, these data show that swine in the MetS/D-A group 
were indeed diabetic, due to alloxan-induced beta-cell damage. *p < 0.05 compared with 





Figure 2.5: MetS/D-A swine had more advanced disease than lean and MetS-A 
swine. (A) Angiogram showing the LAD and CFX coronary arteries. All IVUS still frames 
collected for analysis were from the proximal 45 mm of the LAD. (B) Representative IVUS 
image of the LAD of a MetS/D-A swine showing 100% wall coverage, the percent of the 
circumference of the arterial wall covered by intimal thickening (original lumen highlighted 
in red, intimal thickening highlighted in yellow). (C) Representative IVUS image of the LAD 
of a MetS/D-A swine illustrating plaque burden, the percent of original lumen that is now 
occupied by a lesion (original lumen highlighted in red, new lumen with lesion highlighted 
in yellow). (D) The MetS/D-A swine had significantly greater wall coverage compared to 
MetS-A and lean swine. (E) The MetS/D-A swine had significantly greater plaque burden, 
compared to MetS-A and lean swine. *p < 0.05 compared with lean swine; ‡p < 0.05 
compared with MetS-A swine. (Lean = 6; MetS-A = 7; MetS/D-A = 7.) 
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Figure 2.6: MetS/D-A swine showed greater spotty calcification compared to lean 
swine and MetS-A swine. (A) Representative IVUS image from the proximal LAD of a 
MetS/D-A swine. IVUS images were analyzed for calcification severity by using the 
calcium index measurement. The lumen is outlined in red, with the arc of spotty 
calcification and acoustic shadowing outlined in yellow. (B) Representative Von Kossa-
stained histological section from the proximal LAD of a MetS/D-A swine, with noticeable 
spotty calcification in the neointimal layer (blue arrows). (C) Calcium index is higher in 
MetS/D-A swine as compared to lean and MetS-A swine. (D) Findings from analysis of 
IVUS data correlate to the Von Kossa histological staining analysis. *p < 0.05 compared 
with lean swine; ‡p < 0.05 compared with MetS-A swine. (Lean = 6; MetS-A = 7; MetS/D-
A = 7.) 
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Figure 2.7: MetS-A swine showed greater SR store and VGCC function compared to 
lean and MetS/D-A swine. (A) After depolarization with 80 mM K+ to induce calcium influx 
and maximal SR Ca2+ loading, the SR store was released by activating RyR with 5 mM 
caffeine. The time to half signal recovery was measured during caffeine wash-out and 
corresponds to the activity of calcium extrusion mechanisms. (B) A similar protocol was 
used with an additional exposure to a 2 mM barium solution, which enters the cell via 
VGCC and binds to fura-2 but is not transported by Ca2+ ATPases, providing a more 
selective measure of Ca entry. (C) The measured SR store release from CSM in MetS-A 
swine is greater than that seen in MetS/D-A and lean swine. This is consistent with 
previous findings which show biphasic calcium handling alterations in CSM as CAD 
progresses in severity. (D) Extrusion mechanism activity as measured by time to half 
recovery is impaired in MetS/D-A swine. (E) The activity of voltage-gated calcium channels 
as measured by barium influx is increased in CSM from MetS-A swine and decreases 
back to baseline in CSM from MetS/D-A swine. *p < 0.05 compared with lean swine; ‡p < 
0.05 compared with MetS-A swine. (Lean = 6; MetS-A = 8; MetS/D-A = 8.) 






Table 2.1: Insulin therapy and feed algorithms for the maintenance of blood glucose and weight gain 
Measurements Adjustments 
Blood glucose (mg/dL) Behavior Body weight (kg) Insulin glargine (U) Food (by weight) 
> Diabetic target range of 120–200 Normal  Base + 0.1 U/kg No change 
> Diabetic target range of 120–200 Lethargic  Base + 0.2 U/kg No change 
120–200  Normal  Base (0.1–0.3 U/kg) No change 
< Diabetic target range of 120–200 Normal  Base (0.1–0.3 U/kg) Increase 15% 
< Diabetic target range of 120–200 Lethargic  Base (0.1–0.3 U/kg) Increase 15% 
  Decrease >5% in one week Base + 1 U/kg Increase 30% 
  
Less than target weight gain 
at weeks 4, 8, 12, 16, 20 
No change Increase 15% 
  Increase >10% in 1 week No change Decrease 15% 
  
>10% over target weight gain 
at weeks 4, 8, 12, 16, 20 











Table 2.2: Metabolic characteristics of swine show hyperlipidemia and hyperglycemia in the MetS/D-A group 
 Lean MetS MetS-A MetS/D-A 
Body weight at sacrifice (kg) 48 ± 2 87 ± 5* 73 ± 1*,† 70 ± 4*,† 
Age at sacrifice (mo) 17 ± 1.4 15 ± 0.7 11 ± 0.2 14 ± 0.1 
% Male 37.5 50 50 50 
Creatinine (mg/dL) 0.96 ± 0.05 1.26 ± 0.13* 1.14 ± 0.07 1.06 ± 0.10 
BUN (mg/dL) 14.33 ± 1.44 12.11 ± 1.65 15.00 ± 0.98 16.75 ± 0.96 
AST/ALT ratio 0.95 ± 0.08 1.43 ± 0.30 1.29 ± 0.14 2.12 ± 0.49* 
Serum calcium (mg/dL) 10.4 ± 0.1 10.6 ± 0.1 10.1 ± 0.1 10.3 ± 0.2 
Serum phosphorous (mg/dL) 8.1 ± 0.6 7.0 ± 0.3 12.9 ± 0.7*,† 11.6 ± 0.7*,† 
Total chol (mg/dL) 87 ± 3 398 ± 1* 547 ± 109*,† 1005 ± 158*,†,‡ 
Serum TG (mg/dL) 29 ± 3 42 ± 4 40 ± 6 236 ± 96*,†,‡ 
All measurements were taken 6 months after atherogenic diet (except lean swine) and 1 week before euthanasia. Data are mean ± 
SEM. MetS metabolic syndrome, MetS-A metabolic syndrome-alloxan, MetS/D-A metabolic syndrome with diabetes-alloxan, BUN, 
blood urea nitrogen, AST aspartate transaminase, ALT alanine transaminase, bG blood glucose, Chol cholesterol, TG triglycerides. *, 
p < 0.05 compared with lean swine; †, p < 0.05 compared with MetS swine; ‡, p < 0.05 compared with MetS-A swine. (Lean = 9; MetS 




CHAPTER 3: DIABETOGENIC ACTIONS OF ALLOXAN ARE DEPENDENT ON AGE IN 
OSSABAW MINIATURE SWINE 
Background 
 The diabetic effect of alloxan was discovered in 1943, and since then it has been 
used in biomedical research to recapitulate the physiology of diabetes in various animal 
models [193]. Alloxan is a glucose analogue specific to glucose transporter 2 (GLUT2), 
which is expressed almost exclusively by hepatocytes and pancreatic beta cells [193, 
194]. When GLUT2 transports alloxan into the cytosol of pancreatic beta cells it reacts 
with intracellular glutathione in a redox reaction, resulting in the formation of reactive 
oxygen species that cause beta cell death [194-196]. After administration of alloxan 
extensive beta cell necrosis is often observed [193]. Some studies show a long-term 
recovery from alloxan-induced diabetes, which is suspected to be due to either 
multiplication of surviving beta cells or the formation of new beta cells from the duct 
epithelium or the exocrine portion of the pancreas [193, 197-199]. 
 The efficacy of alloxan can be unpredictable and is dependent on several factors, 
including species [196], route of administration [195, 198], speed of administration [198], 
and diet [193]. Although it is widely accepted that alloxan and streptozotocin, another 
diabetogenic agent, affect younger animals to a lesser extent compared to older animals, 
this is only based on a small number of studies in mice [200, 201]. The only study to cite 
the age-dependence of alloxan in a large animal model was published almost 70 years 
ago in dogs [193, 195, 198, 202]. With the variation between species and even between 
individuals in the same species, the possible age-dependent effects of alloxan in large 
animal models need to be re-examined.  
In this study, I used the clinically relevant Ossabaw miniature swine (Sus scrofa 
domestica) model of metabolic syndrome (MetS), which is the clustering of risk factors 
that include obesity, dyslipidemia, glucose intolerance, insulin resistance, and 
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hypertension, to determine whether there is age-conferred protection against the diabetic 
effects of alloxan in swine. This will either contradict the alloxan/age dogma or serve as 
more evidence of the age-dependent effects of alloxan in large animal models.  
Methods 
Animals, Housing, and Diet 
All experimental procedures involving animals were approved by the Institutional 
Animal Care and Use Committee at Indiana University School of Medicine with the 
recommendations outlined by the National Research Council and the American Veterinary 
Medical Association Panel on Euthanasia [170, 171]. Swine were obtained from a closed, 
SPF breeding colony at Purdue University. The swine herd has historically tested negative 
for Brucella spp, pseudorabies, vesicular stomatitis virus serovars Indiana and New 
Jersey, Mycoplasma hyopneumoniae, porcine reproductive and respiratory syndrome 
virus, porcine parvovirus, swine influenza virus serotypes H1N1 and H3N2, antibody levels 
to transmissible gastroenteritis virus, and Leptospira interrogans serovars (canicola, 
grippotyphosa, hardjo, icterohaemorrhagiae, pomona, and bratislava). All animals were 
housed in pairs in 24 ft2 pens and provided a 12:12-h light:dark cycle. Temperature was 
maintained at 20-22°C throughout the study, and humidity was not controlled. After 
induction of diabetes (see below), all swine were immediately placed on a hypercaloric 
atherogenic diet for 6 months (1000-1350 g/day for both groups) consisting of 43% of total 
caloric intake from fat, 16% from protein, and 41% from carbohydrates (KT324, Purina 
Test Diet, Richmond, IN), similar to previous studies [203]. Swine were fed once a day in 
order to promote gorging behavior to ensure the daily allotment of food was completely 
consumed. Feed intake and blood glucose were measured daily, and body weight was 




Central Venous Line Placement 
Swine were restrained in a sling and anesthetized with 5% isoflurane in 100% O2 
administered by mask. The unconscious pig was placed in the supine position and a 
percutaneous needle with a syringe attached was inserted into the angle formed by the 
sternum and clavicle. Negative pressure was maintained in the syringe, and when it began 
to fill with dark red venous blood the needle was held in place and the syringe was 
removed. A guidewire was fed through the percutaneous needle, at which point the needle 
was removed. A central venous catheter was fed over the guidewire, which was then 
removed. The catheter was capped and secured to the animal using a non-absorbable 
suture. The pig was moved back to the sternal position and isoflurane was discontinued, 
allowing the swine to regain consciousness under observation. The central line catheter 
was flushed twice a week to ensure its patency. 
Induction of Diabetes 
Alloxan, a pancreatic beta cell toxin, was rapidly administered intravenously to 
Ossabaw miniature swine of mixed gender aged 4-8 months to induce diabetes. Swine 
were placed into two age groups at time of alloxan administration: “juvenile” (age < 6 
months; n = 8) and sexually mature “adult” (age > or equal to 6 months; n = 8) [102]. 
Briefly, alloxan (Sigma Chemical Co., St. Louis, MO) was dissolved in 14 mL of 1M NaOH 
and 20 mL of 0.9% NaCl, for a final volume of 34 ml and a pH of 7.4. The alloxan solution 
was delivered through a 0.20-μm sterile filter into the jugular vein via a central venous line 
at an average dose of 140 mg/kg (range: 125-175 mg/kg). Two juvenile swine only had 
one dose while six juvenile swine were given two doses over the course of one week due 
to lack of hyperglycemic response from the first dose.  The average first dose was 140 
mg/kg (range: 75-175), and the average second dose was 120 mg/kg (range: 125-150 
mg/kg). To protect against possible renal toxicity, pigs were given 250 mL of 0.9% NaCl 
through intravenous drip prior to and after alloxan dosing (for full protocol, see Appendix 
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A). The pigs were fed ad libitum and received 24 hours of critical care following induction 
of diabetes to monitor for hypoglycemic shock. Swine received daily insulin glargine (Eli 
Lilly and Company, Indianapolis, IN) via subcutaneous injection to the flank according to 
an algorithm previously published in my lab [120, 204] to maintain glycemic control below 
300 mg/dL, a clinically relevant hyperglycemic level[172]. The insulin dose for all pigs was 
between 0.1-0.6 U/kg and was individually adjusted based on daily blood glucose 
measurements, weight measurements obtained weekly, and the presence or absence of 
lethargic behavior [204]. The diabetic disease state was allowed to stabilize for one week 
after alloxan administration, at which point all swine were immediately placed on a 
hypercaloric atherogenic diet for 6 months (see above). Non-alloxanized age-matched 
controls on the same hypercaloric atherogenic diet were utilized in some analyses. 
Metabolic Phenotyping 
Blood was collected one week pre-alloxan, one week post-alloxan, and 6 months 
post-alloxan for analysis (ANTECH Diagnostics, Fishers, IN). Homeostasis model 
assessment-insulin resistance (HOMA-IR) is a calculation that takes into account fasting 
glucose and insulin concentrations in order to assess insulin resistance [205]. A larger 
HOMA-IR value indicates greater insulin resistance [206]. HOMA-IR was calculated using 
the following equation: fasting insulin (µU/mL) x fasting glucose (mg/dL)/405. 
Blood Pressure Measurements 
From the beginning of the study, pigs were acclimated to a low-stress sling [151, 
207] for conducting intravenous glucose tolerance tests (see below) and blood pressure 
measurements. Blood pressures were measured by using a tail cuff sphygmomanometer 
[151]. 
Intravenous Glucose Tolerance Test 
Insulin treatments were suspended 2 days prior to testing to determine 
endogenous glucose regulation. To assess pancreatic beta cell response to glucose, 
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conscious swine that were fasted overnight were given a 50% glucose solution 
intravenously at 1 g glucose/kg body weight via the central venous line. To obtain fasting 
glucose concentration, pigs were placed in a low-stress restraint sling (see above) and 
blood samples (3 mL) were taken at –10, –5, and 0 min before glucose injection, then at 
5, 10, 20, 30, 40, 50, and 60 min after glucose injection. Blood glucose values were 
monitored by use of an Accu-Chek Advantage glucose meter, and plasma insulin values 
were obtained by insulin assays done at the Indiana University School of Medicine 
Diabetes Research Core.  
Euthanasia 
After an overnight fast, swine were anesthetized via intramuscular injection of 2.2 
mg/kg xylazine and 5.5 mg/kg Telazol (Fort Dodge Animal Health, Fort Dodge, IA). Swine 
were intubated and anesthesia was maintained with 2–4% isofurane in 100% O2. The 
isofurane level was adjusted to maintain anesthesia with stable hemodynamics. Pigs were 
euthanized via cardiectomy. 
Immunohistochemistry 
Sections from the tail of the pancreas were placed in 10% phosphate-buffered 
formalin for 24-48 hours then embedded in paraffin. Tissue sections were stained with 
guinea pig anti-insulin polyclonal antibody (Agilent, Santa Clara, CA) as a marker for beta 
cells by the Department of Pathology at Indiana University School of Medicine 
(Indianapolis, IN). Images were captured using a Leica DM 3000 photomicroscope and 
analyzed with ImageJ software. Relative beta-cell mass was quantified by calculating the 
percentage of 3,3′ diaminobenzidine (DAB)-stained nuclear area to the total nuclear area 
using the ImmunoRatio ImageJ plugin. 
Statistics 
Statistical analysis was performed using GraphPad Prism 5.0 (San Diego, CA). 
Student’s t-test, one-way analysis of variance (ANOVA) with Tukey post-hoc analysis, or 
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two-way analysis of variance (2-way ANOVA) with Bonferroni post-hoc analysis was 
performed. Data are represented as mean ± SEM. p < 0.05 was considered statistically 
significant. 
Results 
Adult swine have more severe metabolic syndrome and insulin resistance 
The juvenile and adult swine had comparable metabolic parameters before alloxan 
administration, so they were pooled into the “pre-alloxan” group. The juvenile swine were 
significantly younger than the adult swine, but both exhibited comparable weights and BMI 
measurements after 6 months on an atherogenic diet. Total cholesterol was elevated in 
juveniles 6 months post-alloxan compared to levels before alloxan administration and one 
week after. Total cholesterol and serum triglycerides were elevated in the adult swine 6 
months post-alloxan compared to levels before alloxan administration and juvenile swine 
6 months post-alloxan. HOMA-IR calculations show that adult swine 6 months post-
alloxan were more insulin resistant than swine before alloxan administration and juveniles 
6 months post-alloxan. To determine kidney function, creatinine and blood urea nitrogen 
(BUN) levels were measured. Creatinine levels were comparable between groups, with 
non-alloxanized controls exhibiting slightly elevated levels, while adult swine one-week 
post-alloxan exhibited elevated BUN levels that normalized by six months post-alloxan. 
To measure liver function, the aspartate aminotransferase (AST)/alanine 
aminotransferase (ALT) ratio was calculated. Both groups at six months post-alloxan had 
elevated AST/ALT, but this was equivalent to the non-alloxanized high-fat fed control 
swine. Blood pressure measurements were not statistically different between groups 




Glucose clearance is more severely impaired in adult versus juvenile swine treated with 
alloxan 
Blood glucose was monitored 60 minutes after intravenous administration of a 
bolus of glucose one week (Fig. 3.1A-C) and six months (Fig. 3.1D-F) after alloxan 
administration. One week post-alloxan, intravenous glucose tolerance test (IVGTT) 
analysis showed that adult swine had significantly higher blood glucose measurements at 
all time points when compared to both juvenile swine and all swine before alloxan 
administration (Fig. 3.1A).  This is reflected in a higher baseline fasting glucose (Fig. 3.1B) 
and a greater area under the glucose curve (Fig. 3.1C). This hyperglycemia persists six 
months after alloxan administration, with adult swine exhibiting significantly higher glucose 
at most time points during glucose challenge compared to juveniles and pre-alloxan swine 
(Fig. 3.1D), higher baseline fasting glucose (Fig. 3.1E), and a greater area under the 
glucose curve (Fig. 3.1F). Juvenile swine had significantly greater area under the glucose 
curve compared to non-alloxanized swine six months after alloxan administration (Fig. 
3.1F), demonstrating a progression of glucose intolerance in juvenile pigs.  
Age is correlated to fasting blood glucose in alloxanized swine 
Fasting blood glucose of swine one week after the final alloxan dose was plotted 
against age when each individual swine was alloxanized (Fig. 3.2). Analysis revealed that 
there is a strong positive correlation of blood glucose with age at the time of alloxan 
administration, even at comparable dosages of alloxan. 
Hypoinsulinemia persists in both juvenile and adult swine 
Serum insulin levels were measured during IVGTT assessments. One week after 
alloxan administration, both the juvenile and adult swine exhibited lower glucose levels 
compared to swine before alloxan administration at all time points except t=0 (Fig. 3.3A). 
This is reflected in the area under the insulin curve analysis (Fig. 3.3B). This 
hypoinsulinemia persists six months after alloxan administration, with juvenile and adult 
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swine exhibiting lower insulin levels at several time points when compared to non-
alloxanized, age-matched swine (Fig. 3.3C). Again, juvenile and adult alloxanized swine 
have a lower area under the insulin curve compared to non-alloxanized swine (Fig. 3.3D). 
An outlier in the juvenile group that was 5x greater than the standard deviation was 
removed from this analysis. 
Juvenile swine exhibited greater insulin response recovery 
The areas under the insulin curves (Figs. 3.3B and 3.3D) were used to determine 
potential recovery from alloxan. Juvenile swine exhibited a ~2.5 fold increase in peripheral 
insulin levels from one week to six months post-alloxan (Fig. 3.3E). The peripheral insulin 
levels in adult swine, however, remained constant six months after alloxan administration 
(Fig. 3.3E). 
Pancreatic beta cell area is decreased in juvenile and adult swine 
 Immunohistochemical analysis of sections of pancreas from juvenile (Fig. 3.4A), 
and adult (Fig. 3.4B) swine shows that both juvenile and adult alloxanized swine have 
comparable pancreatic beta cell area six months after alloxan administration (Fig. 3.4C). 
This is lower than non-alloxanized high-fat fed swine, whose pancreatic beta cell mass 
was calculated previously to be ~7.5% [204].   
Discussion 
 In this study I showed that juvenile swine administered alloxan had a blunted 
response to the drug and did not have the severe diabetic effects that developed in adult 
swine administered alloxan. Swine that received alloxan regardless of age exhibited 
decreased pancreatic beta cell mass (Fig. 3.4C) and reduced peripheral plasma insulin 
after a bolus of glucose (Fig. 3.3C-D). However, only the juvenile swine exhibited insulin 
response recovery, which I define as the recovery or partial recovery of peripheral insulin 
levels, six months post-alloxan (Fig. 3.3E). Adult alloxanized swine developed more 
severe MetS, as evidenced by their elevated HOMA-IR and increased levels of total 
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cholesterol and serum triglycerides (Table 3.1). These swine did not exhibit hepatoxicity 
or renal toxicity, as indicated by their BUN, creatinine, and AST/ALT levels (Table 3.1), 
similar to previous studies [151, 167]. Also, fasting blood glucose was higher and 
significantly correlated to age of swine one week after alloxanization even though the 
dosages of alloxan were comparable (Fig. 3.2). Glucose clearance was more impaired in 
the adult swine, as well (Fig. 3.1F). Taken together these results show that fasting glucose 
and glucose clearance is more impaired in Ossabaw miniature swine administered alloxan 
as adults compared to as juveniles and that juvenile swine can at least partially recover 
from the alloxan treatment. 
Pancreatic beta cell mass and peripheral plasma insulin were not statistically 
different between the juvenile and adult alloxanized swine, even though adult swine 
exhibited greater hyperglycemia, both fasting and after a glucose challenge, compared to 
juvenile swine. At its surface this seems like a paradox, but it can be explained partly by 
the increased peripheral resistance seen in the adult swine as calculated by the HOMA-
IR [208, 209]. Under normal physiological conditions, insulin resistance is counteracted by 
increased insulin secretion by beta cell compensation [210]. However, the decreased beta 
cell mass due to alloxan treatment of adult swine was accompanied by a decreased 
functional compensation to increasing insulin secretion. So, comparable levels of 
circulating insulin would have less of an impact on glucose clearance in the insulin-
resistant adult swine as compared to juvenile swine. 
 Hyperglycemia-induced secondary insulin resistance is a well-documented 
phenomenon in type 1 diabetic humans [211, 212] and in animal models, including swine 
[151, 213-218]. In a previous publication, my lab has determined that the drastic decrease 
in insulin sensitivity observed in alloxan-induced diabetic Yucatan swine is almost solely 
due to hyperglycemia [151]. This hyperglycemia-induced insulin resistance is at least 
partially due to the downregulation of glucose transfer type 4 in skeletal muscle by high 
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circulating glucose levels [215]. The initial hyperglycemic event after alloxan 
administration would cause the adult swine to become more insulin-resistant. This would 
also partially explain why the adult swine had glucose clearance that is more impaired 
than the juvenile swine six months after alloxan administration (Fig. 3.1D-F), even though 
peripheral insulin levels (Fig. 3.3C-D) and pancreatic beta cell mass (Fig. 3.4) were 
comparable between those two groups. The initial differential effects of alloxan in juvenile 
versus adult swine contribute to the greater hyperglycemia exhibited in adult swine. 
 The liver plays a vital role in glucose metabolism and may have a role in the 
differential effects seen in the alloxanized juvenile and adult swine. Insulin secreted from 
the pancreas travels via the portal vein to the liver where it binds 60% of the insulin [219]. 
The remaining insulin then goes into the peripheral circulation where it binds to insulin-
sensitive tissues such as skeletal muscle and adipose. However, it has been found that 
hepatic insulin binding doubles in streptozotocin-induced diabetes [220]. As there is an 
inverse relationship between circulating insulin levels and hepatic insulin binding [220], 
this may affect insulin circulation in the alloxanized animals. It is possible that more insulin 
was secreted in juvenile pigs, but much of the insulin was bound by the liver, thereby 
resulting in greater insulin-mediated glucose uptake by the liver and lower fasting glucose 
compared to these parameters in adult pigs. Portal vein insulin levels or c-peptide levels 
would be needed to provide direct evidence for this possibility.  
While juvenile swine six months post-alloxan exhibited elevated levels of total 
cholesterol and serum triglycerides that were on par with non-alloxanized pigs fed the 
same atherogenic diet, adult swine exhibited 5 times higher triglyceride levels and 2 times 
higher cholesterol levels compared with juvenile and non-alloxanized swine (Table 3.1). 
This may be attributed, at least in part, to the alloxan treatment itself. Alloxan causes 
chronic hyperglycemia due to ablation of pancreatic beta cells. Hyperglycemia is a main 
cause of insulin resistance [151], which has been shown to alter several components 
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involved in metabolic processes. For example, rabbits with alloxan-induced diabetes had 
increased intestinal HMG-CoA reductase levels, leading to increased cholesterol 
synthesis and thus increased transport of cholesterol from the intestine to the circulation 
and increased availability of cholesterol for lipoprotein formation [221, 222].  
Chronic hyperglycemia also alters components of the renin-angiotensin system 
(RAS), which includes increasing production of angiotensin II (AngII). AngII has been 
shown to reduce glucose utilization and insulin sensitivity, increase insulin resistance, 
impair insulin signaling, and impair insulin secretion [223]. Hyperglycemia also decreases 
the activity of angiotensin converting enzyme, leading to increased levels of AngII and 
decreased production of angiotensin-(1-7) [224]. In fact, when angiotensin-(1-7) was 
upregulated in a rat model it enhanced glucose tolerance, insulin sensitivity, and insulin-
stimulated glucose uptake [225]. Triglyceride and cholesterol levels were also lower [225]. 
Furthermore, inhibition of RAS has been shown to improve TG, HDL, LDL, and total 
cholesterol [223], and administration of exogenous insulin to hyperglycemic rats reversed 
some of these negative effects, including normalizing the expression levels of several 
compounds involved with AngII synthesis and activity [223].  
Several studies have shown that creatinine increases progressively with time in 
alloxanized animals, signaling kidney dysfunction [226-228]. However, both groups six 
months post-alloxan have comparable creatinine and BUN levels as pre-alloxan and non-
alloxanized controls, and the AST/ALT ratio is comparable to non-alloxanized controls, 
indicating little kidney damage and no additional liver damage due to the drug.  
 Spontaneous recovery from streptozotocin- and alloxan-induced diabetes has 
been well-documented [193, 198, 199, 229] and works through several potential 
mechanisms. A recent study in mice found evidence that islet delta cells can be converted 
into beta cells, an ability which is lost in adulthood [229]. Other hypotheses involve 
proliferation of surviving beta cells [193, 197, 198, 229], islet alpha cells reprogramming 
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into beta cells [229, 230], and duct epithelium conversion to beta cells [193, 197, 198]. 
This is the first study to show recovery from alloxan-induced diabetes in a large animal 
model. However, while this study determined that peripheral insulin levels recover in 
juvenile swine, it does not delve into the mechanisms that drive this recovery.  Future 
studies should focus on non-beta islet cell reprogramming in swine of different ages.  
Swine do not reach developmental maturity until 6 months of age [102, 231-233]. 
In this study, although there is only a difference of about three months between the ages 
of the two experimental groups, developmentally it is the difference between juvenile and 
adulthood [102, 232, 233]. In addition to the blunted acute (1 week) beta cell destruction 
by alloxan in juvenile pigs, they also showed more relative recovery of glucose tolerance 
and peripheral insulin responses 6 months after alloxan compared to adult pigs. This 
speaks to the immense sensitivity of alloxan to age and the more robust resistance of 
juvenile pig beta cells to alloxan.  
The juvenile group contained 3 castrated males and 5 females, while the adult 
group contained 5 castrated males and 3 females (Table 3.1). The non-alloxanized control 
group contained 4 of each sex (Table 3.1). These sex differences could potentially impact 
metabolic parameters, but the differences were not statistically significant. The effect of 
sex in regard to weight gain shows different results in different studies, depending on the 
diet and breed of pig [234, 235]. In Large White x Landrace pigs, intact boars were larger 
than females while the weights of castrated males were comparable to that of females 
[235]. Female swine reliably exhibit elevated serum cholesterol [234, 236-238], but the 
effects of sex on triglyceride levels and insulin resistance are less predictable [234, 237, 
238]. Of note, the blood urea nitrogen, creatinine, alanine aminotransferase, and aspartate 
aminotransferase levels are comparable between male and female swine [237, 238]. In 
this study, even though the adult swine group contained more males than females these 
swine exhibited greatly elevated serum triglycerides, cholesterol, and HOMA-IR (Table 
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3.1). If sex did impact the metabolic profile, then correcting for it would only make these 
results more robust.  
Furthermore, the vasoprotective effects of estrogen in the circulation have been 
well documented [239-241], as well as the harmful effects of testosterone [241, 242]. 
However, the sex differences in this study might not be that simplistic, as female Yucatan 
swine have similar serum testosterone levels as castrated males [79] and intact female 
dogs have comparable estradiol as neutered males [243]. While serum estrogen levels 
were not measured in this study, the literature supports the hypothesis that females and 
castrated males from various species have a similar sex hormone profile. 
This is the first study since 1949 to investigate whether the effects of alloxan are 
dependent on age in large animals. Since alloxan is a very mercurial drug, different 
species at different stages of maturity need to be tested. Alloxan is widely used to elicit 
diabetes in animal models, so by characterizing responses to alloxan researchers can be 
sure the drug will have the desired effects. Studies examining how the diabetic effects of 
alloxan are dependent on age in different species is of the utmost importance, as different 
animal species and even different breeds within a species react differently. For example, 
it has been found that pigs require a higher dose of alloxan to develop a similar diabetic 
state as rats, dogs, and rabbits [196, 244]. Clearly, alloxan has very different effects based 
on the physiology of the species and breed. Therefore, one study in one species is not 
adequate to make such a sweeping generalization about the age of an animal on a drug’s 
effectiveness. The field of diabetic animal models needs additional studies both to verify 
Creutzfeldt’s 1949 findings and to determine if this effect is typical among commonly used 
animal models of diabetes.  
In the current study, I show that alloxan more efficaciously elicited acute and 
sustained hyperglycemia when administered to adult swine compared to juvenile swine. 
This supports the 70-year-old dogma that the diabetic effects of alloxan are dependent on 
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age, at least in the dog and the minipig [202]. Future studies will need to examine other 
laboratory animal species to determine the ubiquity of this age-dependence. These 
studies should focus on several ages to create a dose-response curve for frequently used 
animal models. This study provides an important step in clarifying the effects of a widely 
used yet relatively unpredictable drug, thereby enabling researchers to better choose 
which animal and stage of maturation will be best for their study design. This information 
can save researchers time and money and can prevent needlessly wasting research 







Figure 3.1: Adult swine exhibited prolonged impaired glucose clearance after an 
intravenous glucose tolerance test. Blood glucose levels were tested for 60 minutes 
after a bolus of glucose. (A) Adult swine showed a deficit in glucose clearance at all time 
points compared to pre-alloxanized and young swine one week after alloxan 
administration. (B) Baseline fasting blood glucose was elevated in juvenile animals and 
higher in the adult group one week after alloxan administration. (C) Area under the curve 
analysis shows impaired glucose clearance in adult alloxanized animals. (D) Adult swine 
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continued to exhibit impaired glucose clearance at most time points compared to non-
alloxanized swine and juvenile swine six months after alloxanization. (E) Baseline fasting 
glucose was elevated in adult swine six months after alloxan administration. (F) Area 
under the curve analysis using the fasting blood glucose as a baseline for each group 
shows impaired glucose clearance in juvenile alloxanized animals compared to non-
alloxan controls, and this impaired glucose clearance is exacerbated in adult alloxanized 
animals six months after alloxan administration. *, p < 0.05. (Pre-Alloxan = 16; Non-













Figure 3.2: Fasting blood glucose correlates to age at alloxan administration. 
Fasting blood glucose taken one week after alloxan administration is significantly 
positively correlated to the age of swine at time of alloxan administration (black). The dose 
of alloxan, however, is not correlated to age (red) and is not significantly different between 








Figure 3.3: Hypoinsulinemia persists in both juvenile and adult swine six months 
after alloxanization. (A) Time course of peripheral insulin during intravenous glucose 
tolerance test was significantly lower in juvenile and adult swine compared to pre-alloxan 
controls one week after alloxan administration. (B) Area under the curve analysis reveals 
comparable hypoinsulinemia in both the juvenile and adult alloxanized swine one week 
after alloxan administration. (C) Juvenile and adult swine still exhibited hypoinsulinemia at 
several time points compared to non-alloxanized, age-matched controls six months after 
alloxan administration. (D) Area under the curve analysis revealed comparable 
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hypoinsulinemia in both juvenile and adult alloxanized swine six months after alloxan 
administration. (E) The fold change in peripheral insulin from one week to six months post-
alloxan was greater in juvenile than adult swine. *, p < 0.05 vs. Pre-Alloxan or Non-












Figure 3.4: Decreased beta cell mass is evident in both young and older alloxanized 
swine. Immunohistochemical staining of insulin in pancreas sections from juvenile (A) and 
adult (B) swine revealed that 6 months post-alloxan both juvenile and adult swine had a 
lower beta cell mass when compared to non-alloxanized controls having insulin staining 










Table 3.1: Metabolic profiles show hyperlipidemia and insulin resistance in swine six months after consumption of an 
atherogenic diet 
 Pre-Alloxan 1 Week Post-Alloxan 6 Months Post-Alloxan 
Non-alloxanized 
MetS swine  
  Juvenile Adult Juvenile Adult  
Age (mo) - 4.3 ± 0.2 7.4 ± 0.2† 11.0 ± 0.2† ‡ 14.0 ± 0.1† ‡ § 12.6 ± 1.1† ‡ 
Sex (M/F) 8/8 3/5 5/3 3/5 5/3 4/4 
Body Weight (kg) 24.9 ± 1.6 22.2 ± 1.0 29.7 ± 1.0 67.8 ± 2.6* † ‡ 73.5 ± 2.8* † ‡ 91.7 ± 2.6* † ‡ $ 
BMI (kg/m2) - - - 58.6 ± 2.4 59.4 ± 3.2 69.4 ± 1.3§ $ 
Serum TG (mg/dL) 33 ± 16 66 ± 15 82 ± 16 41 ± 7 211 ± 87* § 40 ± 5$ 
Total Chol (mg/dL) 91 ± 16 93 ± 5 110 ± 7 500 ± 114* † ‡ 988 ± 138* † ‡ § 421 ± 59* † ‡ $ 
HOMA-IR 2.9 ± 0.4 3.3 ± 0.3 4.6 ± 0.3 2.3 ± 0.3 5.4 ± 1.0* § 2.7 ± 0.2$ 
Creatinine (mg/dL) 1.1 ± 0.1 0.9 ± 0.1 1.2 ± 0.1 1.1 ± 0.1 1.1 ± 0.1 1.3 ± 0.1† 
BUN (mg/dL) 14.7 ± 0.8 16.5 ± 3.1 27.4 ± 3.4* † 14.9 ± 0.9‡ 16.9 ± 1.0‡ 11.9 ± 1.5‡ 
AST/ALT 0.66 ± 0.04 0.99 ± 0.06 0.74 ± 0.07 1.68 ± 0.43* 1.73 ± 0.36* 1.56 ± 0.30* 
Systolic BP (mmHg) 131 ± 6 - - 142 ± 10 158 ± 6 138 ± 9 
Diastolic BP (mmHg) 74 ± 5 - - 83 ± 6 88 ± 3 90 ± 7 
MAP (mmHg) 93 ± 5 - - 103 ± 6 112 ± 3 106 ± 7 
Data are means ± SEM. M, male; F, female; TG, triglycerides; Chol, cholesterol; HOMA-IR, homeostasis model assessment-insulin 






mean arterial pressure. Measurements were taken either one week or six months after alloxan administration. *, p < 0.05 compared 
with pre-alloxan swine; †, p < 0.05 compared with juvenile swine one week post-alloxan; ‡, p < 0.05 compared with adult swine one 






























CHAPTER 4: EFFECT OF METABOLIC SYNDROME AND AGING ON Ca2+ 
DYSFUNCTION IN CORONARY SMOOTH MUSCLE AND CORONARY ARTERY 
DISEASE SEVERITY IN OSSABAW MINIATURE SWINE 
Background 
Atherosclerosis is a complex, progressive disease that develops over many years 
when cholesterol, fatty material, cellular waste products, fibrin, collagen, and extracellular 
Ca2+ accumulate in large and medium-sized arteries throughout the body. Coronary artery 
disease (CAD) is the build-up of atherosclerotic plaque in the coronary arteries leading 
towards occlusion and myocardial ischemia and is the leading cause of death in 
industrialized nations [245]. 
Modifiable risk factors such as physical inactivity and an unhealthy diet can 
potentiate metabolic changes like hypertension, dyslipidemia, obesity, insulin resistance, 
and glucose intolerance.  Metabolic syndrome (MetS) is the clustering of 3 or more of 
these cardiometabolic risk factors and is associated with a 2-fold greater risk of developing 
CAD and a 1.6-fold increase in mortality [246, 247]. However, modifiable risk factors are 
only part of the story. Sir William Osler, a prolific physiologist and one of the founders of 
Johns Hopkins University, once wrote, “A man is as old as his arteries” [38]. Indeed, 
advancing age is one of the major non-modifiable risk factors for CAD. The prevalence of 
CAD increases progressively with age, and more than 50% of CAD-related deaths occur 
in individuals older than 75 [40, 41]. The population aged 65 and older in the US is 
projected to double to 83.7 million by the year 2050, causing a growing public health 
concern [248]. 
Ca2+ is vital to vascular smooth muscle function, as cytosolic Ca2+ levels regulate 
various cellular functions including contraction [68, 187], proliferation [68, 70, 249, 250], 
migration [184, 185], and transcription [186, 188]. Previous research (reviewed in ([69])) 
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has identified several functional alterations in Ca2+ transporters associated with metabolic 
disorders (MetS, diabetes, dyslipidemia) that induce CAD.  
The Ossabaw miniature swine model of MetS/CAD has been well-characterized 
[102]. These swine exhibit a “thrifty genotype” that allows them to store excess fat for later 
use during times of famine in their natural habitat [102, 107]. In captivity, when the pigs 
are kept sedentary and fed a high-calorie atherogenic diet, they reliably develop all the 
risk factors associated with MetS in addition to diffuse atheroma and coronary artery 
calcification (CAC), making them a clinically relevant animal model of human MetS and 
subsequent CAD/CAC [80, 81, 103, 105, 106, 108, 124].  
Age-related alterations in Ca2+ transporter activity depend heavily on the tissue, 
animal, and co-existing disease states [251]. These heterogeneous patterns of Ca2+ 
dysregulation are similar to the heterogeneity of metabolic dysfunction [69]. It is 
astounding that there are no reports on age-related alterations in Ca2+ transporter activity 
in coronary smooth muscle (CSM), especially since CSM Ca2+ dysregulation would 
precede extracellular CAC, which has been extensively documented in aging [41]. The 
pathophysiology of MetS- and aging-induced atherosclerotic disease may be different; 
however, MetS-induced and aging-induced atherosclerotic CAD and the associated 
alterations in CSM intracellular Ca2+ transporter activities have yet to be compared directly.    
Methods 
Animals 
All experimental procedures involving animals were approved by the Institutional 
Animal Care and Use Committee at Indiana University School of Medicine with the 
recommendations outlined in the Guide for the Care and Use of Laboratory Animals and 
the American Veterinary Medical Association Panel on Euthanasia [170, 171]. Ossabaw 
miniature swine were separated into four groups based on age and diet: lean young, MetS 
young, lean old, and MetS old swine (Table 1). Both lean groups were fed 725 g/day of 
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regular chow (5L80, Purina Test Diet, Richmond, IN) that contained 18% kcal from protein, 
71% kcal from complex carbohydrates, and 11% kcal from fat.  To induce MetS, swine in 
both MetS groups were fed 1000 g/day of an excess-calorie, atherogenic diet for 11 
months (KT324, Purina Test Diet, Richmond, IN) that provided 16.3% kcal from protein, 
40.8% kcal from complex carbohydrates, 19% kcal from fructose, and 42.9% kcal from fat.  
Fat calories were derived from a mixture of lard, hydrogenated soybean oil, and 
hydrogenated coconut oil and was supplemented with 2.0% cholesterol and 0.7% sodium 
cholate by weight.  All animals had free access to drinking water. 
Intravenous glucose tolerance testing 
Prior to intravenous glucose tolerance testing (IVGTT), conscious swine were 
acclimatized to low-stress restraint in a sling. The pigs fasted overnight before an IVGTT 
and fasting baseline blood samples were obtained. Glucose (1 g/kg body weight, IV) was 
administered and timed blood samples were collected as previously described by my 
laboratory [80, 102, 124] for blood glucose measurements (YSI 2300 STAT Plus Glucose 
analyzer, YSI Life Sciences, Yellow Springs, OH).  
Metabolic phenotyping 
Blood samples were obtained before euthanasia and triglycerides, total 
cholesterol, and blood chemistry profiles were assessed (Antech Diagnostics, West 
Lafayette, IN). Blood pressures were measured while swine were under anesthesia with 
isoflurane.  
Intravascular ultrasound 
Swine were anesthetized and intravascular ultrasound was performed as 
previously described [80, 135]. Still frame IVUS pullback images were obtained offline at 
1 mm intervals. Percent wall coverage and percent plaque burden were obtained using 
Image J software (1.48v, National Institutes of Health, USA). Pigs were euthanized after 
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the IVUS procedure via cardiectomy and coronary arteries were removed for further 
analysis.  
Assessment of [Ca2+]i regulation 
CSM cells from the freshly-dissected left anterior descending (LAD) coronary 
artery were enzymatically isolated and loaded with the ratiometric fluorescent Ca2+ 
indicator, fura-2 AM (3.0 mmol/L Molecular Probes, Life Technologies, Eugene, OR) as 
previously described [252, 253] (for full protocol, see Appendix E). Measurements of whole 
CSM cell [Ca2+]i levels were obtained using the InCa++ Calcium Imaging System 
(Intracellular Imaging, Cincinnati, OH) as previously described [76, 80, 174, 252]. 
Histology 
Coronary artery segments were collected at euthanasia and fixed in 10% 
phosphate buffered formalin for 24 hours before being switched to 70% ethanol solution.  
Samples were paraffin embedded, sectioned (5 μm thick), mounted on a slide and stained 
by the Indiana University Histology Core (Indiana University School of Medicine, 
Indianapolis, IN).  Verhoeff-Van Gieson (VVG) elastin staining was performed to 
determine the location of the external elastic lamina (EEL) and the internal elastic lamina 
(IEL) to assess wall thickness, medial area, and the intima/media ratio as measures of 
atherosclerosis progression [80, 81]. Wall thickening (percent media plus percent 
neointima) was measured by the following equation:  
[(
𝐴𝑟𝑒𝑎 𝑤𝑖𝑡ℎ𝑖𝑛 𝐸𝐸𝐿 − 𝐴𝑟𝑒𝑎 𝑤𝑖𝑡ℎ𝑖𝑛 𝐼𝐸𝐿
𝐴𝑟𝑒𝑎 𝑤𝑖𝑡ℎ𝑖𝑛 𝐸𝐸𝐿
) + (
𝐴𝑟𝑒𝑎 𝑤𝑖𝑡ℎ𝑖𝑛 𝐼𝐸𝐿 − 𝐴𝑟𝑒𝑎 𝑜𝑓 𝐿𝑢𝑚𝑒𝑛
𝐴𝑟𝑒𝑎 𝑤𝑖𝑡ℎ𝑖𝑛 𝐸𝐸𝐿
)] × 100% 
The media area was calculated as the area within the EEL minus the area within the IEL. 
The intima area was calculated as the area within the IEL minus the area of the lumen. All 
images were captured with a Leica DM3000 microscope connected to Leica Application 
Suites V4.1 software (Leica Microsystems GmbH, Wetzlar, Germany) and analyzed using 




Statistical analysis was performed using GraphPad Prism 5.0 (San Diego, CA). 
One-way analysis of variance (ANOVA) with Tukey post hoc analysis was performed. Data 
are represented as mean ± SEM and p < 0.05 was considered statistically significant. 
Results 
Ossabaw Swine Cardiometabolic Characteristics 
The experimental groups’ cardiometabolic characteristics are presented in Table 
4.1. The Ossabaw swine were separated by age and disease state.  Lean old swine were 
shown to be healthy as indicated by their normal body weight, blood pressure, cholesterol 
triglyceride, and fasting glucose levels, and peak glucose and area under the curve 
analysis derived from the IVGTT assessment. My laboratory and others have extensively 
characterized cardiometabolic profiles in Ossabaw swine fed regular chow diets and 
hypercaloric, atherogenic diets to induce MetS [69, 80, 81, 107, 110, 135, 149, 203].  MetS 
was confirmed in the MetS young and MetS old swine groups, both of which developed 
obesity, hypercholesterolemia, and elevated peak glucose and area under the curve 
during IVGTTs [80, 135].  However, only the MetS old swine exhibited hypertension, with 
elevated systolic blood pressure and mean arterial pressure (MAP). Blood pressures were 
measured while swine were anaesthetized. The lean old swine had significantly lower 
serum triglycerides and fasting blood glucose, which is characteristic of older swine [238, 
254].  
Histological Assessment of Vascular Health 
Atherosclerosis progression was assessed by VVG staining in the proximal right 
coronary arteries (Fig. 4.1A-D) that enabled measurement of wall thickness (%media + 
%neointima), media thickness, and intima:media ratio (Fig. 4.1E-G). MetS young and lean 
old swine had similarly elevated wall thickening over the lean young swine group, and 
MetS old swine had significantly greater wall thickening than the other three groups (Fig. 
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4.1E). MetS young and lean old swine had similarly elevated media thickness over the 
lean young swine group, and MetS old swine had comparable media thickness to lean 
young swine (Fig. 4.1F).  To determine whether this change was due mainly to media 
thickening, which is characteristic of aging [255, 256], or intimal thickening, which is 
characteristic of CAD [255], the intima:media area ratio was assessed (Fig. 4.1G). The 
MetS young swine trended towards a higher intima:media ratio and the MetS old swine 
had a significantly higher intima:media ratio, indicating that a bulk of the wall thickening in 
both MetS groups was due to neointimal thickening while the wall thickening in the lean 
old swine was due to medial thickening.  
IVUS Assessment of Coronary Plaque Severity 
After angiography was employed to locate the LAD and circumflex (CFX) arteries 
for catheter placement (Fig. 4.2A), cross-sectional images of the arteries were taken using 
an IVUS catheter (representative IVUS still frames in Fig. 4.2B-C). Unfortunately, 2 out of 
the 3 MetS old swine died on the operating table before IVUS could be recorded, so this 
group was not included in the IVUS analyses. Percent wall coverage increased in MetS 
young swine (Fig. 4.2D) and percent plaque burden increased in both MetS young and 
lean old swine (Fig. 4.2E). These data suggest that MetS young swine and lean old swine 
have similar disease severities.  
Correlation of percent wall coverage and percent plaque burden with age 
Percent wall coverage (Fig. 4.2F) and percent plaque burden (Fig. 4.2G) of the 
lean young and lean old swine were plotted against age of the individual pig. Analysis 
revealed that both percent wall coverage and plaque burden are positively correlated with 
age. This supports the notion that CAD severity increases with age and that older 





Assessment of the Effects of MetS and Advancing Age on CSM cell [Ca2+]i 
Figure 4.3A-B shows a representative CSM [Ca2+]i response from a cell isolated 
from a lean young swine. When I assessed the caffeine-sensitive sarcoplasmic reticulum 
(SR) store release in the absence of extracellular Ca2+ to measure the SR storage 
capacity, I observed that the MetS young swine had an elevated SR store that was even 
higher in the lean old swine compared with the lean young group (Fig. 4.3C). The MetS 
old swine had a comparable SR store release when compared to lean young and MetS 
young swine but not lean old swine (Fig. 4.3C). When I measured the undershoot after 
SR store release in the absence of extracellular Ca2+ to get an index of sarco-endoplasmic 
reticulum Ca2+ ATPase (SERCA) activity, I observed that the lean old swine had an 
attenuated undershoot compared with the lean young and MetS young swine (Fig. 4.3D). 
The SERCA activity of the MetS old swine seemed to mirror that of the MetS young swine, 
but neither of these were significantly different from the lean young swine. When voltage-
gated calcium channel (VGCC) activity was assessed using a Ba2+ challenge, CSM cells 
from MetS young and MetS old swine trended towards an increased Ba2+ influx rate and 
net accumulation of Ba2+, but only the lean old swine had a significantly higher Ba2+ influx 
rate and net accumulation of Ba2+ compared with the lean young swine group (Fig. 4.3E).    
Discussion 
Cytosolic Ca2+ is a primary regulator of contraction and phenotypic modulation of 
CSM, which plays an integral role in atherosclerosis pathology and has been reviewed 
elsewhere [68, 69]. MetS- and aging-induced changes of the structure of the vascular 
have been well documented, but CSM Ca2+ dysregulation in MetS- and age-induced CAD 
have never before been directly compared. 
This study characterized aging-related CSM Ca2+ dysregulation and provides 
insight into the disease characteristics of two common etiologies of atherosclerosis. I show 
for the first time that, although MetS-induced CAD and aging occlude the arteries to a 
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similar degree in the swine model, the Ca2+ handling mechanisms present in lean old 
swine are exaggerated compared with MetS-induced CAD. This indicates that MetS young 
swine have CSM Ca2+ dysregulation that mirrors severe disease and lean old swine have 
CSM Ca2+ dysregulation that mirrors mild disease [81]. The MetS old swine had similar 
Ca2+ dysregulation as the MetS young swine, but a much greater wall thickness and 
neointima formation.  
 My laboratory has explored changes in Ca2+ handling in CSM throughout the time-
course of CAD progression in Ossabaw swine from healthy, lean pigs to obese, MetS pigs 
with advanced calcified CAD lesions. “Early stages” of CAD were characterized by pigs 
on the same atherogenic diet used in the present study for 6-9 months, while “later stages” 
of CAD were defined by pigs on an atherogenic diet for ~12 months [81]. In vivo 
assessment of atherosclerosis confirmed greater CAD burden in those pigs fed an 
atherogenic diet for a longer duration [81]. Interestingly, Ca2+ influx after membrane 
depolarization with 80 mM K+ and caffeine-sensitive SR store-release was elevated in 
early CAD, which began to decline in later stages of CAD [81]. 
 Specific Ca2+ handling dysfunction is associated with certain structural changes in 
the arterial wall. For example, increased SR Ca2+ store has been implicated with CSM 
proliferation and wall thickening [69, 257, 258]. In the present study, I show that lean young 
swine and MetS old swine have similar medial thickness (Fig. 4.2B), which is reflected in 
their comparable SR Ca2+ store release capacities (Fig. 4.3C). This could be due to the 
decreased proliferative ability of CSM cells or an increase in apoptotic CSM cells in MetS 
old swine [259, 260]. MetS young swine have elevated media thickness that is related to 
their elevated SR Ca2+ store release and lean old swine had even more elevated media 
thickness and associated SR Ca2+ store release. Thus, functional alterations in Ca2+ 
handling mechanisms affect the structural changes that are typical of the different age and 
disease states.  
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 Aging-induced changes in Ca2+ handling in smooth muscle vary depending on 
tissue bed and species [251]. Although cardiac events are the leading cause of death in 
aged individuals [245], there is a paucity of literature about the effects of age on CSM Ca2+ 
handling despite its structural and functional importance. I fill that gap of knowledge by 
demonstrating that swine with MetS exhibit Ca2+ dysfunction that is characteristic of severe 
CAD regardless of the age of the animal, and lean old swine exhibit Ca2+ dysfunction that 
is characteristic of mild CAD. The lean old swine have increased SR Ca2+ store, increased 
VGCC activity, and decreased SERCA function in CSM (Fig. 4.3C-E).  
 While the short maturation time and lifespan of rodents and rabbits makes them 
tempting to use in aging studies, their size and cardiovascular anatomy brings their clinical 
relevance into question [261]. However, because of their anatomy and physiology, the 
Ossabaw swine are a far more superior model than rodents or rabbits. Due to cost, space, 
and time limitations, Ossabaw swine have not previously been used in an aging study. 
This truly unique study compared CSM Ca2+ dysfunction in lean young, MetS young, lean 
old, and MetS old swine, a feat never before published due to the long lifespan of swine.  
The concept that MetS accelerates vascular aging is supported in this study. Even 
though plaque severity was comparable between the MetS young and lean old group (Fig. 
4.2E), the MetS young swine exhibited Ca2+ dysfunction that was on par with more severe 
CAD (Fig. 4.3C-E) [81]. In fact, the Ca2+ dysfunction exhibited by the MetS young swine 
more closely resembled that of MetS old swine as opposed to the lean young swine, 
indicating that MetS causes Ca2+ dysregulation that is typical of severe CAD regardless of 
the actual age of the individual animal. Lean old swine exhibited Ca2+ dysfunction that is 
characteristic of mild disease, where Ca2+ transporter function is enhanced (Fig. 4.3C-E) 
[81].  
The similarities in Ca2+ dysfunction, but differences in plaque severity, between the 
MetS young and MetS old swine brings forth the possibility that the aging milieu 
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predisposes individuals to exhibit accelerated plaque growth. Indeed, age has been 
associated with dyslipidemia [262], oxidative stress [263], insulin resistance [264], 
hypertension [263], and inflammation [265]. These, along with increased cellular 
senescence, which has been shown to play a part in atherosclerotic progression at all 
stages of the disease and is associated with advanced atherosclerotic plaques [266], 
comprise a perfect storm for plaque progression, and could cause plaques to develop 
more rapidly after Ca2+ dysfunction develops.  
Dyslipidemia, particularly elevated levels of LDL-cholesterol (LDL-C) is a strong 
individual risk factor predicting coronary artery disease progression [267]. Cumulative LDL 
exposure over a lifetime will be higher in older individuals and results in a greater risk of 
CAD development and progression [267]. This could explain why the lean old swine have 
similar wall thickness and plaque burden compared to MetS young swine even though the 
lean old swine had significantly lower cholesterol levels at time of sampling (Table 4.1). 
This cumulative LDL exposure could be considered a part of the aging milieu that 
contributes to accelerated CAD progression.  
One limitation of this study is the sex differences between groups. While the two 
MetS groups only contained female swine, the two lean groups contained both female and 
castrated male swine (Table 4.1). Estrogen has been shown to be vasoprotective in the 
coronary circulation in several studies [239, 240, 268], while testosterone has been shown 
to be harmful in the context of the coronary circulation [242, 268]. However, castrated 
male and intact female Yucatan swine have similar serum testosterone levels [79]. 
Furthermore, intact female dogs have similar estradiol levels as neutered males [243]. 
While the current study did not include serum estrogen levels of all the swine, the literature 
supports the hypothesis that castrated males and intact females have a similar sex 
hormone profile.  
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I report here that MetS young and lean old swine have similar elevated plaque 
burden and wall thickening due to media remodeling while MetS old swine have even 
greater wall thickening due to neointima formation. However, the Ca2+ dysfunction seen in 
MetS young and MetS old are comparable and follow the same pattern as that seen in 
severe CAD. Lean old swine have Ca2+ dysfunction that is indicative of mild disease. 
Therefore, I can conclude that, although Ca2+ handling is similar in a younger animal with 
less overt disease, the aging milieu causes more advanced coronary plaques to develop 






Figure 4.1: Histological staining reveals structural changes in MetS and old swine. 
Representative VVG histological stain of right coronary arteries reveals lean young swine 
(A) have almost no neointima formation. MetS young swine (B) and lean old swine (C) 
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have similar media thickness. MetS old swine (D) had the most advanced neointimal 
thickening. (E) MetS young and lean old swine both have significantly greater wall 
thickness compared to lean young swine, and MetS old swine exhibited the most severe 
wall thickness. (F) MetS young and lean old swine both exhibit media thickening that is 
significantly greater compared to lean young swine. (G) MetS young swine trend towards 
a greater intima:media area ratio compared to lean young, and MetS old swine have a 
greater intima:media ratio than the other groups, indicating a greater contribution of 
neointimal growth to disease pathology. External elastic lamina = green dashed line; 
internal elastic lamina = yellow dotted line; lumen = red dashed line. A, adventitia; M, 
media (wall); I, intima (plaque); L, lumen. *, p < 0.05 compared with lean swine; †, p < 0.05 






Figure 4.2: MetS young swine and lean old swine have comparable CAD severity as 
measured by intravascular ultrasound. (A) Angiogram showing the LAD and Cfx 
coronary arteries from a lean young swine. (B) Cross sectional view of a lean old swine 
with mild disease. (C) Cross sectional view of a MetS young swine with more severe 
disease. (D) MetS young swine have higher percent wall coverage than lean young swine 
in the proximal 15 mm of the LAD. (E) MetS young and lean old swine have greater percent 
plaque burden compared to lean young swine. Both percent wall coverage (F) and percent 
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plaque burden (G) are positively correlated to age in lean swine. Original lumen = yellow 
dotted line; plaque encroachment = red dashed line; wall coverage = white line with 
arrows. The distance between blue dots in B and C is 1 mm. *, p < 0.05 compared with 


















Figure 4.3: Ca2+ handling changes observed in MetS young and MetS old swine are 
exacerbated in old lean swine. (A) Representative tracing showing the change in the 
F340/F380 excitation fluorescence emission ratio of a CSM cell isolated from a lean young 
swine. Treatments and duration are indicated by solid lines. Ca2+ influx was initiated by 
depolarization of the cell with an 80 mM K+ solution, which maximally loaded the SR store. 
The 5 mM caffeine activated ryanodine receptors, causing total SR store release. After 
caffeine wash-out, the undershoot (black arrow), which is indicative of SERCA activity, 
was measured. (B) Representative tracing of a CSM cell isolated from a lean young swine 
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and treated with a solution containing 2 mM Ba2+, 80 mM K+, and 5 mM Na+ (2Ba80K5Na). 
Rate of barium entry is indicative of VGCC activity. Caf, caffeine. (C) Caffeine-induced SR 
store release was elevated in MetS young and lean old swine. (D) The undershoot, which 
is a direct measurement of SERCA function, was attenuated in MetS young and lean old 
swine (E) Increased Ba2+ influx was observed in the MetS young and lean old swine. *, p 
< 0.05 compared with young lean swine; †, p < 0.05 compared with young MetS swine; ‡ 
p < 0.05 compared with old lean swine. (Lean young = 6; MetS young = 10; Lean old = 4; 
MetS old = 3.) 
  






Table 4.1: Ossabaw swine cardiometabolic characteristics 
 Lean Young MetS Young Lean Old MetS Old 
Age (years) 2.0 ± 0.0 2.5 ± 0.2 9.2 ± 1.1* † 8.8 ± 1.2* † 
Body Weight (kg) 74 ± 4 108 ± 2* 87 ± 5† 113 ± 7* ‡ 
Sex (Male/Female) 2/4 0/10 3/2 0/3 
Total Cholesterol (mg/dL) 77 ± 6 474 ± 79* 60 ± 4† 411 ± 66‡ 
Triglycerides (mg/dL) 65 ± 18 56 ± 5 17 ± 4* † 20 ± 6 
Fasting Glucose (mg/dL) 70 ± 2 81 ± 2 52 ± 12† 78 ± 7 
Peak Glucose (mg/dL) 563 ± 27 755 ± 22* 688 ± 20 733 ± 44* 
Blood Glucose AUC 10120 ± 667 18124 ± 919* 12237 ± 464† 15297 ± 1556* 
Data are means ± SEM. MetS, metabolic syndrome; MAP, mean arterial pressure; AUC, area under curve. Fasting glucose was taken 
during intravenous glucose tolerance tests or during routine blood glucose monitoring for the lean old group. *, p < 0.05 compared with 
young lean swine; †, p < 0.05 compared with young MetS swine; ‡, p < 0.05 compared with old lean swine. (Lean young = 6; MetS 
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CHAPTER 5: SINGLE CELL RNA SEQUENCING ANALYSIS OF ORGAN-CULTURED 
PORCINE CORONARY ARTERIES REVEALS TRANSCRIPTOMIC DIVERSITY 
BETWEEN CORONARY SMOOTH MUSCLE CELL PHENOTYPES, BUT NO 
DIFFERENCE IN THE EXPRESSION OF INTRACELLULAR Ca2+ HANDLING GENES 
Background 
Under certain environmental stimuli such as growth factors, inflammation, and 
vascular injury, quiescent, contractile coronary smooth muscle (CSM) cells that normally 
populate the tunica media and are responsible for vascular tone undergo phenotypic 
modulation [70, 269]. This phenotypic transition is characterized by a downregulation of 
genes involved in contraction and an upregulation of genes involved with various other 
cellular functions, such as proliferation, migration, inflammation, and calcification [270]. 
Phenotypic plasticity is a hallmark of CSM and is necessary for adaptations to a dynamic, 
changing microenvironment [72, 269].  
CSM phenotypic modulation plays a major role in the development and 
progression of several diseases such as diabetes, hypertension, and coronary artery 
disease (CAD) [72]. In fact, the phenotypic modulation from a contractile phenotype to a 
synthetic phenotype is arguably required for cardiovascular diseases [269]. In 
atherogenesis, endothelial dysfunction leads to the upregulation of cell adhesion 
molecules, which bind circulating macrophages and immune cells and facilitate their 
infiltration into the vessel wall [271]. This early stage inflammation and vascular injury 
sparks CSM dedifferentiation into a synthetic phenotype that migrates to the neointima, 
proliferates, and secretes extracellular matrix (ECM) proteins. As such, synthetic CSM are 
associated with outward remodeling, neointimal formation and growth, and collagen 
deposition. Further dedifferentiation into an osteogenic phenotype is associated with the 
initiation of vascular calcification and the progression of calcified lesions. Coronary artery 
calcification (CAC) is a major independent predictor of acute myocardial infarction and 
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mortality in patients with CAD and there are currently no known therapies to treat CAC [8, 
272]. 
 Ca2+ is an important secondary messenger in many signaling pathways that 
regulate a diverse range of basic cellular functions, including contraction [68, 187], 
transcription [186, 188], proliferation [68, 70], and migration [184, 185]. Different CSM 
phenotypes differ in their intracellular Ca2+ ([Ca2+]i) signaling, due at least in part to the 
differential expression and functionality of resident Ca2+ transport proteins [72, 273]. The 
contractile phenotype is associated with high voltage-gated Ca2+ channel (VGCC) activity 
and a functional sarco-endoplasmic reticulum Ca2+ ATPase (SERCA) that maintains low 
basal [Ca2+]i [72, 274]. The synthetic phenotype is associated with greater sarcoplasmic 
reticulum (SR) Ca2+ storage capacity, greater SERCA function, and  increased basal 
[Ca2+]i due to greater VGCC activity [69, 70, 72, 73, 81, 274]. The osteogenic phenotype 
is associated with diminished [Ca2+]i handling, including a decreased SR Ca2+ store and 
decreased SERCA activity [80, 81]. This pattern of augmented Ca2+ handling in the 
synthetic phenotype and diminished Ca2+ handling in the osteogenic phenotype is 
consistent with the biphasic nature of [Ca2+]i dysregulation seen in CAD [81]. Clearly, the 
[Ca2+]i handling modifications seen in these disparate phenotypes have important clinical 
ramifications for cardiovascular diseases [69, 81, 125, 155, 158]. 
The contractile and synthetic phenotypes have classically been defined as two 
ends of a phenotypic spectrum [269, 270, 275, 276], but increasing evidence for the 
heterogeneity of VSMC suggests much more complexity. As stated previously, several 
phenotypes have been identified, including inflammatory, osteogenic, chondrogenic, 
fibroblastic, and adipogenic [277]. These CSM phenotypes have diverse functions, 
indicating that they have highly differential gene expression [269, 278]. However, while 
contractile CSM cells have well-defined characteristics, phenotypically-modulated, non-
contractile CSM represent a broad range of cells with different characteristics and 
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functions that have no formal definition or guidelines for identification [72, 273, 275]. 
Indeed, after vascular injury it was found that, although global expression levels of 
contractile phenotypic markers decreased, the response among CSM in the vessel wall 
was highly heterogeneous, indicating many intermediate phenotypes [278-281].  
To further complicate this situation, many studies delving into CSM cell phenotypic 
heterogeneity have been conducted in mice. Using this animal model may have led to the 
underestimation of the true diversity of CSM phenotypic modulation [276]. Ossabaw 
miniature swine superbly mimic human metabolic syndrome (MetS) and CAC, indicating 
that the phenotypic diversity observed in CSM from Ossabaw miniature swine may better 
reflect the heterogeneity seen in the human population [69, 80].  
Although CSM cell phenotypes have been extensively studied, no large-scale 
transcriptome-wide comparison of CSM has been accomplished yet. Individual cell 
transcriptomics is important for understanding complex biological tissues, but the 
heterogeneity of transcriptomes in a CSM cell population has not yet been fully elucidated. 
Therefore, the aims of the present study were to utilize organ-cultured coronary arteries 
from lean Ossabaw miniature swine and single-cell RNA sequencing (scRNA-seq) to 1) 
characterize the heterogeneity of a CSM cell population from a singular tissue source, 2) 
determine the extent to which osteogenic media modulates the CSM transcriptome, and 
3) examine whether differential expression of [Ca2+]i transporter genes is associated with 
dysregulated [Ca2+]i handling in different CSM cell subpopulations.  
Methods 
Animals  
All experimental procedures involving animals were approved by the Institutional 
Animal Care and Use Committee at Indiana University School of Medicine with the 
recommendations outlined by the National Research Council and the American Veterinary 
Medical Association Panel on Euthanasia [170, 171]. Ossabaw miniature swine (n = 7) 
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provided by CorVus Biomedical, LLC were fed 725 g/day of standard chow (5L80, Purina 
Test Diet, Richmond, IN) that contained 18% kcal from protein, 71% kcal from complex 
carbohydrates, and 11% kcal from fat. Swine were euthanized via cardiectomy. Coronary 
arteries were excised and stored for no longer than 24 hours in a physiological salt solution 
containing (in mM): 2 CaCl 2 , 138 NaCl, 1 MgCl 2 , 5 KCl, 10 HEPES, 10 glucose; pH 
7.4.  
Ex vivo coronary artery organ culture 
Conduit coronary arteries were cut into 2-4 mm long segments and organ cultured 
for 3 days in osteogenic media (DMEM supplemented with 10% FBS, 1% Penicillin-
Streptomycin, 180 mg/dL glucose, 3.8 mM inorganic phosphate, and 7.5 U/ml alkaline 
phosphatase (ProMega, Madison, WI)) at 37°C in a 95% O2, 5% CO2 incubator. The 
osteogenic media was changed on day 2 (for full protocol, see Appendix G).  
CSM cell dispersion 
CSM in the arterial segments were enzymatically dispersed with serial dispersions 
in 300 U/mL collagenase (Worthington Biochemical, Lakewood, NJ) and suspended in a 
0.2% bovine serum albumin solution in 0.9% NaCl on ice. Greater than 95% of cells 
acutely isolated from coronary arteries are elongated, thus highly indicative of CSM 
phenotype [282]. To facilitate separation of cells for single-cell RNA-sequencing, cells 
were exposed to 0.25% trypsin to yield spherical cells and then passed through a 40 μm 
cell strainer to remove cells too large for single-cell RNA-sequencing (for full protocol, see 
Appendix H). 
Single-cell RNA-sequencing 
Single-cell RNA-sequencing was performed in the Center for Medical Genomics 
at Indiana University School of Medicine (Indianapolis, IN). The Chromium Single Cell 3’ 
Library & Gel Bead Kit v2 (10X Genomics) was used, and all the steps outlined in the 10X 
protocol were followed (http://resources.qiagenbioinformatics.com/manuals/ 
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clcgenomicsworkbench/752/User_Manual.pdf). Briefly, all samples and reagents were 
prepared and loaded into the chip. Then, the Chromium Controller generated droplets 
where reverse transcription was conducted. cDNA was recovered through demulsification 
and bead purification. Pre-amplified cDNA was further subjected to library preparation. 
Libraries were sequenced on an Illumina Hiseq 4000 and aligned to the publicly available 
Sus scrofa genome. 
Intracellular free Ca2+ imaging 
Whole-cell intracellular free Ca2+ levels were measured at room temperature (22–
25 °C) by using the fluorescent Ca2+ indicator fura-2 AM (InCa++ Ca2+ Imaging System, 
Intracellular Imaging, Cincinnati, OH) as previously described [80, 81, 204, 283]. Briefly, 
freshly dispersed smooth muscle cells from the left anterior descending (LAD) artery were 
incubated with 3.0 μM fura2 AM (Molecular Probes, Eugene, OR) in a shaking water bath 
at 37 °C for 45 min before being washed in a solution containing low Ca2+ concentration. 
An aliquot of cells loaded with fura-2 AM was placed on a coverslip contained within a 
constant-flow superfusion chamber that was mounted on an inverted epifluorescent 
microscope (model TMS-F, Nikon, Melville, NY), with flow maintained at a constant rate 
of 1–2 mL/min. Basal Ca2+ levels were measured in physiologic salt solution composed of 
the following (in mM): 2 CaCl2, 138 NaCl, 1 MgCl2, 5 KCl, 10 HEPES, 10 glucose; pH 7.4. 
Calcium influx and maximal sarcoplasmic reticulum (SR) Ca2+ loading was accomplished 
by depolarization with high (80 mM) K+ solution (2 CaCl2, 63 NaCl, 1 MgCl2, 80 KCl, 10 
HEPES, 10 glucose; pH 7.4) (Neeb et al., 2010). SR Ca2+ stores were released with 5 mM 
caffeine in Ca2+-free solution (138 NaCl, 1 MgCl2, 5 KCl, 10 HEPES, 10−5 M K+-EGTA, 10 
glucose; pH 7.4) (for solution recipes, see Appendix F). The undershoot below baseline 
after caffeine wash-out was used to measure SERCA function. Fura-2 in CSM was excited 
by light from a 300 W xenon arc lamp that was passed through a computer-controlled filter 
changer containing 340 nm and 380 nm bandpass filters every 0.30 and 0.05 s, 
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respectively. The fluorescence emission at 510 nm was collected by using a monochrome 
charge-coupled device camera (COHU, San Diego, CA) (for full protocol, see Appendix 
E). Whole-cell fura-2 fluorescence was expressed as the 340 nm/380 nm ratio of fura-2 
emission. A graph demonstrating the experimental protocol is shown in Fig. 6A. 
Histology 
Coronary artery segments (2–4 mm in length) were placed in 10% phosphate-
buffered formalin for 24–48 hours, then transferred to 70% ethanol. Histology was 
performed in the Department of Anatomy and Cell Biology at Indiana University School of 
Medicine (Indianapolis, IN). Verhoeff van Gieson (VVG) staining was used to assess the 
percent media (for full protocol, see Appendix B), Masson’s trichrome staining was used 
to assess the percent collagen (for full protocol, see Appendix C), and Von Kossa (VK) 
staining was used to assess the percent vascular calcification (for full protocol, see 
Appendix D). Images were captured using a LEICA DM 300 inverted microscope and 
analyzed with Adobe Photoshop CS6 (Adobe Systems, Inc. San Jose, CA). 
Immunohistochemistry 
Coronary artery segments (2–4 mm in length) were placed in 10% phosphate-
buffered formalin for 24–48 hours, then embedded in paraffin. Tissue sections were 
stained with anti-mouse CD9 monoclonal antibody (BD Pharmingen, San Diego, CA) as 
a marker for VSMC-derived exosomes by the Department of Pathology at Indiana 
University School of Medicine (Indianapolis, IN). Images were captured using a LEICA DM 
300 inverted microscope and analyzed with Adobe Photoshop CS6 (Adobe Systems, Inc. 
San Jose, CA). 
Statistics 
I used the Seruat software package (https://satijalab.org/seurat/) for tSNE analysis 
[284, 285] and Ingenuity Pathway Analysis (IPA) for analysis of canonical pathways 
(QIAGEN, Inc., https://www.qiagenbioinformatics.com/products/ingenuity-pathway-
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analysis). Statistical analysis was performed using GraphPad Prism 5.0 (San Diego, CA). 
Student’s t test was performed when appropriate. P < 0.05 was considered statistically 
significant. 
Results 
Organ-cultured arterial rings exhibited pathological remodeling 
After three days cultured in osteogenic media, coronary rings exhibited greater 
medial thickening (Fig. 5.1A, D, G), greater collagen formation (Fig. 5.1B, E, H), and a 
greater vascular calcification (Fig. 5.1C, F, I) compared to non-cultured rings.  
Organ culture conditions induce greater expression of exosomes 
CD9 expression, a marker of vascular smooth muscle cell-derived exosomes that 
form the nidus for calcification [276, 286], was increased after 3 days in culture (Fig. 5.2A-
C).  
CSM from organ-cultured arterial rings exhibited lower overall expression of contractile 
markers 
Global RNA analysis revealed a decrease in contractile markers in CSM harvested 
from cultured arterial rings compared to CSM from non-cultured rings (Fig. 5.3A-C). Cells 
from cultured arteries also showed greater expression of proliferative markers (Fig. 5.3D-
E) and osteogenic markers (Fig. 5.3F).  
Counting Map Reads 
Control, non-cultured rings yielded data from 3,296 cells. On average, there were 
71,715 reads per cell and 92% of the reads were confidently mapped to the genome. An 
average of 14,786 genes were detected, with 787 genes per cell. Cultured rings yielded 
data from 5,322 cells. On average, there were 62,735 reads per cell and 93 of the reads 
were confidently mapped to the genome. An average of 15,230 genes were detected, with 
1,666 genes per cell. The t-distributed stochastic neighbor embedding (t-SNE) method of 
unsupervised learning was used to visualize the various cell types present in the sample, 
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as represented by differently colored clusters (Fig. 5.4A-B). There were 11 unique cell 
types identified in the cells isolated from control arterial rings (Fig. 5.4A) and 12 unique 
cell types identified in the cells isolated from cultured arterial rings (Fig. 5.4B). Cell clusters 
were identified as CSM if they had positive expression of at least three genes associated 
with either the contractile or synthetic CSM phenotype (Table 5.1). 46% of the total cells 
from 5 unique clusters in the control condition and 39% of the total cells from 6 unique 
clusters in the organ-culture condition were identified as smooth muscle. Various other 
cell types were identified in the sample, such as fibroblasts, macrophages, endothelial 
cells, and adipocytes (data not shown). In the control condition, 32% of total smooth 
muscle cells were identified as contractile, while 69% were identified as synthetic. In the 
organ-culture condition, only 17% of total smooth muscle cells were identified as 
contractile, 78% were identified as synthetic, and 5% were identified as an intermediate 
phenotype expressing three or more markers for both the contractile and synthetic 
phenotype.  
Coronary smooth muscle exhibited remarkable diversity 
Two cell clusters from the control condition were identified as contractile and three 
were identified as synthetic. Different clusters of CSM exhibited augmented expression of 
genes involved in different cellular processes, as illustrated by the top ten highly 
expressed genes for each cluster (Fig. 5.5A-B). For example, one cluster of contractile 
CSM cells exhibited increased expression of genes involved in transcription and cell cycle 
activation (“Contractile #1”) while the other contractile CSM cell group (“Contractile #2”) 
had a lower expression of these genes but even higher expression of genes involved in 
contraction (Fig. 5.5A). Synthetic CSM cells were enriched in genes involved in 
extracellular matrix remodeling and inflammation (Fig. 5.5A). The organ-cultured condition 
contained one contractile CSM cell cluster, four synthetic CSM cell clusters, and one CSM 
cell cluster that was an “intermediate” phenotype between contractile and synthetic (Fig. 
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5.5B). Similar genes were upregulated in the cultured clusters compared to the non-
cultured clusters, but genes involved in vascular calcification, including matrix 
metallopeptidase 9 (MMP9), osteopontin (SPP1), and sphingomyelin phosphodiesterase 
acid like 3B (SMPDL3B), were also upregulated in some cell clusters from organ-cultured 
arteries (Fig. 5.5B).  
Coronary smooth muscle cells show extensive intra-phenotype variation in gene 
expression 
Both contractile and synthetic CSM cells from cultured arterial rings exhibited 
extensive variation in gene expression when compared to their phenotypic counterparts 
in cells from non-cultured rings. Culture conditions induced greater pro-inflammatory, pro-
calcific gene expression in both contractile and synthetic CSM cells (Table 5.2). 
Furthermore, even the contractile markers themselves were lower in contractile CSM cells 
from cultured arteries compared to contractile CSM cells from non-cultured arteries (Table 
5.2). 
Intracellular calcium handling is dysregulated in coronary smooth muscle cells from 
cultured arterial rings 
Fig. 5.6A shows a representative CSM [Ca2+]i response from a freshly isolated 
control CSM cell. Treatments and durations are marked by the solid lines. The basal [Ca2+]i 
levels during superfusion with a physiological salt solution were lower in cells from arteries 
cultured for 3 days (Fig. 5.6B). Depolarization-induced Ca2+ influx and the SR Ca2+ storage 
capacity, as measured by the caffeine-sensitive SR Ca2+ store release, both drastically 
decreased in CSM cells from cultured arteries (Fig. 5.6C-D). SERCA function as 
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Coronary smooth muscle from cultured rings did not exhibit any direct changes in Ca2+ 
transporter gene expression 
None of the CSM cell clusters from either condition exhibited differential 
expression of transcripts for Ca2+ transporters, including VGCC, transient receptor 
potentiation (TRP) channels, SERCA, sodium-calcium exchangers (NCX), plasma 
membrane Ca2+-ATPases (PMCA), IP3 receptors (IP3R), and ryanodine receptors (RyR). 
The phosphate transporters PiT-1 and PiT-2 also did not exhibit any changes in gene 
expression (data not shown).  
CSM exhibited extensive canonical pathway diversity 
The canonical pathways feature from IPA was used to determine the cell clusters’ 
relative activation or repression of signaling pathways implicated in SMC differentiation, 
phenotypic switching, disease severity, and cellular stress responses (Fig. 5.7). Every cell 
cluster from both conditions exhibited an upregulation of at least one canonical signaling 
pathway associated with contractile phenotype maintenance and synthetic phenotypic 
modulation. Even though baseline [Ca2+]i, Ca2+ influx, and SR store release were 
diminished in cells from organ cultured arteries (Fig. 5.5B-D), specific clusters such as the 
“Contractile #2” and “Synthetic #1” groups from the control condition and the “Contractile” 
group from the organ-cultured condition exhibited upregulated Ca2+ signaling. All of these 
groups displayed upregulation of the NFAT pathway, a Ca2+-dependent transcription 
factor [273]. However, many other cell clusters that did not show augmented Ca2+ 
signaling still exhibited the upregulation of the Ca2+-dependent transcription factors NFAT 
and CREB. The Wnt/β-catenin canonical pathway, which is involved in osteogenic 
dedifferentiation and vascular calcification [287-291], was downregulated in both 
contractile groups from the control, non-cultured condition and in the “Synthetic #2” and 
“Synthetic #3” groups from the organ cultured condition. However, the synthetic groups 
also exhibited upregulation of the osteoarthritis canonical pathway, which has also been 
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implicated in CSM osteogenic dedifferentiation and vascular calcification [292]. Clearly, 
the regulation of these signaling pathways and their downstream effects in the cell are 
highly complex.  
Several genes involved in vascular calcification are upregulated in synthetic CSM 
Many genes involved in the canonical osteoarthritis pathway are involved in the 
active vascular calcification process [292]. Synthetic CSM cell clusters exhibited enhanced 
expression of several genes involved in vascular calcification, including osteopontin 
(SPP1), annexins A2 and A5 (ANXA2/5), matrix metallopeptidase 9 (MMP9), and 
sphingomyelin phosphodiesterase acid like 3B (SMPDL3B). Both contractile groups from 
the control condition exhibited the lowest expression of genes involved in this pathway 
(Fig. 5.8).  
Discussion 
This study validates the concept of extensive CSM phenotypic heterogeneity in 
both control and pathological conditions by utilizing single-cell RNA-sequencing and tissue 
from a clinically relevant large animal model (Fig. 5.3). Organ-cultured arteries exhibited 
greater media area, collagen content, and vascular calcification (Fig. 5.1), with a dramatic 
overexpression of CD9, a marker for vascular smooth muscle cell-derived exosomes (Fig. 
5.2). CSM cell subpopulations that were identified as synthetic were present in both the 
control and organ-cultured conditions (Fig. 5.4). However, different genes were 
upregulated in the synthetic phenotype groups from the different conditions; synthetic cells 
from organ-cultured conditions exhibited the upregulation of several genes involved in 
inflammation and vascular calcification (Table 5.2). All cell clusters expressed an 
upregulation of at least one canonical pathway associated with the contractile and 
synthetic phenotypes (Fig. 5.6). All cell groups exhibited upregulation of at least four genes 
that are involved in the osteoarthritis pathway, and both contractile cell groups from the 
control condition exhibited the lowest expression levels of genes involved in this pathway 
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(Fig. 5.7). While basal [Ca2+]i levels and [Ca2+]i handling was dysregulated after 3 days in 
organ culture (Fig. 5.5), there was no difference in Ca2+ transporter gene expression in 
any of the CSM groups. Therefore, the differences seen in [Ca2+]i handling may be due to 
protein expression and/or post-translational modifications that change the functionality of 
the Ca2+ transporters.  
 CSM phenotypic modulation is associated with altered [Ca2+]i handling and Ca2+ 
transporter gene expression. In the current study the organ culture conditions induced a 
global decrease in basal [Ca2+]i, Ca2+ influx, and SR Ca2+ store release, all indicative of 
the osteogenic phenotype present in severe CAD [80, 105]. Despite this profound Ca2+ 
dysregulation, none of the Ca2+ transporters exhibited differential expression in any of the 
cell subpopulations. Therefore, the difference seen in [Ca2+]i handling might be exclusively 
due to functional changes. Many cell populations in this study exhibited evidence of 
oxidative stress through the pathways that were upregulated, such as the NRF2-mediated 
oxidative stress response. When SERCA is irreversibly oxidized on cysteine residues its 
activity is greatly reduced [293, 294]. This reduces the sequestration of [Ca2+]i, leading to 
increased basal [Ca2+]i levels and decreased SR Ca2+ storage capacity [294]. This could 
diminish Ca2+ transporter function without affecting expression of that transporter. 
Although in this study no change in SERCA function was detected, oxidative stress has 
also been associated with modified activity of many other Ca2+ transporters, including 
VGCC, RyR, IP3R, and PMCA [295-297]. These translate into functional changes in vivo 
such as decreased contractility [295]. Future studies will be needed to delineate the 
contributions of specific Ca2+ transporter functional changes to dysregulated [Ca2+]i 
handling. Further, the possibility should be investigated that decreased SR Ca2+ storage 
capacity could trigger endoplasmic reticulum stress response genes that have been 
implicated in vascular calcification [89].  
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 Even though overall [Ca2+]i handling was diminished in CSM cells from cultured 
arteries, the IPA canonical pathways analysis predicted that some cell clusters would 
exhibit increased Ca2+ signaling. These clusters were the “Contractile #2” group and the 
“Synthetic #1” group from the control condition and the “Contractile” group from the organ-
cultured condition. This finding is expected, as localized Ca2+ signaling events such as 
Ca2+ sparks and waves are necessary for CSM contraction [69]. Subsequently, these 
clusters also predicted greater activation of the Ca2+-dependent transcription factor NFAT, 
which was consistent with the NFAT gene expression. The [Ca2+]i handling patterns in 
CSM cells from a single tissue source exhibit vast diversity. Therefore, future experiments 
using VSMCs should not treat them as a monolith.  
In the current study, I show that CSM phenotypic modulation is not a discreet event 
or a continuum, but rather is a network of interconnected phenotypes. Indeed, CSM cells 
have the capacity to exhibit characteristics and markers of several different phenotypes. 
This is in agreement with the literature, with several studies identifying the upregulation of 
genes associated with both the contractile and synthetic phenotypes in the neointima after 
vascular injury [269, 298, 299]. Some studies even point to a range of contractile 
phenotypes in certain vascular beds [276].  
 The complex heterogeneity of phenotypic modulation is exemplified by differing 
identity markers present in vascular smooth muscle cells (VSMC). More than 80% of 
VSMC-derived cells lacked any measurable expression of VSMC markers and 30% 
expressed traditional markers for macrophages in vivo in ApoE-/- mice [300-302]. This is 
in contrast to in vitro experiments showing that a vast majority of proliferating VSMC 
continue to express contractile markers for several days in culture [303, 304]. To further 
complicate the situation, a study using human coronary artery sections discovered that 
40% of foam cells express VSMC markers [301, 302]. While the macrophage-like, 
inflammatory SMC phenotype is common in human atherosclerotic lesions, these studies 
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indicate that even cells expressing VSMC markers may not be of VSMC origin [302, 305]. 
Future studies should use caution when identifying VSMC by phenotype, as traditional 
markers may not be adequate.  
 The great range of VSMC phenotypes points to complex transcriptional regulatory 
pathways that are involved in phenotypic modulation [276]. Different canonical pathways 
are associated with VSMC switching to various phenotypes. For example, the PI3K/AKT 
pathway is associated with maintenance of the contractile phenotype [306-308], the 
PDGF, ERK, and VEGF pathways are associated with the synthetic phenotype [307-312], 
and the STAT3 and Wnt/β-catenin pathways are associated with the osteogenic 
phenotype [276, 287-291]. However, some pathways such as TGF-β, PKA, and NF-κB 
are involved in the expression of multiple VSMC phenotypes [273, 276, 311-316]. The 
balance of these pathways has an important role in phenotypic modulation. In fact, one 
study found that VSMC phenotype is determined primarily by the balance between the 
PI3K/AKT pathway and the ERK and p38 MAPK pathways [307]. This balancing act of 
various different canonical pathways adds to the complexity and heterogeneity of CSM 
cells.  
 In this study, coronary arteries were cultured in osteogenic media supplemented 
with high amounts of inorganic phosphorous. Hyperphosphatemia is associated with 
VSMC transition to an osteogenic phenotype and vascular calcification [276, 317]. High 
calcium and phosphate levels have been implicated in the differential expression of genes 
involved with ion transport, such as PiT-1 and PiT-2 [318]. PiT-1 and PiT-2 may have had 
augmented functionality, as none of the CSM cell groups exhibited differential expression 
of these transporters. Genes involved in the calcification process such as annexins A2 
and A5, osteopontin, and aggrecanases were upregulated even before differential 
expression of Ca2+ transporters. This supports the notion that events leading to vascular 
calcification occur early in the atherosclerotic process [105].  
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The osteogenic media did induce phenotypic switching, as evidenced by the 
changes in the transcriptome and the higher level of vascular calcification. Elevated 
extracellular Ca2+ has been found to induce calcification through an exosome-dependent 
pathway through upregulation of sphingomyelin phosphodiesterase acid like 3B 
(SMPDL3B) [286]. The current study showed the upregulation of the SMPDL3B gene in 
several CSM cell subpopulations in the cultured arteries, along with higher expression of 
the vascular SMC-derived exosome marker CD9 (Fig. 5.2). This points to the osteogenic 
shift in transcriptomes of cells from the cultured condition.  
 A major conclusion is that the markedly impaired [Ca2+]I handling in the absence 
of decrease in the Ca2+ transporter gene expression indicate a crucial role for Ca2+ 
signaling in excitation-transcription coupling [63, 188] in regulation of vascular calcification 
[286]. Wamhoff and coworkers elegantly showed that upregulation of Ca2+ influx through 
voltage-gated Ca2+ channels increased activation of vascular smooth muscle 
differentiation marker gene expression [286]. The functional increase in Ca2+ influx 
occurred with no change in Ca2+ channel gene expression. The proatherogenic stimuli act 
on Ca2+ transporters to cause Ca2+ dysregulation. The “proatherogenic stimuli” in the 
current organ culture study are the calcification media and organ culture itself. I also 
showed the phenomenal increase in CD9 expression (Fig. 5.2), providing the exosome 
nidus for vascular calcification and the expression of sphingomyelin phosphodiesterase 
acid like 3B (SMPDL3B) that drives exosome trafficking to the plasma membrane [286]. 
The functional studies of [Ca2+]I handling and single-cell RNA sequencing of the vascular 
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Figures 
 
Figure 5.1: Organ culture induced pathological arterial remodeling. Representative 
Verhoeff van-Gieson histological staining from a control, non-cultured artery (A) and an 
artery cultured for 3 days in osteogenic media (D) exemplifies significant medial thickening 
in the organ culture condition (G). Representative Masson’s trichrome histological staining 
from a control artery (B) and an artery cultured for 3 days in osteogenic media (E) 
exemplifies significant collagen accumulation (H). Representative Von Kossa histological 
staining from a control artery (C) and an artery cultured for 3 days in osteogenic media (F) 
shows overt vascular calcification in the culture conditions (I). Black arrows point to the 
thickened media (A, D), an area of collagen accumulation (E), and areas of calcification 
(F). (n = 16 arterial rings for control; n = 12 arterial rings for day 3.) 
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Figure 5.2: Exosome expression is increased in cultured arterial rings. 
Immunohistochemical analysis using an antibody against CD9, a marker of VSMC-derived 
exosomes, revealed minimal to no expression in non-cultured arteries (A) and extensive 
expression (brown staining) in cultured arteries (B). The expression of CD9 is significantly 
upregulated in cultured arteries (C). (n = 18 arterial rings for control; n = 12 arterial rings 
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Figure 5.3: Culture conditions induce a global decrease of contractile smooth 
muscle cell markers. Violin plots show the expression level and density of expression for 
the ACTA2 (A), MYL9 (B), and MYH11 (C) genes, which are decreased after 3 days in 
organ culture. TGFB1 (D) and SMARCA4 (E), makers of the synthetic smooth muscle cell 
phenotype, exhibited higher expression after 3 days in organ culture. Sox9 (F), a marker 
for the osteo/chondrogenic phenotype, was also upregulated after 3 days in organ culture. 








 106   
 
Figure 5.4: t-SNE analysis shows the heterogeneity of cells that compose the 
coronary vasculature. (A) Unsupervised clustering for cells dispersed from control 
arterial rings. There were 11 distinct cell clusters, of which 5 (clusters 0, 2, 6, 8, 10) were 
identified as CSM. (B) Unsupervised clustering for cells dispersed from arterial rings 
cultured in osteogenic media for 3 days. There were 12 distinct cell clusters, of which 6 
(clusters 2, 4, 5, 6, 10, 11) were identified as CSM. Unsupervised clustering provides a 
means to identify cells of interest that share a common phenotype.  
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Figure 5.5: The top ten differentially expressed genes per CSM cluster show that 
CSM from cultured arterial rings have greater phenotypic diversity. (A) CSM 
dispersed from non-cultured arteries showed actively proliferating contractile cells 
(“Contractile #1) and non-proliferating contractile cells (“Contractile #2). Cells with the 
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synthetic phenotype were characterized by the upregulation of genes involved in 
extracellular matrix remodeling (“Synthetic #1 and #2”) and genes involved in the immune 
response (“Synthetic #3”). (B) CSM dispersed from cultured arteries exhibited the 
contractile phenotype and a phenotype that was between contractile and synthetic 
(“Intermediate”). Cells with the synthetic phenotype were characterized by the 
upregulation of genes involved in inflammation (“Synthetic #1), extracellular matrix 
remodeling (“Synthetic #2 and #3), and vascular calcification (“Synthetic 4”). Genes are 
color-coded based on function: orange, extracellular matrix remodeling; blue, immune 
response; green, proliferation; red, contraction and cytoskeleton organization; purple, 
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Figure 5.6: CSM from rings cultured for 3 days in osteogenic media exhibited 
blunted [Ca2+]i handling. (A) After measuring baseline [Ca2+]i levels (red dashed line), the 
cell was depolarized with an 80 mM K+ solution to induce Ca2+ influx via voltage-gated 
Ca2+ channels (blue double-headed arrow) and to maximally load the sarcoplasmic 
reticulum (SR) store. The SR Ca2+ store (purple double-headed arrow) was then released 
by activating ryanodine receptors with 5 mM caffeine. SERCA function (small green arrow) 
was measured as the undershoot below baseline after a caffeine wash-out phase. (B) 
Baseline [Ca2+]i levels were lower 3 days after organ culture. (C) The measured Ca2+ influx 
upon membrane depolarization was drastically reduced in CSM from cultured arteries. (D) 
The measured SR store release from CSM from cultured arteries was also greatly 
reduced. (n = 169 cells for control; n = 31 cells for day 3.) 
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Figure 5.7: Heat map of canonical pathways differentially expressed in CSM 
clusters. While clusters differed in their relative expression of canonical pathways, every 
cell cluster exhibited upregulation of at least one pathway involved in contractile 




 111   
 
Figure 5.8: Genes involved in the canonical osteoarthritis pathway. Pathways and 
cell clusters are grouped based on hierarchical clustering. The “Day 3 Synthetic #4” cluster 
had greatly augmented expression of several genes involved in the vascular calcification 
process. The contractile clusters from the non-cultured control arteries exhibited the 
lowest expression of genes involved in this pathway.  
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Tables 
 
Table 5.1: Markers used for identifying SMC phenotypes  




ACTA2 Smooth muscle alpha-2 actin [319-323] 
CALD1 Caldesmon 1 [324-327] 
CNN1 Calponin 1 [324, 328-330] 
MYH11 Myosin heavy chain 11 [319, 331-333] 
MYL9 Myosin light chain 9 [334-336] 
MYLK Myosin light chain kinase [337-340] 
MYOCD Myocardin [341-344] 
SMTN Smoothelin [324, 333, 339] 
TAGLN Smooth muscle 22-alpha [323, 324, 345] 





COL1A1/2 Collagen type 1A1/2 [342, 348-351] 
COL3A1 Collagen type 3A1 [333, 350, 352] 
GJA1 Gap junction alpha-1; connexin 43 
[278, 320, 331, 
353] 
ICAM1 Intercellular adhesion molecule 1 [321, 354-356] 
MMP2/9 Matrix metallopeptidase 2/9 [332, 333, 357] 
MSN Moesin [278, 358-360] 
NFAT Nuclear factor of activated T-cells 
[72, 273, 305, 
342, 361] 
SDC4 Syndecan 4 
[278, 322, 323, 
345] 
SMARCA4 
SWI/SNF related matrix associated 
actin dependent regulator of 
chromatin A4 
[362-364] 
TGFB1 Transforming growth factor beta-1 [365, 366] 
TPM4 Tropomyosin 4 
[324, 341, 367, 
368] 
VCAM1 Vascular cell adhesion molecule 1 [342, 354, 369] 
VIM Vimentin 
[319, 324, 328, 
370] 
For a cluster to be identified as either contractile or synthetic smooth muscle, it had to 
exhibit expression of at least three of these markers.  
   





Table 5.2: CSM cells from cultured arterial rings follow similar expression pattern changes when compared to the same 
cellular phenotype in fresh, non-cultured arteries 
  Select Specific Genes Involved 
Cellular Function Change from Control Contractile Phenotype Synthetic Phenotype 
Contractile SMC marker Decrease 
TPM1/2,  ACTA2, MYL9, CNN1, 
SMTN, MYH11 
N/A 
Pro-inflammatory Increase LGALS3, MIF 
SERPINB2, CCL20,CCL2, IL-6, 
CXCL14, CXCL8 
Anti-proliferative Decrease 
DUSP1, FZP36, WIF1, BTG2, 
IER5, RASSF3 
DUSP1, FZP36, BTG2, 
SERPINF1, RASD1 
Pro-calcification Increase ANXA1 MMP14, CTSB, SMPDL3B 
Anti-calcification Decrease MGP, ASPN MGP, TIMP3, ASPN 
Pro-Apoptosis Increase BNIP3, CAP6, RASSF1 TNFRSF12A, ACSL4 
Anti-protein aggregation Decrease CLU, ITM2B, HSPH1, DNAJB1 
DNAJA1, CRYAB, HSPH1, 
DNAJB1, SELENBP1 
Endoplasmic Reticulum/           
Ox stress response modulator 
Increase SOD2, NUPR1, GPX1 SOD2, NUPR1, SRXN1 
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CHAPTER 6: INTRACELLULAR Ca2+ DYSREGULATION IN CORONARY SMOOTH 
MUSCLE IS SIMILAR IN CORONARY DISEASE OF HUMANS AND OSSABAW 
MINIATURE SWINE 
Background 
Metabolic syndrome (MetS) is characterized by a clustering of three or more of the 
following five conditions: central obesity, hypertension, dyslipidemia, insulin resistance, 
and glucose intolerance [8]. MetS affects one-third of all adults in the United States and 
increases the risk of developing coronary artery disease (CAD), which continues to be the 
primary cause of mortality worldwide and accounts for 1 in 7 deaths in the United States 
[8]. CAD-induced ischemic cardiomyopathy is the leading cause of heart failure, followed 
by dilated non-ischemic cardiomyopathy, hypertension, and valvular heart disease [371].  
CAD is a progressive disease where initial endothelial damage leads to lipid and 
inflammatory cell infiltration of the arterial wall, causing medial thickening and neointima 
formation [372, 373]. This arterial restructuring is exacerbated by the proliferation and 
recruitment of coronary smooth muscle (CSM) cells to the plaque, which is accomplished 
by the phenotypic switching of CSM from a differentiated, contractile phenotype to a 
proliferative, migratory phenotype [68]. These migratory CSM cells secrete and deposit 
extracellular matrix like collagen, elastin, and fibrin into the thickening artery wall. While 
the presence of CSM inside the plaque contributes to plaque stability, over time the 
accumulation of lipid and cellular debris results in a necrotic core and plaque 
destabilization often leading to plaque rupture and myocardial infarction. In one study, 
patients hospitalized for ST elevation myocardial infarction who had multivessel CAD had 
an 8-year mortality from heart failure rate of 11%, as opposed to only a 1% mortality rate 
for individuals similarly hospitalized without multivessel CAD [374]. Further, CSM 
dedifferentiation into an osteogenic phenotype is associated with vascular calcification, 
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which is directly related to increased mortality and cardiac events [162], plaque instability, 
and rupture [163]. 
 Ca2+ is a vital secondary messenger involved in the regulation of several key 
smooth muscle cell functions such as transcription [186, 188], migration [184, 185], 
proliferation [68, 70, 249, 250], and contraction [68, 187]. Previous research (reviewed in 
[69]) has shown that CAD is accompanied by alterations in many CSM Ca2+ transporters, 
including voltage-gated Ca2+ channels [74, 76], transient receptor potential channels [125], 
sarco-endoplasmic reticulum Ca2+ ATPases [76, 77, 80], plasma membrane Ca2+ 
ATPases [76], and Na+/Ca2+ exchangers [76]. My lab recently showed that intracellular 
Ca2+ ([Ca2+]i) handling alterations that accompany CAD occur in a biphasic manner in 
Ossabaw miniature swine, with enhanced Ca2+ handling in early, mild disease and 
decreased Ca2+ handling in late, severe disease [81]. Furthermore, when the plaque was 
separated from the arterial wall in diseased coronary arteries, CSM isolated exclusively 
from the plaque region exhibited diminished SR Ca2+ store and SR Ca2+ pump activity, 
while CSM isolated from the arterial wall exhibited increased SR Ca2+ store SR Ca2+ pump 
activity [81].  
There is difficulty in finding an animal model for human CAD, as there are many 
risk factors and uncontrollable variables in the human population. My lab has thoroughly 
characterized the Ossabaw miniature swine model of MetS and CAD. Due to their “thrifty 
genotype,” Ossabaw swine have a propensity to develop all the characteristics of MetS 
when fed an atherogenic, hypercaloric diet without any further chemical or genetic 
interventions [204, 283]. While Ossabaw swine develop diffuse, human-like coronary 
plaques [80], CSM [Ca2+]i handling patterns have never been compared to freshly isolated 
CSM from human patients. Therefore, the aims of the current study are: 1) to determine 
how disease severity, arterial restructuring, and cardiometabolic risk factors are 
associated with [Ca2+]i dysfunction in fresh, non-cultured human CSM and 2) to determine 
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whether the Ossabaw miniature swine is a clinically relevant large animal model of MetS 
and CAD with regards to [Ca2+]i handling. These results will aid in characterizing the 
association between pathological arterial remodeling and dysfunctional [Ca2+]i handling in 
human heart failure patients and will strengthen the Ossabaw miniature swine as a model 
for CAD and CAD-related heart failure at the cellular level.  
Methods 
Collection of human tissue 
The current study implemented the collection of explanted human hearts from 24 
patients (15 male, 9 female; aged 51.0 ± 2.5 years) undergoing heart transplantation 
surgery at the Methodist Hospital in Indianapolis, IN between September 2015 and March 
2018. Explanted human hearts were collected at time of removal and stored for no longer 
than 24 hours in a physiological salt solution containing (in mM): 2 CaCl2, 138 NaCl, 1 
MgCl2, 5 KCl, 10 HEPES, 10 glucose; pH 7.4. Epicardial coronary arteries were excised 
and used for further analyses.  
Animals 
All experimental procedures involving animals were approved by the Institutional 
Animal Care and Use Committee at Indiana University School of Medicine with the 
recommendations outlined by the National Research Council and the American Veterinary 
Medical Association Panel on Euthanasia [170, 171]. Ossabaw miniature swine were fed 
either 1000 g/day of standard chow diet yielding 11% of total caloric intake from fat, 18% 
from protein, and 71% from carbohydrates for 11 months (5L80; Purina Test Diet, 
Richmond, IN) or 1000 g/day of a hypercaloric, atherogenic diet yielding 43% of total 
caloric intake from fat, 16% from protein, and 41% from carbohydrates, supplemented with 
cholesterol (2.0%), hydrogenated coconut oil (4.70%), hydrogenated soybean oil (8.40%), 
cholate (0.70%), and high fructose corn syrup (5.0%) by weight (n = 7 for both groups). 
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Pigs were euthanized via cardiectomy and coronary arteries were removed for further 
analysis.  
Swine metabolic phenotyping 
Blood from Ossabaw swine was collected at time of euthanasia and used for 
analysis (ANTECH Diagnostics, Fishers, IN). 
Histology 
Coronary artery segments from proximal epicardial arteries (2–4 mm in length) 
were placed in 10% phosphate-buffered formalin for 24–48 h, then transferred to 70% 
ethanol. Histology was performed in the Department of Anatomy and Cell Biology at 
Indiana University School of Medicine (Indianapolis, IN). Arterial cross-sections were 
stained using Verhoeff-Van Gieson (VVG), Von Kossa (VK), and Masson’s Trichrome 
staining techniques. The VVG elastin stain was used to determine media area and plaque 
burden, which I define as the percentage of the original lumen that is occupied by 
atherosclerotic plaque. The VK staining technique stains calcified areas black to determine 
the overall percent vascular calcification. The Masson’s Trichrome staining technique was 
used in order to visualize the collagen (blue) and cellular composition (red) in the coronary 
artery sections. All images were captured with a Leica DM3000 microscope connected to 
Leica Application Suites V4.1 software (Leica Microsystems GmbH, Wetzlar, Germany) 
and analyzed using Adobe Photoshop® CS6) (for full protocols, see Appendices B, C, and 
D). 
Assessment of [Ca2+]i regulation 
Whole-cell intracellular free Ca2+ levels were measured at room temperature (22 
to 25°C) by using the fluorescent Ca2+ indicator fura-2 AM (InCa++ Ca2+ Imaging System, 
Intracellular Imaging, Cincinnati, OH) as previously described [80, 125, 204, 283]. Briefly, 
freshly dispersed smooth muscle cells from the left anterior descending (LAD) artery were 
incubated with 3.0 μM fura-2 AM (Molecular Probes, Eugene, OR) in a shaking water bath 
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at 37 °C for 45 min before being washed in a solution containing a low Ca2+ concentration. 
An aliquot of cells loaded with fura-2 AM was placed on a coverslip contained within a 
constant-flow superfusion chamber that was mounted on an inverted epifluorescent 
microscope (model TMS-F, Nikon, Melville, NY), with flow maintained at a constant rate 
of 1-2 mL/min. Basal Ca2+ levels were measured in physiologic salt solution composed of 
the following (in mM): 2 CaCl2, 138 NaCl, 1 MgCl2, 5 KCl, 10 HEPES, 10 glucose; pH 7.4. 
Calcium influx and maximal sarcoplasmic reticulum (SR) Ca2+ loading was accomplished 
by depolarization with high (80 mM) K+ solution (2 CaCl2, 63 NaCl, 1 MgCl, 80 KCl, 10 
HEPES, 10 glucose; pH 7.4) to activate voltage-gated Ca2+ channels (VGCCs). SR Ca2+ 
stores were released with 5 mM caffeine in Ca2+-free solution (138 NaCl, 1 MgCl2, 5 KCl, 
10 HEPES, 10-5 M K+-EGTA, 10 glucose; pH 7.4) to activate ryanodine receptors (RyRs) 
(for solution recipes, see Appendix F). A caffeine wash-out phase was used to determine 
sarco-endoplasmic reticulum Ca2+ ATPase (SERCA) function via the undershoot below 
baseline during this recovery period [105, 203, 375]. The increased [Ca2+]i after caffeine 
exposure stimulates Ca2+ extrusion, allowing [Ca2+]i to equilibrate to baseline levels [376]. 
However, SERCA is also stimulated by high [Ca2+]i and low concentrations of Ca2+ inside 
the SR after caffeine exposure [376, 377]. As the SR initially accumulates Ca2+ quicker 
than Ca2+ can enter the cell, the signal drops below baseline (the “undershoot”) [376]. 
Furthermore, application of the SERCA inhibitor cyclopiazonic acid abolishes this 
undershoot [376]. Therefore, SERCA function is directly responsible for this undershoot 
below baseline [376-378]. Fura-2 in CSM was excited by light from a 300 W xenon arc 
lamp that was passed through a computer-controlled filter changer containing 340 nm and 
380 nm bandpass filters every 0.30 and 0.05 seconds, respectively. The fluorescence 
emission at 510 nm was collected by using a monochrome charge-coupled device camera 
(COHU, San Diego, CA) (for full protocol, see Appendix E). Whole-cell fura-2 fluorescence 
   
  119   
was expressed as the 340 nm/380 nm ratio of fura-2 emission. A graph demonstrating the 
experimental protocol is shown in Fig. 6.2. 
Statistics 
Statistical analysis was performed using GraphPad Prism 5.0 (San Diego, CA). 
Unpaired student’s t test was performed for comparisons in swine and one-way analysis 
of variance (ANOVA) with Newman–Keuls post hoc analysis for comparison of the human 
groups was performed. Data are presented as mean ± standard error. Correlations were 
determined using Pearson’s product-moment coefficient of correlation. Simple regression 
analyses were performed to determine statistical significance of the correlations. p<0.05 
was considered statistically significant. 
Results 
Structure of human and swine coronary arteries 
Representative histological stains for humans (Fig. 6.1A-F) and swine (Fig. 6.1G-
L) are shown. Human arteries show great diversity in disease state and structure and have 
been grouped based on percent plaque burden (Fig. 6.1M). While calcification was similar 
between human groups due to high within-group variability (Fig. 6.1N), fibrosis as 
measured by percent collagen was increased in the >75% plaque burden group compared 
to the <50% plaque burden group (Fig. 6.1O). Similar to the human groups, swine with 
MetS-induced CAD exhibited a significantly higher percent plaque burden (Fig. 6.1M), 
similar vascular calcification (Fig. 6.1N), and significantly greater collagen content (Fig. 
6.1O) as compared to their lean counterparts. The double bar on the x-axes of the graphs 
separates the human and swine data and signifies that statistics were done only between 
experimental groups of the same species.  
Clinical characteristics are similar in humans with different CAD severities 
Clinical characteristics of patients and swine are outlined in Table 6.1. All human 
groups exhibit similar clinical and metabolic characteristics. Measured heart function 
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parameters were also similar between the groups, including ejection fraction, left 
ventricular end diastolic pressure, and coronary output as qualitatively recorded in patient 
records (data not shown). Overall, while these groups differ in terms of CAD severity, they 
exhibit comparable metabolic and functional disease parameters, i.e. similar increased 
cardiometabolic risk above healthy subjects. Swine on an atherogenic diet, however, 
developed significantly higher weight, systolic blood pressure, fasting blood glucose, total 
cholesterol, and triglyceride levels compared to lean controls. This is unsurprising, as 
these elevated parameters are indicative of MetS / cardiometabolic risk.  
Disease severity, arterial structure, and certain metabolic parameters are correlated to 
changes in [Ca2+]i handling 
Figure 6.2 shows a sample Ca2+ tracing from a representative human CSM cell. 
Linear regression analyses were performed to evaluate the relationship between structural 
changes or individual cardiometabolic risk factors and alterations in CSM [Ca2+]i handling 
(Table 6.2). Greater CAD severity, as measured by the intima/media ratio and percent 
collagen [81], was significantly correlated to a decreased Ca2+ influx (as measured by the 
height of the depolarization-induced Ca2+ influx peak and by the area under the curve of 
that peak) and a decreased SR Ca2+ store release. In contrast to those inverse 
correlations, an increased media area was positively correlated to enhanced Ca2+ influx 
and SR Ca2+ store release. Increased vascular calcification was correlated to a decreased 
Ca2+ influx. BMI and the number of MetS risk factors present in the patient were correlated 
to a decreased Ca2+ influx. Dyslipidemia, including increased LDL and total cholesterol 
levels, was correlated not only to decreased Ca2+ influx, but also to SERCA dysfunction. 
Age was significantly correlated to an increased SR Ca2+ store release. Correlation graphs 
are presented in Supplemental Figs. 6.1 and 6.2. Some of these correlations can also be 
seen in recent papers utilizing the Ossabaw miniature swine model of MetS/CAD [81, 204, 
283].  
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[Ca2+]i handling in Ossabaw swine recapitulates [Ca
2+]i handling in human CSM in both 
health and disease 
A representative single cell tracing from a lean swine and a MetS swine are 
graphed with a representative single cell tracing from a human with mild CAD, as defined 
by a plaque burden below 50%, and a human with severe CAD, as defined by a plaque 
burden of over 75% (Fig. 6.3A). The CSM cell tracing from the human with mild CAD 
closely resembles the tracing from the lean swine, while the CSM cell tracing from the 
human with severe CAD closely resembles the tracing from the MetS swine. Humans with 
less than 50% plaque burden and 50-75% plaque burden did not exhibit any differences 
in [Ca2+]i handling, while humans with greater than 75% plaque burden had a significantly 
lower Ca2+ influx (Fig. 6.3B), SR Ca2+ store release (Fig. 6.3C), and undershoot (Fig 6.3D). 
Swine with MetS-induced CAD showed remarkably similar directional changes, with a 
lower Ca2+ influx (Fig. 6.3B), SR Ca2+ store release (Fig. 6.3C), and undershoot (Fig 6.3D) 
in the MetS group compared to the lean group. This clearly illustrates that similar [Ca2+]i 
handling alterations are present in CAD in humans and Ossabaw miniature swine.  
Discussion 
This study provides insight into [Ca2+]i handling in freshly isolated CSM from human 
cardiomyopathy patients with undergoing heart transplantation. I found that a thickened 
media layer, which is associated with mild CAD, and aging were correlated to enhanced 
[Ca2+]i signaling. Advanced CAD progression, as measured by plaque burden and percent 
collagen, and  the number of MetS / cardiometabolic risk factors, BMI, and LDL and total 
cholesterol levels, are correlated to decreased [Ca2+]i signaling. Increased vascular 
calcification was accompanied by a decrease in Ca2+ influx. A more severe dyslipidemic 
state, as measured by higher LDL and total cholesterol levels, was also correlated to 
greater SERCA dysfunction. These trends exemplify that [Ca2+]i regulation is 
compromised in patients with severe, more occlusive disease and in patients with certain 
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MetS risk factors. By measuring [Ca2+]i from freshly dispersed, non-cultured CSM from 
human patients undergoing heart transplantation, I provide novel insight into the intricacies 
of [Ca2+]i dysregulation in diseased human CSM ex vivo and how CAD severity and certain 
metabolic risk factors are correlated with this dysregulation. The [Ca2+]i dysregulation 
patterns seen in Ossabaw miniature swine with MetS, CAD, and advanced age are 
consistent with the human data [81, 204, 283], supporting the strong clinical relevance of 
this large animal model, both on the whole-animal level and on the cellular level.  
Recently, my lab has clarified that CSM Ca2+ handling dysfunction occurs in a 
biphasic manner during CAD progression, with upregulated [Ca2+]i handling in early CAD 
and downregulated [Ca2+]i handling in late CAD [81]. Dysregulation of Ca2+ signaling 
pathways are associated with CSM dedifferentiation into a synthetic or osteogenic 
phenotype, which is followed by proliferation, migration to the growing neo-intima, and 
deposition of hydroxyapatite crystals in the extracellular matrix leading to vascular 
calcification [379]. Often, this change in phenotype occurs due to CSM adaptations to 
changes in the extracellular environment, such as increased reactive oxygen species 
(ROS) and dyslipidemia [310, 380, 381].  
The oxidation of LDL cholesterol (ox-LDL) is a key step in atherogenesis. It has 
been found that exposure to ox-LDL decreases SERCA activity in cultured New Zealand 
white rabbit aortic smooth muscle cells and in cultured bovine aortic endothelial cells due 
to the irreversible oxidation of the SERCA protein [382-384]. This study supports this 
notion, as humans with greater dyslipidemia, including a higher level of LDL cholesterol, 
exhibited more dysfunctional SERCA activity. 
Heart failure is a complex, heterogeneous disease with many different etiologies, 
risk factors, and pathophysiologies. CAD is the leading cause of heart failure, and it’s been 
found that progression of CAD is related to progression of left ventricular dysfunction, a 
common characteristic of heart failure [385]. While the clinical diagnosis of ischemic 
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cardiomyopathy is an important predictor of 5-year mortality, the extent of CAD is a much 
better predictor of survival in heart failure patients [386]. In the current study I used 
histology obtained from the proximal segment of a conduit epicardial coronary artery from 
patients with cardiomyopathy in order to classify their coronary disease state. Histology 
can be considered a “snapshot” of one specific cross-section of the vessel, not necessarily 
indicative of total vessel health. However, as both humans and Ossabaw swine develop 
diffuse coronary plaque throughout the proximal, middle, and distal sections of the artery 
[80], the histology could be considered a representative snapshot of overall coronary 
health and plaque development.  
I determined that patients with different cardiac and coronary disease severities 
have similar clinical characteristics and biochemistry. It is especially important to note, 
however, that the patients have similarly increased cardiometabolic risk above healthy 
subjects. There is enough variability within all the groups that enabled excellent regression 
analysis.  This allowed us to test for associations between cardiometabolic risk factors 
and [Ca2+]i regulation. Additionally, I show that the number of MetS risk factors, as 
opposed to the diagnosis of MetS itself, affects [Ca2+]i regulation. This is in agreement with 
several different studies [14, 387, 388]. A Japanese study found that patients with either 
dilated non-ischemic cardiomyopathy or ischemic cardiomyopathy have an incidence of 
MetS twice as frequently as the general population and have comparable metabolic 
components, indicating that the risk factors associated with MetS influence the etiology of 
both ischemic and nonischemic cardiomyopathy [389].  
Although humans and swine cannot and should not be directly compared, it is 
apparent that, while humans in general have a greater plaque burden than swine (Fig. 
6.1M), swine exhibit more highly altered [Ca2+]i handling in all the measured parameters 
(Fig. 6.3B-D). This may be due to the duration of the disease and severity of the risk 
factors. Atherosclerosis is a chronic disease occurring over several decades in the human 
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population. Conversely, the Ossabaw swine with MetS-induced CAD are on a diet 
specifically designed to expedite plaque development over a time span of only 11 months. 
This could lead to more rapid changes in the cellular milieu, potentially causing more 
extreme adaptations in CSM leading to enhanced [Ca2+]i dysfunction as compared to the 
slower, more chronic condition as is seen in humans. This also supports the concept that 
[Ca2+]i handling changes occur before and potentiate structural changes in the artery.  
Hearts from healthy humans without heart failure were not included due to a dearth 
of tissue. Therefore, this study indirectly compares arteries from pathological human 
hearts to physiologically healthy, lean swine. While there is no perfect animal model to 
recapitulate human disease, this presents a weakness of this study. However, as I am 
concerned with relationships in [Ca2+]i handling as a function of cardiometabolic risk and 
are not comparing these two species directly, I can still extrapolate from the data that the 
directional changes in [Ca2+]i dysregulation patterns from a state of mild or no disease to 
a state of greater disease is maintained in both species. Another weakness of this study 
is the relatively small human sample set, so future studies should expand on these 
findings.  
An adequate animal model for coronary artery disease and subsequent heart 
failure is of utmost importance, as a better understanding of the pathophysiology of 
cardiomyopathies could lead to the development of more effective heart failure 
therapeutics. This report is the first characterization of [Ca2+]i dysregulation in freshly 
harvested CSM from explanted human hearts. The data strongly support the clinical 
relevance of the Ossabaw miniature swine model of MetS and CAD. A reliable, clinically 
relevant animal model that recapitulates human disease on a cellular level provides far 
more confidence of the translatability of the data.  
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Figures  
 
Figure 6.1: Histological staining reveals pathological remodeling in both humans 
and swine. Coronary artery histological sections from a human with <50% plaque burden 
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(A-C), a human with >75% plaque burden (D-F), a lean swine (G-I), and a MetS swine (J-
L). VVG elastin staining was used to determine plaque burden and the areas of the tunica 
media and tunica intima using the highly visible external elastic lamina (EEL, red dashed 
line) and internal elastic lamina (IEL, yellow dashed line) (A, D, G, J). VK staining was 
used to determine percent of vascular calcification (black) (B, E, H, K). Masson’s 
Trichrome staining was used to determine the percent collagen (blue) (C, F, I, L). Humans 
(grey bars) were binned based on percent plaque burden and swine (red bars) showed 
significantly increased plaque burden in the MetS group compared to the lean group (M). 
Percent vascular calcification was not significantly different between human or swine 
groups (N). The percent collagen increased with disease in both the human and swine 
groups (O). EEL, external elastic lamina; IEL, internal elastic lamina; M, tunica media; I, 
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Figure 6.2: Sample Ca2+ tracing showing the change in the F340/F380 excitation 
fluorescence emission ratio from a human CSM cell. Treatments and duration are 
indicated by solid lines. Baseline Ca2+ values were established during the first minute in a 
physiological salt solution (red dashed line). Cell depolarization was accomplished with an 
80 mM K+ solution, which initiated Ca2+ influx via VGCCs and maximally loaded the SR 
Ca2+ store. The height of the Ca2+ influx peak (blue arrow) and the area under the curve 
(orange area) were calculated to quantify Ca2+ influx activity. SR Ca2+ store was released 
by activating ryanodine receptors with 5 mM caffeine and can be measured by the height 
of the caffeine-induced peak (purple arrow).  The undershoot below baseline was used to 
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Figure 6.3: Sample Ca2+ tracing showing the change in the F340/F380 excitation 
fluorescence emission ratio from a human and swine CSM cells. (A) Typical Ca2+ 
tracings show similarities between humans with mild CAD and lean swine and between 
humans with severe CAD and MetS swine (A). Mild CAD was defined by a plaque burden 
below 50%, while severe CAD was defined by a plaque burden of over 75%. In disease, 
both humans and swine exhibit decreased Ca2+ influx (B), SR Ca2+ store capacity (C), and 
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Tables 
Table 6.1: Clinical characteristics of human subjects and swine 
Humans <50% PB 50-75% PB >75% PB p 
N 7 11 6 - 
Anthropometric Data     
Height (cm) 170 ± 4 176 ± 3 176 ± 4 N.S. 
Weight (kg) 81 ± 6 86 ± 5 86 ± 10 N.S. 
BMI (kg/m2) 28 ± 2 27 ± 1 27 ± 2 N.S. 
Clinical Data     
Age (years) 52 ± 5 51 ± 4 49 ± 5 N.S. 
Male/Female 3/4 7/4 5/1 N.S. 
SBP (mmHg) 107 ± 5 110 ± 5 104 ± 4 N.S. 
DBP (mmHg) 67 ± 5 70 ± 5 69 ± 4 N.S. 
Ex-smoker 2 (29%) 3 (27%) 4 (67%) N.S. 
LVAD 3 (43%) 7 (64%) 4 (67%) N.S. 
Presence of MetS 3 (43%) 4 (36%) 3 (50%) N.S. 
No. MetS risk factors 1.9 ± 0.7 2.1 ± 0.4 2.5 ± 0.6 N.S. 
Biochemistry Data     
Fasting bG (mg/dL) 128 ± 18 106 ± 15 106 ± 10 N.S. 
HbA1c (%) 5.6 ± 0.2 5.5 ± 0.1 5.0 ± 0.3 N.S. 
Total cholesterol 
(mg/dL) 
139 ± 7 161 ± 20 136 ± 18 N.S. 
LDL (mg/dL) 75 ± 7 97 ± 17 81 ± 18 N.S. 
HDL (mg/dL) 40 ± 4 38 ± 4 34 ± 2 N.S. 
LDL/HDL Ratio 2.0 ± 0.2 2.7 ± 0.4 2.3 ± 0.5 N.S. 
Triglycerides (mg/dL) 117 ± 19 128 ± 14 108 ± 13 N.S. 
Comorbidities     
Atrial Fibrillation 2 (29%) 5 (45%) 3 (50%) N.S. 
Diabetes mellitus 2 (29%) 2 (18%) 0 (0%) N.S. 
Kidney Disease 3 (43%) 3 (27%) 1 (17%) N.S. 
Cancer 1 (14%) 1 (9%) 0 (0%) N.S. 
Clinical Depression 3 (43%) 3 (27%) 4 (67%) N.S. 
Treatments     
Aspirin 4 (57%) 10 (91%) 3 (50%) N.S. 
ACEI/ARB 2 (29%) 4 (36%) 2 (33%) N.S. 
β-blocker 3 (43%) 8 (73%) 2 (33%) N.S. 
Ca-blocker 1 (14%) 1 (9%) 0 (0%) N.S. 
Diuretics 4 (57%) 9 (82%) 4 (67%) N.S. 
Lipid-lowering drugs 2 (29%) 4 (36%) 2 (33%) N.S. 
Anti-diabetic drugs 2 (29%) 2 (18%) 0 (0%) N.S. 
Anti-arrhythmic drugs 4 (57%) 8 (73%) 4 (67%) N.S. 
Antidepressants 3 (43%) 3 (27%) 4 (67%) N.S. 
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Swine Lean MetS p 
N 7 7 - 
Weight (kg) 77 ± 4 110 ± 3 <0.05 
Age (years) 2.6 ± 0.1 2.8 ± 0.2 N.S. 
Male/Female 4/3 1/6 N.S. 
SBP (mmHg) 82 ± 3 90 ± 5 <0.05 
DBP (mmHg) 59 ± 3 60 ± 5 N.S. 
Fasting bG (mg/dL) 69 ± 3 80 ± 3 <0.05 
Total cholesterol 
(mg/dL) 
80 ± 6 391 ± 108 <0.05 
Triglycerides (mg/dL) 52 ± 6 67 ± 4 <0.05 
Data are presented as number (%) or mean ± SEM. PB, plaque burden; BMI, body mass 
index; SBP, systolic blood pressure; DBP, diastolic blood pressure (humans conscious; 
swine under anesthesia); LVAD, left ventricular assistance device; MetS, metabolic 
syndrome; bG, blood glucose; HbA1c, glycated hemoglobin; LDL, low-density lipoprotein; 
HDL, high-density lipoprotein; ACEI, angiotensin converting enzyme inhibitors; ARB, 
angiotensin II receptor blockers; Ca, calcium. MetS was defined by a blood pressure 
above 130/85 mmHg, a fasting blood glucose above 110 mg/dL, an HDL-C level below 40 
mg/dL for men or below 50 mg/dL for women, a triglyceride level above 150 mg/dL, and a 
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Table 6.2: Linear regression analyses for CSM [Ca2+]i handling measures versus 
histology measurements and patient parameters 
 p R 
Structural (Histology) Parameters   
Percent Media vs.   
Ca2+ Influx 0.01 0.51 
80K AUC 0.03 0.44 
SR Store Release 0.08 0.38 
Intima/Media Ratio vs.   
Ca2+ Influx 0.02 -0.50 
80K AUC 0.03 -0.43 
Percent Total Collagen vs.    
Ca2+ Influx 0.01 -0.51 
80K AUC <0.01 -0.60 
SR Store Release 0.02 -0.49 
Percent Calcification vs.    
Ca2+ Influx 0.02 -0.48 
Patient Biochemistry Parameters   
BMI vs.   
Ca2+ Influx 0.03 -0.42 
80K AUC 0.01 -0.52 
Age vs.    
SR Store Release 0.02 0.47 
Number of MetS Risk Factors vs.    
80K AUC 0.01 -0.51 
LDL vs.    
Ca2+ Influx 0.01 -0.48 
Undershoot 0.03 -0.45 
Cholesterol vs.   
Ca2+ Influx 0.04 -0.41 
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CHAPTER 7: CONCLUSION 
Summary of Findings 
Metabolic syndrome (MetS) is a growing public health concern in the United States 
that currently affects 1 in 3 Americans. MetS is positively associated with age and greatly 
increases the risk of developing comorbidities such as type 2 diabetes. MetS, age, and 
T2D are all independent risk factors for coronary artery disease (CAD), which continues 
to be the leading cause of death in the US and globally [8]. With the growing aging 
population, determining the mechanisms of disease progression is of utmost importance 
to provide molecular targets for therapies for this expanding demographic.  
Pathological arterial remodeling necessitates coronary smooth muscle (CSM) 
phenotypic switching from a contractile phenotype to non-contractile phenotypes with 
differing functional capabilities, such as proliferation and extracellular matrix synthesis, 
inflammation, and mineralization [269]. Recently, the biological complexity of CSM 
phenotypic modulation is beginning to be elucidated with cutting-edge techniques such as 
single-cell RNA sequencing.  
 Calcium is a vital secondary messenger that controls numerous cellular functions, 
such as contraction, migration, proliferation, transcription, and apoptosis [270]. As such, 
intracellular Ca2+ ([Ca2+]i) handling is closely coupled to changes in phenotype. Altered 
[Ca2+]i handling modes in different CSM phenotypes throughout CAD progression are 
shown in Fig. 7.1. A great number of Ca2+ transporters, including voltage-gated Ca2+ 
channels (VGCC), sarco-endoplasmic reticulum Ca2+-ATPase (SERCA), extrusion 
mechanisms like the sodium-calcium exchanger (NCX) and the plasma membrane Ca2+-
ATPase (PMCA), as well as SR Ca2+ storage itself, exhibit altered activity and/or 
expression in CAD. This results in different global and localized [Ca2+]i levels and Ca2+ 
dynamics, which are important for transcriptional events (“excitation-transcription” 
coupling) and lead to CSM phenotypic modulation [63, 68, 72, 273, 379, 390, 391]. In 
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particular, sarcoplasmic / endoplasmic reticulum (SR / ER) Ca2+ store capacity in vascular 
smooth muscle has received attention due to its association with proliferation [70, 392-
396], activation (or repression) of store-operated Ca2+ entry (SOCE) [397-401], localized 
SR Ca2+ release (“Ca2+ sparks”) activation of plasmalemmal ion channels [70, 402-404], 
and ER stress [89, 405].  
Therefore, the primary aim of this dissertation work was to investigate Ca2+ 
dysregulation patterns, primarily with regard to SR Ca2+ store capacity, in several 
etiologies of MetS and how that corresponds to modulation of the coronary smooth muscle 
transcriptome and phenotype. This was done through several independent research 
projects that investigated these specific aims:  
Investigative Aim 1: SR Ca2+ store capacity is correlated with coronary smooth 
muscle cytodifferentiation and subsequent arterial remodeling in Ossabaw 
miniature swine models of different CAD etiologies. The results of these studies show 
that ([Ca2+]i) handling throughout CAD progression is uniform in several etiologies of the 
disease, including T2D and aging. Diabetes on a MetS background exacerbated CAD and 
elicited [Ca2+]i handling typical of severe disease. However, even though MetS old swine 
had similar Ca2+ dysregulation as the MetS young swine, they showed a much greater wall 
thickness and neointima formation. This indicates that the aging milieu may be responsible 
for more advanced coronary plaques in the context of MetS. Overall, these findings 
support the notion of common [Ca2+]i handling dysregulation among different etiologies.  
Investigative Aim 2: Proliferative and osteogenic coronary smooth muscle cells will 
exhibit altered transcriptomic profiles and SR Ca2+ store capacity depending on 
disease progression. In this novel study utilizing single-cell RNA sequencing with a 
singular tissue source, I determined that CSM from an organ-cultured model of CAD 
exhibit different transcriptomic profiles, with a decrease in global expression of contractility 
markers and an upregulation of genes involved in proliferation, migration, coronary artery 
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calcification (CAC), and inflammation. However, every CSM subgroup contained markers 
for many different phenotypes and an upregulation of genes associated with various 
cellular functions. This supports the notion that phenotypic switching is not a discreet event 
or a singular continuum as described previously in the literature (Fig. 7.2), but a complex 
network of overlapping genes and functions (Fig. 7.3).  
Investigative Aim 3: CSM SR Ca2+ store capacity changes in humans with coronary 
artery disease (CAD) and heart failure are similar to those found in Ossabaw swine. 
Results from animal studies are only as clinically relevant as the animal model used. In 
this study I compared [Ca2+]i dysregulation seen in Ossabaw miniature swine with MetS to 
humans with ischemic and non-ischemic heart failure undergoing heart transplantation. 
Results show similar [Ca2+]i handling dysregulation in humans with heart failure and 
Ossabaw swine with MetS, including similar trends in reduced depolarization-induced Ca2+ 
influx, SR store release, and SERCA function. Furthermore, data in humans supports the 
[Ca2+]i handling trends seen in aged swine, further validating the clinical relevance of this 
animal model.  
Future Directions 
There is ample evidence for CSM [Ca2+]i dysregulation in CAD. In this work, I have 
established that [Ca2+]i dysregulation patterns are common among different etiologies of 
CAD and that the phenotypic switching events associated with this [Ca2+]i dysregulation 
are highly complex and deserving of further investigation.  
 It has been known for about three decades [406] that stimuli such as cytokines and 
growth factors can initiate phenotypic modulation of quiescent, contractile CSM cells to a 
proliferative, synthetic phenotype. This phenotypic plasticity is necessary for vascular 
remodeling, and as such it is associated with many various cardiovascular diseases, 
including CAD. The transcriptome of this complex process is just now being elucidated. 
While the literature repeatedly describes this phenotypic switch as a “spectrum” (Fig. 7.2), 
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I determined that it more closely follows a complicated upregulation of genes involved in 
multiple functions, including extracellular matrix synthesis, cellular proliferation, 
inflammation, and mineralization (Fig. 7.3). CSM cells in the vascular wall are composed 
of various different phenotypes that may express differential expression of genes involved 
in one or more of these processes. While many studies focus on either a shift in canonical 
phenotypic markers or simply a loss of contractile markers [278], this may not be an ideal 
technique of phenotype identification [407]. Several studies have shown that actively 
proliferating cultured cells express genes associated with both the contractile and 
synthetic phenotypes [269, 298, 299]. This is even more confounded by the time course 
of expression of certain contractile markers, with some markers like SM α-actin and 
transgelin expressed early in development and other markers like smooth muscle myosin 
heavy chain and calponin are only expressed in mature, late differentiation [408]. It has 
been shown that there can be multiple phenotypes of contractile cells themselves. 
Vascular injury induces even greater phenotypic heterogeneity, illustrating the diversity of 
CSM cell subpopulations in coronary plaques [276].  
 This complicates experiments that aim to elucidate mechanisms of phenotypic 
transition or characteristics of a particular phenotype, as CSM cell subpopulations do not 
fit into neat and orderly groups. In fact, previous studies have shown that a majority of 
CSM cells within atherosclerotic plaques lose expression of contractile markers, and other 
cells populating the plaque such as macrophages and foam cells can highly express CSM 
contractile markers [300-302, 409]. Therefore, the origin of cells in the vascular wall needs 
to be established to adequately identify CSM-derived cells. Some studies have already 
set out to track cell lineages to ensure the cells being studied are indeed of CSM origin as 
opposed to macrophage, myeloid, or adventitial origin [408]. Experiments utilizing smooth 
muscle cell (SMC)-specific conditional lineage tracing mouse models [408, 410] have 
shown that more than 80% of SMC-derived cells within advanced atherosclerotic plaques 
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do not have detectable levels of contractile marker expression and about 20% of cells 
expressing macrophage markers were of SMC origin [408]. Therefore, typical methods of 
CSM phenotype identification such as immunostaining may not reflect the number of 
CSM-derived cells and may also misidentify cell types [408].  
 Without adequate lineage experiments, we run the risk of mischaracterizing the 
origins of different cell types, possibly confounding the results. This is illustrated in a study 
by Tang et al., which found that mature SMCs are terminally differentiated and that the 
primary source of neointimal cells after vascular injury is derived from what they claimed 
was a novel previously uncharacterized medial stem cell population [411]. However, the 
conclusions made in this paper were quickly refuted by experts in the field, who also 
pointed to major design flaws in the Tang et al. study [303, 408]. Various other 
controversies surround phenotypic modulation, such as whether CSM-like cells within 
lesions are of myeloid origin [408, 412-414]. One study even showed that a proportion of 
myeloid cells can express early but not late contractile markers [408, 415]. CSM 
phenotypic switching is a complicated biological process involved in pathological vascular 
remodeling that deserves further investigating.   
 Phenotypic switching is accompanied by changes in [Ca2+]i handling, [Ca2+]i 
dynamics, and Ca2+ transporter activity and expression. Briefly, in contractile CSM that 
populate the tunica media, Ca2+ influx is primarily achieved via VGCCs. These Ca2+ 
“sparklets” increase the rate of SR Ca2+ loading and can induce Ca2+-induced Ca2+ release 
(CICR) via ryanodine receptors (RyR) and IP3 receptors (IP3R) on the sarcoplasmic 
reticulum (SR) membrane [390, 416]. CICR results in local increases in [Ca2+]i that can 
propagate throughout the length of the cell by activation of adjacent RyRs and IP3Rs. This 
forms Ca2+ waves from these discreet SR Ca2+ release events and serves as the basis for 
excitation-contraction (E-C) coupling [390, 417]. RyR are known to couple with large-
conductance Ca2+-activated K+ channels (BKCa), so Ca2+ sparks resulting from opening of 
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RyR can activate BKCa channels and cause membrane hyperpolarization and relaxation 
[70, 417]. [Ca2+]i levels return to baseline by efflux mechanisms on the plasma membrane 
including the sodium-calcium exchanger (NCX) and the plasma membrane Ca2+ ATPase 
(PMCA), but the sarco-endoplasmic reticulum Ca2+ ATPase (SERCA) pump sequesters 
about 70% of cytosolic Ca2+ into the SR and is principally responsible for keeping basal 
[Ca2+]i levels low [71, 72]. These localized and dynamic [Ca2+]i changes control contraction 
and have been shown to promote the contractile phenotype by VGCC-dependent 
expression of serum response factor (SRF), a transcription factor that, along with the 
coactivator myocardin, stimulates the expression of CSM contractile markers [188, 418].  
 Phenotypic switching from a contractile state to a non-contractile state is 
characterized by a higher basal [Ca2+]i and a greater contribution of store-operated Ca2+ 
entry (SOCE). Briefly, depletion of the SR Ca2+ store causes STIM1 translocation from the 
SR to the plasma membrane where it forms a channel with the Orai1 protein known as 
the Ca2+-release activated Ca2+ channel (CRAC; ICRAC). The Ca2+ content of the SR store 
dictates the activity of CRAC, and increased ICRAC is associated with higher global basal 
[Ca2+]i levels, [390, 419]. High basal [Ca2+]i levels activate the Ca2+-dependent 
transcription factors CREB and NFAT, which translocate to the nucleus and promote 
expression of genes involved in proliferation, migration, and inflammation [63, 72, 420, 
421]. The relationship between SR Ca2+ store and the regulation of CSM phenotype can 
be considered a “dose-response” relationship. The optimal SR Ca2+ store promotes the 
contractile phenotype, an increase in SR Ca2+ store is associated with proliferation, and a 
decrease in SR Ca2+ store is associated with ER stress, apoptosis, and severe vascular 
calcification [81, 89]. Future research should focus on the relationship between SR Ca2+ 
store and MetS duration. The SR Ca2+ store could be experimentally altered using SERCA 
activators such as CDN1163 or inhibitors such as cyclopiazonic acid, then running scRNA-
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seq at the same time point in order to elucidate a more definitive role of the SR Ca2+ store 
size on the CSM transcriptome.  
 However, cells undergoing phenotypic transition in the context of CAD display a 
biphasic pattern of [Ca2+]i dysregulation, with increased Ca2+ influx via VGCC, SR Ca2+ 
store release, and SERCA function in early, mild disease and decreased Ca2+ influx via 
VGCC, SR Ca2+ store release, and SERCA function in late, severe disease [81]. Perhaps 
initial elevated Ca2+ transporter activity and SR Ca2+ store, which has been documented 
in phenotypic switching in some studies [419], results in greater release of Ca2+ via RyR 
and IP3R, leading to increased basal [Ca2+]i levels. Stressors in the disease milieu 
including reactive oxygen species (ROS), oxLDL, inflammation, and ER stress. 
Overproduction of ROS can lead to release of SR Ca2+ store via the IP3R and inhibition of 
SERCA and PMCA [422]. Increased oxLDL infiltration in the vessel wall leads to increased 
ER stress and decreased VGCC activity [89, 423]. Inflammation is associated with 
decreased SERCA expression [424]. All of these listed stressors also induce CAC by 
upregulating genes associated with the osteogenic phenotype [425-428]. What is the 
specific time course of the changes in Ca2+ transporter activity during phenotypic 
switching? What triggers the biphasic Ca2+ handling pattern? Can any therapeutic 
interventions stop this aberrant [Ca2+]i handling and  thus prevent pathological CSM 
phenotypic switching? Clearly, the precise molecular switch(es) controlling the transition 
from increased Ca2+ handling in mild disease to decreased Ca2+ handling in late disease 
and the accompanying phenotypic transitions needs further investigating.  
 In this dissertation work, I used the intracellular Ca2+ indicator fura-2 on a wide-
field microscope. This enabled the measurement of global [Ca2+]i in individual cells. 
However, as discussed earlier in this section, Ca2+ dynamics and localized Ca2+ signaling 
events are of utmost importance for E-C coupling, E-T coupling, and phenotypic 
transitions. Other microscopy techniques such as laser scanning confocal microscopy and 
   
  139   
total internal reflection fluorescence (TIRF) can measure highly localized Ca2+ signaling 
events on a micro- and nano-domain level [429]. Future studies should utilize these 
microscopy techniques to visualize more localized [Ca2+]i handling, which may paint a 
more complete picture of cellular Ca2+ handling dysregulation in diseased cells (e.g. [394, 
430]). 
 In this work, I investigated the CSM Ca2+ handling patterns and arterial structure 
of Ossabaw swine with alloxan-induced diabetes and advanced age. More than 65% of 
patients with diabetes will die from cardiovascular disease [431]. Chronic hyperglycemia 
has been shown to modulate CSM phenotype by the activation of NF-κB via the activation 
of receptor of advanced glycation end-products (RAGE) [432]. The ligand for RAGEs, 
advanced glycation end-products (AGEs) are also known to promote CAC by osteogenic 
de-differentiation [433]. Reduced production of NO also activates NF-κB to promote 
inflammation and is associated with a lower expression of RyR, less Ca2+ sparks, less 
BKCa activation, and less relaxation in general [431]. Changes in SR store capacity is 
associated with disease and aging, and [Ca2+]i has been shown to increase in both 
diabetes and aging [402, 431]. This is consistent with the higher proliferation rate seen in 
CSM from older animals. The increased proliferation rate is tied to cellular senescence, 
which is known to increase CAC through osteogenic transition [434]. Aging is also 
associated with increased response to vasoconstrictors, formation of ROS, and collagen 
synthesis [256]. Studies in New Zealand white rabbits determined that older rabbits on a 
hypercholesterolemic diet developed more severe atherosclerotic lesions compared to 
younger counterparts despite the fact that both groups were on the same diet for the same 
amount of time and had similar blood lipid profiles [55, 435]. The aging milieu primes the 
vasculature for atherosclerotic development, and many view atherosclerosis as a form of 
accelerated aging [55]. 
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Both diabetes and aging are associated with phenotypic modulation from a 
contractile phenotype to a synthetic and osteogenic phenotype, but through different 
mechanisms and in different microenvironments. Single-cell RNA sequencing analysis 
should be done in arterial tissue from diabetic animals and aged animals in order to 
characterize their unique cellular heterogeneities. This can be coupled with localized Ca2+ 
visualization with TIRF microscopy to gain a complete picture of the gene expression and 
Ca2+ signaling functionality of cell populations in these disparate etiologies.  
As stated previously, CSM phenotypes differ significantly in their intracellular Ca2+ 
signaling, which is a consequence of differential expression of Ca2+ transport proteins [72]. 
However, in my study I did not observe changes in any of the Ca2+ transporter genes. 
Therefore, the dramatic differences seen in global [Ca2+]i handling are most likely due to 
functional changes. This would be consistent with the literature, as vascular SMCs have 
been shown to exhibit altered Ca2+ transporter activity before the development of 
atherosclerotic lesions, indicating that functional changes precede structural changes 
brought about by proliferative and synthetic SMCs [436]. Organ culture conditions should 
be extended to 7 or 10 days in order to determine whether differential Ca2+ transporter 
expression does indeed follow functional changes. If Ca2+ transporter functional changes 
precede or even cause transcriptomic changes, one would expect to observe [Ca2+]i 
handling changes without transcriptomic changes in arterial rings cultured for a shorter 
timeframe.  
 Future studies should continue to utilize the Ossabaw miniature swine large animal 
model, as the [Ca2+]i handling alterations seen in Ossabaw with MetS follow a similar 
pattern as humans with CAD. Therefore, one can state with certainty that this breed is 
clinically relevant for cardiovascular studies.  
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Closing Remarks 
This dissertation supports the previous finding that [Ca2+]i handling alterations 
occur in a biphasic manner during atherosclerotic progression [81]. Aging and diabetes, 
both major risk factors for cardiovascular events and common comorbidities with MetS, 
exhibited [Ca2+]i handling alterations that were indicative of the biphasic pattern. This 
indicates that [Ca2+]i handling alteration patterns are common among different etiologies 
of CAD.  
CSM phenotypic switching has previously been described either in terms of a 
discreet event or in terms of a spectrum with the contractile phenotype at one end and the 
synthetic phenotype at the other [269, 270, 275, 276]. Cutting-edge methods like single 
cell RNA sequencing have made possible transcriptomic analyses for individual cells, 
enabling the identification of many different CSM phenotypes [284, 285]. Researchers are 
only now starting to elucidate the true extent of phenotypic heterogeneity in cells that line 
the vessel walls.  
There is an immense complexity of CSM phenotypic modulation, and future studies 
should investigate CSM phenotype diversity in different etiologies of CAD. Perhaps the 
different microenvironments associated with different CAD etiologies contribute to CSM 
diversity in different ways. While both diabetes and aging are associated with phenotypic 
switching to synthetic and osteogenic phenotypes, they could exhibit unique cell 
subpopulations. This could be a possibility, as some CAD etiologies are associated with 
medial calcification while others are associated with intimal calcification [437-439]. Single 
cell RNA sequencing could help elucidate the mechanisms and Ca2+ signaling events that 
lead to this structural difference in calcification. Understanding the diversity of CSM cell 
populations in CAD will allow more personalized patient treatment and care.  
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Figures 
 
Figure 7.1: [Ca2+]i handling alterations during atherosclerotic progression occurs in 
a biphasic manner. Mild atherosclerosis is associated with proliferation and increased 
VGCC activity, SERCA function, and SR Ca2+ store. Severe atherosclerosis is associated 
with vascular calcification and decreased VGCC activity, SERCA function, and SR Ca2+ 
store. SERCA, sarco-endoplasmic reticulum Ca2+ ATPase; [Ca2+]SR, sarcoplasmic 
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Figure 7.2: CSM phenotypic switching has traditionally been described as two ends 
of a phenotypic spectrum. Figure adapted from [324, 440].  
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Figure 7.3: CSM phenotypic switching can more accurately be described as a 
network. CSM phenotypic switching involves genes associated with different cellular 
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APPENDIX A 
 
PROTOCOL FOR ALLOXANIZATION OF SWINE 
 
1. Fast the swine for at least 12 hours before alloxanization 
2. Prepare alloxan dose (average: 140 mg/kg body weight) in a 50 mL centrifuge 
tube 
3. In a separate 50 mL centrifuge tube, prepare 4 mL of NaOH (1 M) and 8 mL of 
NaCl for a final volume of 12 mL at a pH of 7.3. 
4. Place the fasted pig in a sling so the central venous line (CVL) can be accessed. 
Begin administering 500 mL of 0.9% NaCl. 
5. After 250 mL of 0.9% NaCl has been administered, the alloxan is mixed with the 
prepared NaCl-NaOH solution and shaken until a pinkish color (Note time shaken 
and color). Aspirate the solution into a 20 mL or 30 mL syringe and inject through 
a 0.20 µm sterile filter into the CVL (note time of injection).  
6. Administer the remaining 250 mL of 0.9% NaCl to the pig to prevent possible 
renal damage 
7. Closely monitor the pig for 48-72 hours following the injection of alloxan to watch 
for signs of hypoglycemia that can occur due to massive release of insulin into 
the blood. Other possible side effects include vomiting, renal damage, and 
lethargy.  
NOTE: 
 Alloxan is toxic to humans. It can induce pancreatitis and a subsequent permanent state 
of insulin-dependent diabetes mellitus. Other organs can be damaged. Wear protective 
equipment including facemask, nitrile gloves, eyewear, and a laboratory coat. Mix in and 
administer to pigs in a well-ventilated area. 
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APPENDIX B 
 
QUANTIFICATION OF MEDIAL AND INTIMAL AREA IN VERHOEFF VAN-GIESON 
STAINED CORONARY ARTERIES IN ADOBE PHOTOSHOP CS6 
 
1. Open image of Verhoeff Van-Gieson stained artery (taken with 10X microscope 
objective) in Adobe Photoshop CS6. 
2. Ensure that the measurement log is open: Window > Measurement Log. 
3. To set scale: Image > Analysis > Set Measurement Scale > Custom 
a. The ruler tool is automatically selected for this activity. To set pixel length, 
trace the length of the scale bar. 
b. Type in scale bar length in micrometers (ie: 500) for logical length. 
c. Click OK. 
4. Select magnetic lasso tool. Click once at any point along external elastic lamina 
(EEL) to begin tracing. Release, and drag around the external elastic laminar 
border. Click to close circle. 
5. Click “Record Measurements” in measurement log. 
6. Record “Area” value in Excel Spreadsheet as EEL Area. 
7. Repeat steps 4-6, tracing along the internal elastic lamina (IEL). 
8. Select the magic wand tool 
9. Click inside the lumen and click “Record Measurements” in measurement log 
10. Medial area = EEL Area – IEL Area 
11. Intimal area = IEL Area – Lumen Area 
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APPENDIX C 
 
QUANTIFICATION OF COLLAGEN CONTENT IN MASSON’S TRICHROME STAINED 
CORONARY ARTERY SEGMENTS IN ADOBE PHOTOSHOP CS6 
 
1. Open image of Masson’s Trichrome stained artery (taken with 10X microscope 
objective) in Adobe Photoshop CS6. 
2. Ensure that the measurement log is open: Window > Measurement Log. 
3. To set scale: Image > Analysis > Set Measurement Scale > Custom 
a. The ruler tool is automatically selected for this activity. To set pixel length, 
trace the length of the scale bar. 
b. Type in scale bar length in micrometers (ie: 500) for logical length. 
c. Click OK. 
4. Make a “Background copy” as a new layer by right-clicking on “Background” and 
selecting “Duplicate Layer.” Name this layer “Adventitia”. 
5. Working from the “Adventitia” layer, select the magnetic lasso tool, and trace 
along inner border of the blue adventitia, then Ctrl-X (cut) and Ctrl-V (paste) to 
create a new layer containing the medial layer. 
6. Change name of new layer to “Media.” 
7. In the “Media” Layer, use the magnetic lasso to trace the inner border of the 
media, and click “Delete,” leaving only the media in view. 
8. Select both “Adventitia” and “Media” layers concurrently. Using the Magic wand 
tool, set “tolerance” to 20, and select “Sample All Layers.” Click in Adventitia to 
select blue in both layers. You may add to the selected area by holding down 
“Shift” as you click. 
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9. Once you are satisfied that you’ve selected all of the collagen in both layers, click 
“Record Measurements” in the measurement log. Record the area measure 
under “Total Collagen Area” in an Excel file. 
10. Deselect the “Media” layer. 
11. Working with the “Adventitia” layer only, use the Magic Wand tool to select the 
adventitial collagen again. Be especially careful to ensure that you select the 
same amount of the adventitia as you did in step 9. 
12. Click “Record Measurements.” 
13. Record area measure under “Adventitial Collagen Area” in Excel File. 
14. Medial Collagen Area = Total Collagen Area – Adventitial Collagen Area. 
15. Deselect “Adventitia” layer. 
16. Select “Media” layer.  
17. Determine medial area by using magic wand tool to click outside of the media. 
Everything that is not media will be selected. Type Ctrl-shift-I to select the 
inverse. 
18. Click “Record Measurement.” 
19. Record Area measure as “Medial Area” in Excel file. 
20. To express collagen content as a percentage of medial area, % Medial Collagen 
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APPENDIX D 
 
QUANTIFICATION OF VASCULAR CALCIFICATION IN VON KOSSA STAINED 
CORONARY ARTERIES IN ADOBE PHOTOSHOP CS6 
 
1. Open image of Von Kossa stained artery (taken with 10X microscope objective) 
in Adobe Photoshop CS6. 
2. Ensure that the measurement log is open: Window > Measurement Log. 
3. To set scale: Image > Analysis > Set Measurement Scale > Custom 
a. The ruler tool is automatically selected for this activity. To set pixel length, 
trace the length of the scale bar. 
b. Type in scale bar length in micrometers (ie: 500) for logical length. 
c. Click OK. 
4. Select magnetic lasso tool. Click once at any point along external elastic lamina 
(EEL) to begin tracing. Release, and drag around the external elastic laminar 
border. Click to close circle. 
5. Click “Record Measurements” in measurement log. 
6. Record “Area” value in Excel Spreadsheet as EEL Area. 
7. Click inside the lumen and click “Record Measurements” in measurement log 
8. Using the Magic wand tool, set “tolerance” to 20. Click a calcified region (black 
area). You may add to the selected area by holding down “Shift” as you click. 
9. Once you are satisfied that you’ve selected all of the calcified areas, click 
“Record Measurements” in the measurement log. Record the area measure 
under “Total Calcification Area” in an Excel file. 
10. To express calcification as a percentage of artery area, % Calcification = 
(Calcification Area/(EEL Area – Lumen Area))*100. 
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APPENDIX E 
 
PROTOCOL FOR DISPERSION OF VASCULAR SMOOTH MUSCLE CELLS FOR 
INTRACELLULAR CALCIUM HANDLING QUANTIFICATION 
 
Current Date        -       -             Initials_______       
1. Conduit coronary arteries of swine are typically used. The artery is classified as 
proximal, middle, and distal thirds.  At euthanasia/tissue collection, grossly 
dissect vessels by first locating vessel and then making a transverse cut through 
myocardium near ostium.  Remove entire length of conduit artery with minimal 
adjacent cardiac muscle, fat, etc. attached.  Place the tissue into wide-mouth 
bottle containing »50-75 ml ice-cold 2CaNa.  Place immediately into cooler filled 
with ice. (NOTE: in the case of overnight transport, store tissue in EH storage 
media on ice.) 
[Animal:  Pig#               , Age             , Time dead                , Misc.                  ] 
[Portion of artery:  Proximal      , Middle      , Distal         
Artery:  LAD___ RCA        CFX       Other?________]  
[Date         -        -        , Time of storage           ] 
2. Clean artery of adherent connective tissue, fat, cardiac muscle, etc. in cell culture 
hood in 100 x 20 mm culture dish in »30 ml Low Ca. Treat artery gently (do not 
stretch excessively, if possible).   
**At this point, the artery can be stored in the refrigerator in storage media for 2-5 
days, if necessary. 
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[Storage media = EH + PS] 
[In refrigerator:  Date         -        -          Time           ] 
3. Cut open artery longitudinally to reveal lumen. Pin down the artery with the lumen 
facing up in a 30 ml Sylgard jar with 2 mL Collagenase solution.  (Approximately 
a 1 cm2 area of vessel is enough to yield several million SMC.)  Pin the artery 
segment on all corners and at the middle to increase surface area.   
4.  Place jar in 37° C shaking water bath (100 strokes/min; 5.5 on dial) for 60 min. 
The jar should be placed so that the long axis of the vessel segment is parallel 
with the direction of the shaking.   
[Collagenase batch:  Date made:         -        -        , Made by:                          ] 
[Dispersion 1:  Date         -        -        ,  
Time started                     , Time ended                     ] 
5. Aspirate supernatant and pipette over artery several times to loosen isolated 
CSM.  Place drop of supernatant in 35 mm petri dish on microscope and 
observe.  (At this point expect mostly connective tissue, endothelial cells (EC), 
etc., but few CSM.  EC are round and clump together in bunches.) Note 
appropriately and either:  1) discard_____, 2) save in 15 ml tube for immediate 
fura-2 or patch-clamp studies_____.   If #2, transfer supernatant to 15 mL conical 
tube and clearly label with pig number and cell fraction. Centrifuge at 900 rpm 
(Not RCF) for 4 min, remove supernatant (Be careful not to aspirate the 
pellet!), then resuspend pellet in 1 mL of freshly prepared 0.02%BSA in 2CaNa 
(20 mg BSA/10 mL 2CaNa). Add 2.5μL fura-2 AM and triturate several times. 
Place in 37° C water bath for ~30-45 mins.   
Cell fraction: ______________ (Ignore this section if discarded) 
   
  153   
[Dye: Fura-2____, Other_____ Dye concentration               ]  
[Loading:  Date         -        -        ,  
Time started                , Time ended                      ] 
6. Add another 2 mL Collagenase solution to Sylgard jar and repeat steps 4 and 5 
until isolation is complete.  
 Step 4: 
 [Dispersion 2:  Time started                      , Time ended                      ] 
 Step 5: 
  Cell fraction: ______________ 
 [Dye: Fura-2____, Other_____ Dye concentration               ]  
 [Loading:  Date         -        -        ,  
 Time started                , Time ended                      ] 
 Step 4: 
 [Dispersion 3:  Time started                      , Time ended                      ] 
 Step 5: 
  Cell fraction: ______________ 
 [Dye: Fura-2____, Other_____ Dye concentration               ]  
 [Loading:  Date         -        -        ,  
 Time started                , Time ended                      ] 
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7. Centrifuge cells at 900 rpm for 5 min, resuspend in EH solution and put in 37° C 
water bath for ~20 min.  
 [Time started                , Time ended                      ] 
8. Centrifuge cells at 900 rpm for 5 min, resuspend in 0.02%BSA in 2CaNa and chill on 
ice. Wrap tubes in foil to protect from light exposure.  
NOTES: 
1. All steps following fura-2 loading, CSM are light-sensitive. When possible, 
minimize exposure to light.  
2. "Overnight dispersion" - It is also possible to disperse by exposing cells to 2 mL 

















   




Collagenase (in Low Ca) 
Component Concentration 20 mL total 10 mL total Stock Solution 
Collagenase, 
CLS II 
















[Batch:  Date made:         -        -        , Made by:                                          ] 
 
Notes:  
1. Ensure the pH is exactly 7.40 and if not, adjust 
2. Make in 10-20 ml quantities.  Each isolation requires at least 4-6 ml collagenase.  
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3-4 ml of 1.0 M 
 
NOTES: 
1. Sterile solutions all contain PS and are sterilized by filtration through Millex-GS 0.2 
μm filter or Millipore Stericup apparatus.  
2. Penicillin Streptomycin (PS) 100 mg/ml (100 U/ml) is added in a 1:100 (vol:vol) 
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 Concentration (mM) 
 
 1000 ml total 
CaCl2 2.0 20 ml of 0.1 M 
NaCl 135 135 ml of 1.0 M 
MgCl2 1 10 ml of 0.1 M 
KCl 5 50 ml of 0.1 M 
KH2PO4 0.44 4.4 ml of 0.1 M 
Na2HPO4 0.34 3.4 ml of 0.1 M 
NaHCO3 2.6 26 ml of 0.1 M 
Amino Acids 1X 20 ml of 50X 
Vitamins 1X 10 ml of 100X 
Phenol Red 0.001% 2 ml of 0.5% 
HEPES 20 20 ml of 1.0 M 
Glucose 10 1.8 g 
pH 7.4 with NaOH 
PS 1% 10 ml 
Horse Serum 2% 20 ml 
 
NOTES: 
1. EH media is a type of Eagle's Minimal Essential Medium (EMEM), but also has 
HEPES as a pH buffer, so that bubbling the solution with O2 is not necessary for 
maintenance of pH. 
2. Sterile-filter under laminar flow hood with Millipore Stericup system.  
   





 Concentration (mM) 
 
 1000 ml total 
CaCl2 0.5 5.0 ml of 0.1 M 
NaCl 135 135 ml of 1.0 M 
MgCl2 1 10 ml of 0.1 M 
KCl 5 50 ml of 0.1 M 
KH2PO4 0.44 4.4 ml of 0.1 M 
Na2HPO4 0.34 3.4 ml of 0.1 M 
NaHCO3 2.6 26 ml of 0.1 M 
Amino Acids 1X 20 ml of 50X 
Vitamins 1X 10 ml of 100X 
Phenol Red 0.001% 2 ml of 0.5% 
HEPES 20 20 ml of 1.0 M 
Glucose 10 1.8 g 
pH 7.4 with NaOH 
PS 1% 10 ml 
 
NOTES: 
1. Low Ca is exactly like EH, except that the Ca concentration is only 0.5 mM, and 
no horse serum is used. 
2. Low Ca with horse serum may be used to facilitate acquisition of a seal when 
doing patch-clamp studies. 
 
 
   





 Conc. (mM) 
 










































3-4 ml of 1.0 M 
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5-7 ml of 1.0 M 
 
NOTES:  
1. Rationale for low [Ca2+] – Determination of the importance of extracellular Ca2+ 
(presumably Ca2+ influx) for a measured increase in intracellular Ca2+. 
2. CaCl2 removal does not include equimolar addition of MgCl2 or other ions. We 
have only used 1 and 5 mM EGTA on cells when achieving a fura-2 RATIO 
minimum. The cells probably become very leaky to Na+ and other ions, thus 
addition of Mg2+ would “stabilize” the membrane. 
3. Total ml of NaOH added gives number of mM extra Na added; e.g. total [Na+] for 
0CaNa is ~ 143 mM. Note that NaCl increases to 127 mM with –CaNa, 5 EGTA 
solution to keep [Na+; at 143 mM as ~16 mM Na+ used for pH. 
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APPENDIX G 
 
PROTOCOL FOR ORGAN CULTURE OF SWINE CORONARY ARTERY RINGS IN 
OSTEOGENIC MEDIA 
 
1. Euthanasia per standard protocol. With sterile gloves and tools, remove heart with 
pericardial sac intact. 
2. Lay heart on inside of paper from sterile glove pack and remove pericardial sac 
with sterile tools. 
3. Thoroughly rinse the heart with ice cold sterile-filtered 2CaNa + 2% 
penicillin/streptomycin (P/S). 
4. Grossly dissect the coronary arteries and place in individual appropriately pre-
labeled tubes of 2CaNa + 2% P/S. Keep tubes on ice. 
5. Transfer collected specimens to lab on ice for dissection under the sterile laminar 
flow hood. 
6. Open the flow hood and turn off U.V. light. Clean surface with 70% ethanol. 
7. Thaw a frozen aliquot of 50 mL sterile-filtered Low Ca solution for fine dissection. 
8. In flow hood, remove grossly dissected artery and place in Low Ca solution in a 
sterile culture dish on ice. Finely dissect coronary artery from myocardium and 
adventitia carefully and gently. 
9. Allow clean artery to rest in ice cold Low Ca solution while preparing a 6-well plate 
with 4-5 mL of sterile phosphate-buffered saline (PBS) in each well. 
10. Section cleaned artery into rings of 2-4 mm in length, and place in top left well of 
prepared 6-well plate. 
11. Allow rings to sit in PBS for ~30 seconds, and then transfer clockwise to the next 
well. Transfer each ring separately and allow excess solution to drip off of the ring 
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into the previous well before transfer. Continue to transfer rings in a clockwise 
fashion until all rings have undergone complete 6-well serial “sterilization.” 
12. Prepare a 12-well plate for culture by filling each well with 2 mL of culture media 
(Dulbecco’s Modified Eagle’s Medium (DMEM) + 180 mg/dL glucose + 1% P/S + 
10% fetal bovine serum + 3.8 mM inorganic phosphate + 7.5 U/mL alkaline 
phosphatase). 
13. Set aside arterial segments for cold stored controls. 
14. Transfer a single coronary segment into a single well of the prepared 12-well plate. 
15. Cover each plate and label appropriately with pig number, date, and culture 
conditions. 
16. Transfer plates to the 37°C incubator. Check that the CO2 is set to 4.6% and that 
the tray at the bottom of the incubator is full of distilled water. 
17. Change culture media every two days. 
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APPENDIX H 
 
PROTOCOL FOR DISPERSION OF VASCULAR SMOOTH MUSCLE CELLS FOR 
SINGLE-CELL RNA-SEQUENCING  
 
Current Date        -       -             Initials_______       
1. Conduit coronary arteries of swine are typically used. The artery is classified as 
proximal, middle, and distal thirds.  At euthanasia/tissue collection, grossly 
dissect vessels by first locating vessel and then making a transverse cut through 
myocardium near ostium. Remove entire length of conduit artery with minimal 
adjacent cardiac muscle, fat, etc. attached.  Place the tissue into wide-mouth 
bottle containing »50-75 ml ice-cold 2CaNa.  Place immediately into cooler filled 
with ice. (NOTE: in the case of overnight transport, store tissue in EH storage 
media on ice.) 
[Animal:  Pig#               , Age             , Time dead                , Misc.                  ] 
[Portion of artery:  Proximal      , Middle      , Distal         
Artery:  LAD___ RCA        CFX       Other?________]  
[Date         -        -        , Time of storage           ] 
2. Very thoroughly clean artery of adherent connective tissue, fat, cardiac muscle, 
etc. in »30 ml Low Ca. Treat artery gently (do not stretch excessively, if possible).   
**At this point, the artery can be stored in the refrigerator in storage media for 2-5 
days, if necessary. 
[Storage media = EH + PS] 
[In refrigerator:  Date         -        -          Time           ] 
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3. Cut open artery longitudinally to reveal lumen. Pin down the artery with the lumen 
facing up in a 30 ml Sylgard jar with 2 mL of 150 U/mL collagenase in 0.9% 
NaCl. (Approximately a 1 cm2 area of vessel is enough to yield several million 
SMC.)  Pin the artery segment on all corners and at the middle to increase 
surface area.   
4.  Place jar in 37° C shaking water bath (100 strokes/min; 5.5 on dial) for 60 min. 
The jar should be placed so that the long axis of the vessel segment is parallel 
with the direction of the shaking.   
[Collagenase batch:  Date made:         -        -        , Made by:                          ] 
[Dispersion 1:  Date         -        -        ,  
Time started                     , Time ended                     ] 
5. Aspirate supernatant and pipette over artery several times to loosen isolated 
CSM.  Place drop of supernatant in 35 mm petri dish on microscope and observe.  
(At this point expect mostly connective tissue, endothelial cells (EC), etc., but few 
CSM.  EC are round and clump together in bunches.) Note appropriately and 
either:  1) discard_____, 2) save in 15 ml tube for immediate scRNA-seq 
studies_____.   If #2, transfer supernatant to 15 mL conical tube and clearly label 
with pig number and cell fraction. Centrifuge at 900 rpm (Not RCF) for 4 min, 
remove supernatant (Be careful not to aspirate the pellet!), then resuspend 
pellet in 1 mL of freshly prepared 0.02% BSA in 0.9% NaCl.   
 Cell fraction: ______________ (Ignore this section if discarded) 
[Dye: Fura-2____, Other_____ Dye concentration               ]  
[Loading:  Date         -        -        ,  
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Time started                , Time ended                      ] 
6. Add another 2 mL Collagenase solution to Sylgard jar and repeat steps 4 and 5 
until isolation is complete.  
 Step 4: 
 [Dispersion 2:  Time started                      , Time ended                      ] 
 Step 5: 
  Cell fraction: ______________ 
 [Dye: Fura-2____, Other_____ Dye concentration               ]  
 [Loading:  Date         -        -        ,  
 Time started                , Time ended                      ] 
 Step 4: 
 [Dispersion 3:  Time started                      , Time ended                      ] 
 Step 5: 
  Cell fraction: ______________ 
 [Dye: Fura-2____, Other_____ Dye concentration               ]  
 [Loading:  Date         -        -        ,  
 Time started                , Time ended                      ] 
9. Centrifuge cells at 900 rpm for 5 min, resuspend in 1 mL 0.25% trypsin for 5 minutes 
10. Centrifuge cells at 900 rpm for 5 min, resuspend in 2 mL 0.9% saline. Repeat this 
wash step for a total of 3 times 
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11. After final wash, resuspend pellet in 0.02 BSA in 0.9% NaCl 
12. Filter through a 40 µm cell strainer into a 1.5 mL centrifuge tube 
13. Place on ice 
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APPENDIX I 
 
SUPPLEMENTAL FIGURES  
 
 
Supplemental Figure 6.1: Significant correlation of human coronary smooth muscle 
Ca2+ signaling to histological measures. The percent media (A-C), intima/media ratio 
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(D-E), percent calcification (F), and percent collagen (G-I) were significantly correlated to 
Ca2+ influx (A, D, F, G), area under the 80 mM K+ curve (B, E, H), and SR store release 
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Supplemental Figure 6.2: Significant correlation of human coronary smooth muscle 
Ca2+ signaling to cardiometabolic patient data. Patient BMI (A and B), age (C), the 
number of MetS risk factors (D), and dyslipidemia (E-I) were correlated to Ca2+ influx (A, 
E, G), area under the 80 mM K+ curve (B and D), SR store release (C), and undershoot 
(F and H). 
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